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ABSTRACT 
The growth of Rauscher murine leukaemia virus (R-MuLV) in mice 1s 
regulated by a number of autosomal genes. These genes influence virus 
replication or control the antiviral immune response generated toward 
R-MuLV. The experiments described in this thesis were designed to 
examine the role of the immune response in resistance or susceptibility to 
R-MuLV infection. 
In agreement with previous reports, BALB / c mice were found to be highly 
susceptible to R-MuL V infection. High levels of infectious virus and virus 
antigen were present in plasma and spleen of infected mice for at least 3 
weeks post infection. In contrast, C57BL/ 6 mice controlled R-MuL V with 
little viral antigen or infectious virus present in plasma or spleen by 3 
weeks post infection. 
The ability of spleen T and B cells from R-MuLV infected mice to 
proliferate following polyclonal stimulation in vitro was markedly 
impaired following R-MuL V infection. This effect was more pronounced 
in BALB/c mice compared with C57BL/6 mice. In contrast, R-MuLV 
infection had little effect upon lymph node T cell proliferation. 
Investigation of the mechanism(s) which lead to immunosuppression 
suggested that suppressed lymphocyte proliferation may not be due to 
decreased proportion of T or B cells in the spleen of infected mice. The 
proliferation of spleen cells from uninfected BALB / c or C57BL/ 6 mice was 
suppressed by co-culture with splenocytes from infected mice. This 
observation suggested that a suppressive factor was produced by spleen 
cells from R-MuLV infected mice. Further studies showed that 
immunosuppressiv~ molecules nitric oxide or prostaglandins were not 
involved in impaired lymphocyte proliferation. 
The cytokines present during the generation of an immune response are 
integral to determining the character of the response. As certain immune 
responses correlate with susceptibility or resistance to infectious agents 
cytokine expression during R-MuLV infection of BALB/c and C57BL/6 
mice was examined. Analysis of cytokine mRNA in the spleen and 
production of cytokines by spleen and lymph node cells following 
l V 
restimulation in vitro with anti-CD3 antibodies showed that both BALB I c 
and C57BLI 6 mice produced predominantly type 1 cytokines following 
R-MuLV infection. This suggested that inappropriate cytokine production 
was unlikely to be responsible for susceptibility to R-MuL V exhibited by 
BALBlc mice. However, spleen cells from C57BLl6 mice produced higher 
levels of IFN-y compared with cells from BALBI c mice which raised the 
possibility that insufficient IFN-y production may lead to an ineffective 
immune response in BALBI c mice. The role of cytokines in resistance or 
susceptibility to R-MuLV was examined by treating infected mice with 
cytokine neutralising antibodies. Treatment of BALBI c or C57BLI 6 mice 
with antibodies that neutralised IL-2, IL-4, IL-6, IL-10, IFN-y or TNF-a 
during R-MuLV infection suggested that individually these factors 
(including IFN-y) were not essential for resistance or susceptibility to 
R-MuLV. Mice lacking functional IFN-y receptors appeared to control 
R-MuLV infection while wild type mice did not, which suggests that IFN-y 
may be involved in susceptibility to R-MuLV infection in 129 ISv mice. 
Analysis of the role of T cell subpopulation in disease associated with 
R-MuLV infection suggested that in both BALBlc and C57BLl6 mice 
CD4+ T cells may be required for full development of spleomegaly induced 
by R-MuLV. 
Since the role of NO in immunity to retroviral infection is largely 
unknown, the involvement of NO in resistance or susceptibility to 
R-MuL V was examined. Similar levels of mRNA encoding the NO 
producing enzyme inducible NO synthase in spleen cells of both BALBI c 
and C57BLl6 mice following R-MuLV infection. The magnitude and time 
of induction were largely equivalent. Spleen cells from infected mice were 
also found to produce NO following in vitro restimulation with LPS or 
anti-CD3 antibodies. Inhibition of NO production, however failed to affect 
virus growth in vivo. Taken together, these observations suggest that NO 
does not play a major role in the pathogenesis of R-MuL V in susceptible or 
resistant mice. 
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Chapter 1 
Introduction and Literature Review 
1.1 THE IMMUNE RESPONSE - AN OVERVIEW 
The immune response toward a pathogen occurs at two levels - an innate 
and an adaptive response. The innate immune response is rapid, antigen 
independent and generally not restricted by MHC haplotype. It is mediated 
by macrophages, monocytes and natural killer (NK) cells as well as 
non-cellular factors that include interferon (IFN) and complement 
(Janeway Jr, 1989) The aim of the innate immune response is to limit early 
pathogen replication during an infection as well as to promote the 
development of an adaptive immune response (Romagnani, 1992). 
The adaptive immune response is characterised by the activation and 
differentiation of T and B lymphocytes to effector function. It takes several 
days longer to generate than the innate response, is antigen dependent and 
restricted by MHC haplotype. A wide range of host adaptive immune 
responses may be generated following infection with a pathogen or 
immunisation with an antigen. These include the generation of humoral 
and cell mediated immune (CMI) responses. The former response is 
associated with the production of antibodies by B cells while the latter is 
characterised by the generation of delayed type hypersensitivity (DTH), 
activated macrophages, cytotoxic CDS+ T cells and the production of IgG 2a 
antibody (Mosmann and Coffman, 1989). The type and magnitude of the 
response is tightly regulated and coordinated by the production of 
cytokines and cell surface molecules. 
1.2 THE ADAPTIVE IMMUNE RESPONSE 
1.2.1 Antigen recognition 
The central problem faced by the immune system is to distinguish between 
proteins (antigens) synthesised by normal host cells (self) and proteins 
produced by infectious agents (non-self). The innate immune response is 
activated largely independently of antigen. It is induced by alternative 
stimuli including virus infection, microbial products such as bacterial LPS 
and altered expression of MHC class I molecules on the surface of cells 
(Muller-Eberhard, 1989). In contrast, the adaptive immune response is 
driven by recognition of non-self antigens by lymphocytes. Lymphocytes 
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recognise antigen through clonally restricted antigen receptors expressed 
on their cell surface. B cells recognise 3 dimensional shapes of proteins in 
their native state through cell associated antibody (Reth, 1992). In contrast, 
antigen recognition by most T cells occurs through the a / ~ chain 
heterodimeric T cell receptor. These receptors recognise small, proteolytic 
fragments of protein antigens that are presented at the target cell surface in 
association with either class I or class II MHC molecules (Matis, 1990). 
Dependence on antigen ensures that the adaptive immune response 1s 
specific and that it is down regulated once the antigen has been cleared. 
1.2.2 Antigen presentation to T cells 
The recognition of antigen by T lymphocytes is central to the generation 
and mediation of adaptive immune responses. As described above, T cells 
recognise antigen derived peptides presented in association with MHC 
molecules. Specific T cell subsets recognise antigen bound to particular 
classes of MHC molecule. T cells expressing CDS recognise cells presenting 
antigen in association with MHC class I molecules, while CD4+ T cells 
recognise peptides presented by MHC class II molecules. The source of 
peptides presented by each class of MHC molecule determines the function 
of the T cell subsets. Class I MHC molecules present peptides derived from 
proteins synthesised by the cell or present in the cytoplasm (reviewed in 
Braciale et al., 1987; Jardetzky et al., 1991). Virtually all nucleated cells 
express, or can be induced to express, MHC class I molecules. Activated 
CDS+ T cells can, therefore, detect cells producing non-self proteins eg. 
virus infected cells, or those expressing mutated self proteins eg. tumour 
cells (Townsend et al., 1985; Townsend et al., 1986; Fremont et al., 1992; 
Wallny et al., 1992; reviewed in Engelhard, 1994). In contrast, peptides 
presented by MHC class II molecules are generally derived from proteins 
produced outside the antigen presenting cell (Braciale et al., 1987). These 
proteins are internalised via endocytosis or by antibody mediated uptake of 
antigen and are processed in lysosomal or endosomal compartments 
(Cresswell, 1994). It is within these compartments that peptides derived 
from exogenous antigen associate with MHC class II molecules before 
being transported to the cell surface. The expression of MHC class II 
molecules is largely restricted to dendritic cells, macrophages and B cells, 
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although MHC class II expression can be induced on fibroblasts and 
endothelial cells (Benoist and Mathis, 1990). 
1.2.3 T cell activation 
T cell activation requires two signalling events (reviewed in Bretscher, 
1992). Signal 1 is delivered following ligation of the T cell receptor by 
antigen presented in association with MHC molecules on an antigen 
presenting cell (APC). The provision of signal 2 (co-stimulation) is then 
required to stimulate T cells to produce cytokines, to proliferate and to 
differentiate to effector function (Linsley and Ledbetter, 1993). Without 
signal 2, T cells become unresponsive to further stimulation (anergic) or 
undergo apoptosis (Harding et al., 1992; reviewed in Jenkins, 1992). The T 
cell ligand-APC receptor pairs that mediate costimulation include CD28 -
B7-1/B7-2 (Linsley et al., 1991; Harding et al., 1992; Harding and Allison, 
1993), CD40L - CD40 (de Boer et al., 1993), CD2 - LFA-3 (Moingeon et al., 
1989), LFA-1 - ICAM-1,-2 (van Seventer et al., 1990), unknown - HSA (Liu 
et al., 1992) and CDS - CD72 (Verwilghen et al., 1993). The ligation of CD28 
or CTLA-4 by B7-1 or B7-2 appears to be the main co-stimulatory signal to 
CD4+ and CDS+ T cells. The other above mentioned receptor-ligand events 
augment the co-stimulatory response provided by this interaction (Linsley 
et al., 1991; Harding et al., 1992; Azuma et al., 1993; Harding and Allison, 
1993; van Gool et al., 1993; reviewed in Croft, 1994). Seder et al., (1994) 
showed that IL-2 could replace the co-stimulatory activity of the B7-CD28 
interaction which suggests that the role of costimulation may be to 
augment IL-2 production which in turn induces T cell proliferation and 
further cytokine production. 
1.3 REGULATION 01: THE IMMUNE RESPONSE 
A wide range of immune responses can be generated toward an antigen. A 
CMI response is often effective in controlling intracellular viruses, bacteria 
and parasites (Stueckemann et al., 1982; Karupiah and Harris, 1995), while 
a humoral immune response mediates immunity to extracellular bacteria 
and some nematode worms (Urban et al., 1992; Gotschlich, 1993). It has 
been known for some time that humoral and CMI responses can manifest 
as mutually exclusive phenomena (Parish, 1972). In 1986, Mosmann et al. , 
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(1986b) demonstrated that munne CD4+ T cell clones often expressed 
mutually exclusive patterns of cytokines which has led to the hypothesis 
that cytokines are responsible for the reciprocal nature of CMI and 
humoral immune responses (reviewed in Mosmann and Coffman, 1989). 
1.3.1 Cytokine production by T cell clones 
Long term murine CD4 + T cell clones can be subdivided into 2 groups 
based on the cytokines they produce. T helper 1 (Thl) clones produce 
IFN-y, interleukin (IL) -2 and lymphotoxin while T helper 2 (Th2) clones 
produce IL-4, IL-5, IL-6 and IL-10. Both Thl and Th2 clones express TNF-a, 
granulocyte macrophage colony stimulating factor (GM-CSF) and IL-3 
(Mosmann et al., 1986b; Mosmann and Coffman, 1989) . Some clones 
express both Thl and Th2 type cytokines and have been designated Th0 
(Firestein et al., 1989; Street et al., 1990). Cloned CD8+ T cells tend to 
express Thl cytokines (Fong and Mosmann, 1990), however recent 
evidence suggests that under certain conditions, CDS+ T cell clones may 
produce Th2 cytokines (Seder et al., 1992a; Erard et al., 1993; see also Section 
1.3.2). 
The profile of cytokines produced by each subset of T cells is associated 
with different immune functions. Adoptive transfer studies showed that 
Thl clones supported the generation of DTH while Th2 clones did not 
(Cher and Mosmann, 1987; Fong and Mosmann, 1989). Both Thl and Th2 
clones can induce antibody production both in vivo and in vitro (Stevens 
et al., 1988; Rizzo et al., 1992), however in vitro studies indicate that Th2 
cells may be more proficient than Thl cells in this respect (Killar et al., 
1987). This is thought to be due to the lack of IL-2 production by some Thl 
clones (Killar et al., 1,987; Coffman et al., 1988). In addition, Thl and Th2 
clones induce B cells to produce different antibody isotypes. Both clones 
induce the production of IgM and IgG3 while only Thl cells augment 
IgG2a and only Th2 clones promote IgGl and IgE production (Stevens et 
al., 1988). 
The activity of Thl and Th2 clones is dependent on the cytokines they 
produce. Whilst a number of studies have shown that antibody 
production requires cell contact between activated T cells and B cells 
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(reviewed in Parker, 1993), this interaction does not directly influence the 
isotype of antibody produced by stimulated B cells. Rather, the isotype is 
determined by the cytokines produced by the T cell clone (Hodgkin et al., 
1990; Noelle et al., 1991). Similarly, the generation of DTH by antigen 
specific T cell clones is largely due to IFN-y produced by Thl clones (Cher 
and Mosmann, 1987; Fong and Mosmann, 1989). 
It has been conventional to refer to CD4+ T cell clones as T helper cells and 
to the cytokines they produce as either Th2 or Thl. This nomenclature is 
somewhat of a misnomer as CD4+ T cells have many roles other than 
providing the stimulus or 'help' for B cells to proliferate and differentiate 
to antibody producing cells. In addition, studies over the last 5 years have 
clearly shown that the Thl-Th2 model developed using in vitro generated, 
long-term T cell clones represents a vast oversimplification of the 
immune response generated in vivo. Cytokines are produced by cells 
other than CD4+ T cells. These include macrophages (Ehlers et al., 1994) 
NK cells (Cuturi et al., 1989; Beckerman et al., 1993) CDS+ T cells (Morris et 
al., 1982; Fong and Mosmann, 1990) and mast cells (Plaut et al., 1989), 
which can also contribute to the generation and mediation of an effective 
immune response. To take into account the differing origins of cytokines, 
a new nomenclature has been proposed in which the Thl and Th2 
terminology described above, has been replaced with type 1 and type 2 
cytokines, respectively (Cox and Liew, 1992; Clerici and Shearer, 1994). 
This system has the advantage of being based on cytokine function rather 
than on the cell type which produces the factor. In addition, the criteria 
have been widened to encompass cytokines not produced by CD4+ T cells. 
For example, IL-12, produced by macrophages and B cells (Cuturi et al., 
1989; Kobayashi et al.., 1989; D'Andrea et al., 1992) is referred to as a type 1 
cytokine since it plays an integral role in promoting development of cells 
which produce other type 1 cytokines. In the remainder of this thesis, Thl 
and Th2 nomenclature will be replaced with type 1 and type 2 as described 
above, except when referring to CD4+ T cell clones. 
1.3.2 The generation of adaptive immune responses 
A number of factors determine how the immune response develops 
following challenge with an antigen. It is clear from in vitro and in vivo 
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studies that the cytokines present during the initial stages of T cell 
activation affect the differentiation of CD4 + and CDS+ T cells (O'Garra and 
Murphy, 1994). The role of cytokines in the generation of adaptive 
immune responses are illustrated in Figure 1.1. Other factors also 
influence the type of immune response generated. These include the 
route of administration of antigen, the nature of the antigen itself, the type 
of antigen presenting cell and the dose of antigen (Parish and Liew, 1972; 
Gajewski et al., 1991b; Bretscher et al., 1992; reviewed in Parish, 1972; Seder 
and Paul, 1994). 
The cytokine milieu present at early stages of CD4 + T cell stimulation 
markedly influences the development of these cells to secrete different 
profiles of cytokines (Le Gros et al., 1990; Swain et al., 1990; Gajewski et al., 
1991a). The type 1 factors IL-12 and IFN-y promote the differentiation of 
stimulated naive T cells into type 1 cells (Macatonia et al., 1993b; Manetti et 
al., 1993; Seder et al., 1993; Schmitz et al., 1994). Several studies indicate 
that IL-12 acts directly on naive T cells (Manetti et al., 1993; Seder et al., 
1993), however Macatonia et al., (1993b) showed that IFN-y induced by 
IL-12 may also may stimulate differentiation of CD4+ T cells to a type 1 
phenotype in vitro. IL-12 also influences cytokine expression by CD4+ T 
cells in vivo. Endogenous IL-12 production is required for the generation 
of type 1 responses against intracellular parasites (Sypek et al., 1993) while 
administration of IL-12 promotes type 1 responses during intracellular 
parasite infestation and viral infection (Heinzel et al., 1993; Orange et al., 
1994). IL-12 promotes CMI responses by directly acting on CD4+ T cells to 
generate type 1 cells (Manetti et al., 1993) but also by activating NK cells 
and CDS+ CTL (Kobayashi et al., 1989; Gately et al., 1993; Chouaib et al., 
1994). 
IFN-y is also involved in the generation of type 1 responses. Addition of 
IFN-y to cultures of naive T cells inhibits the development of IL-4 
producing cells and yields CD4+ T cells that express IFN-y upon 
restimulation (Gajewski et al., 1991a; Maggi et al., 1992). The role of IFN-y 
in directly promoting the development of type 1 cells is less clear. Studies 
by Seder et al., (1992b) suggest that IFN-y does not promote the generation 
of type 1 cells. In contrast, Swain et al., (1990) found that high levels of 
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Figure 1.1 Role of cytokines in the generation of adaptive immune responses 
Activated CD4+ T cells are integral to the regulation of adaptive immune responses. These cells mediate this regulation via 
the production of cytokines. However, naive T cells predominantly produce only IL-2. The cytokines present during 
activation of CD4+ T cells markedly influences cytokines produced by CD4+ T cells. 
Cytokines produced early in an immune response by activated macrophages and NK cells such as IL-12 and IFN-y act upon 
naive CD4+ T cells to induce their differentiation into cells which express type 1 cytokines (IFN-y, LT and IL-2). Activated CD4+ 
T cells which express type 1 cytokines promote the development of cell mediated immune (CMI) responses such as the 
generation of cytotoxic T lymphocytes (CTL), delayed type hypersensitivity (DTH) and the production of IgG2a antibody. 
Stimuli such as virus infection or factors produced by intracellular bacteria and parasites lead to the activation of macrophages 
and NK cells and the generation of CMI responses. 
Early production of IL-4 during an immune response promotes the differentiation of naive CD4+ T cells into cells which 
express type 2 cytokines (IL-4, IL-10). The production of these factors is associated with the production of a humoral immune 
response characterised by the production of antibodies of the IgGl and IgE subclasses. The source of early IL-4 production is 
unclear however there is evidence to suggest that it may come from mast cells and a rare population of CD4+ NKl.1 + T cells. 
Stimuli such as helminth infestations are associated with the production of type 2 cytokines. 
Type 1 cytokines have been shown to mutually antagonise the production of type 2 cytokines. Similarly type 2 factors impair 
production of type 1 cytokines. The balance of early production of type 1 or type 2 cytokines is integral to the generation of CMI 
or humoral immune responses. The antagonistic effects of each cytokine type may act upon naive CD4 + T cells or other cells 
involved in the generation of adaptive immune responses. In this figure, black arrows indicate positive signals and red arrows 
indicate negative signals. 
Abbreviations: IL - interleukin; IFN - interferon, NK - natural killer, M<j) - macrophage; LT - lymphotoxin 
IFN-y promotes type 1 cell development in the presence of low levels of 
IL-4. Furthermore, as described above, neutralisation of IFN-y in the 
presence of IL-12 inhibited type 1 cell generation in vitro (Macatonia et al ., 
1993b ). The reason for these differing results is unknown, however they 
may be due to the different strains of mice used or differences in culture 
conditions (Seder and Paul, 1994). IFN-y has also been shown to promote 
the development of type 1 cells in vivo. Mice treated with anti-IFN-y mAb 
fail to generate type 1 responses following challenge with the protozoan 
Leishmania major (Belosevic et al., 1989; Scott, 1991). Furthermore, the 
ability of IL-12 to induce a type 1 response is dependent on IFN-y in a 
number of in vivo disease models (Heinzel et al., 1993; Gazzinelli et al., 
1994b; Oswald et al., 1994a). 
Several studies have shown that the presence of IFN-a can promote the 
gen!2ration of Thl CD4+ T cell clones (Parronchi et al., 1992; Brinkmann et 
al., 1993). The mechanism by which IFN-a promotes the generation of 
type 1 cells is unclear, however several studies suggest that IFN-a may act 
by inhibiting IL-4 transcription (Finkelman et al., 1991) and promote IFN-y 
production by NK cells (Biron et al., 1984; Kobayashi et al., 1989) which 
may further augment the development of type 1 cells (Varkila et al., 1993). 
Although IL-2 is produced by most Thl T cell clones (Mosmann et al., 
1986b; Street et al., 1990), the factor has little effect on the development of 
cytokine production by naive CD4+ T cells (Swain, 1991). Rather, IL-2 is 
thought to act as a growth factor for stimulated T cells (Seder et al., 1994) . 
IL-4 is a critical factor in the commitment of CD4+ T cells to the expression 
of a type 2 phenotype both in vitro and in vivo . Naive CD4+ T cells are 
poor producers of IL-4 in vitro, however, the presence of IL-4 during initial 
stimulation of these cells promotes the expression of IL-4 upon 
restimulation (Le Gros et al., 1990; Swain et al., 1990). This effect is 
mediated by a direct action of IL-4 on T cells and occurs independently of 
the type of APC used (Hsieh et al., 1992). Furthermore, the presence of the 
type 1 factors IFN-y or IL-12 does not diminish the ability of IL-4 to 
promote the generation of type 2 cells (Seder et al., 1992b; Scmitt et al., 
1994). IL-4 also plays a major role in the development of type 2 responses 
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in vivo (Sadick et al., 1990; Chatelain et al. , 1992; Kopf et al. , 1993). The 
generation of type 2 cells is also augmented by IL-10 . In vitro studies 
suggest that IL-10 does not directly promote the generation of type 2 cells, 
rather it inhibits the development of type 1 cells (Hsieh et al. , 1992; 
Macatonia et al., 1993a). The mechanism by which IL-10 inhibits type 1 cell 
development is unclear, however IL-10 is known to act directly on 
macrophages which in turn prevent cytokine production by Thl clones 
(Fiorentino et al., 1991). Thus it is possible that IL-10 may act indirectly via 
APC to block the generation of type 1 cells. 
The differentiation of naive CDS+ T cells is also dependent on cytokines 
present during primary stimulation. The generation of classical MHC class 
I restricted, lytic, IFN-y producing CDS+ T cells in vitro is dependent on IL-
2 (Erard et al., 1985). IFN-y, in the presence of IL-2, may also influence CTL 
gen~ration (Maraskovsky et al., 1989). Other factors that promote the 
generation of CDS+ CTL include IL-1 and TNF-a (Vink et al., 1990), IL-6 
(Quentmeier et al., 1992; Kopf et al., 1994), IL-7 (Kos and Miillbacher, 1992) 
and IL-12 (Gately et al., 1993; Chouaib et al., 1994). In marked contrast, 
naive CDS+ T cells cultured in the presence of IL-4 lose the ability to 
express CDS, are not cytolytic and do not produce IFN-y (Erard et al., 1993; 
Tanaka et al., 1993). These cells express IL-4, IL-5 and IL-6 and are capable 
of helping B cells produce antibody (Erard et al., 1993; Tanaka et al., 1993; 
Cronin et al., 1995). 
The powerful influence of cytokines on the generation of particular 
immune responses raises the question of what stimulates these factors to 
be produced. The source of IL-4 that leads to priming of T cell IL-4 
production in vivo is unclear. In vitro studies indicate that IL-4 is 
required to induce T cells to produce IL-4 (Le Gros et al., 1990; Swain et al., 
1990). There is some speculation that the initial source of IL-4 is 
non-T cells such as activated mast cells or basophils (Plaut et al. , 1989; Ben-
Sasson et al., 1990; Romagnani, 1992). However, a recent study using IL-4 
deficient mice reconstituted with naive CD4 + T cells from congenic, 
normal mice, clearly demonstrated that these cells are capable of 
generating sufficient IL-4 for the induction of type 2 responses in v ivo 
(Schmitz et al., 1994). It is therefore interesting to note that a rare 
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population of CD4+ T cells which express the marker NK 1.1 have been 
found to express IL-4 independently of prior exposure to IL-4 (Yoshimoto 
and Paul, 1994). 
The early production of IL-12 and IFN-a may promote the production of 
type 1 responses. In the absence of IL-4, IL-12 induces the differentiation of 
T cells into cells that secrete IFN-y (Seder et al., 1993) while IFN-a inhibits 
IL-4 production (Finkelman et al., 1991). Furthermore, IL-12 and IFN-a 
activate NK cells and stimulate IFN-y production (Biron et al., 1984; 
Kobayashi et al., 1989) which may further augment the development of 
type 1 cells (Varkila et al., 1993). Macrophages produce IL-12 and IFN-a 
following stimulation with viruses (Samuel, 1991; Coutelier et al., 1995) 
parasites (Sypek et al., 1993; Gazzinelli et al., 1994b) and bacterial antigens 
(D'Andrea et al., 1992). These observations suggest that NK cells and 
mac~ophages are important factors in the induction of type 1 cytokines and 
CMI responses (Romagnani, 1992). 
The dose of antigen also plays a role in determining the type of immune 
response which is generated. Bretscher et al., (1992) demonstrated that 
BALBI c mice infected with low doses of L. major generate an effective and 
long lasting CMI response. In marked contrast, when these mice were 
given much higher doses of L. major an ineffective humoral response 
resulted. This extends similar findings of (Parish and Liew, 1972) with 
inert immunogenic proteins to infectious, replicating organisms. The 
potential for manipulation of the class of immune response generated by 
the amount of antigen given clearly has important implications for the 
rational design of vaccines. 
The type of APC involved in the generation of an immune response may 
also influence the development of type 1 or type 2 cells. Gajewski et al ., 
(1991b) showed that T cells prepared from the same lymph nodes could 
develop in to type 1 or type 2 cells depending on the APC used in the 
culture system. Stimulation of lymph node cells in the presence of B cells 
promoted the generation of type 2 CD4 + T cells, while macrophages or 
dendritic cells were required for maximal proliferation of type 1 CD4+ 
T cells. Although co-factors responsible for these differences were not 
identified, they were shown to be produced by the APCs themselves. 
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Other studies have shown that such effects may be mediated by cytokines. 
IL-12 produced by macrophages (Hsieh et al., 1993), or the action of IL-10 on 
macrophages or dendritic cells (Hsieh et al ., 1992) can influence the 
phenotype of CD4 + T cells generated in v itro. In contrast, IL-4 directs the 
development of type 2 cells independently of the APC used (Seder et al., 
1992b). 
1.3.3 Cross-regulation of the immune response 
As described above in Section 1.3.2, type 1 and type 2 cytokines regulate the 
expression of the opposite subset during the induction of an immune 
response. Fully differentiated CD4 + T cells can also exert such cross 
regulation. Early studies of T cell clones showed that IFN-y produced by 
Thl clones suppressed the proliferation of Th2 clones but not their 
production of cytokines such as IL-4 (Fernandez-Botran et al ., 1988; 
Gajewski and Fitch, 1988). In contrast, the type 2 cytokine IL-10, inhibits 
IFN-y production by Thl clones (Fiorentino et al., 1991). This mechanism 
of in vitro cross-regulation by Thl and Th2 clones may underlie immune 
regulation in vivo and therefore explain the exclusive generation of DTH 
or antibody responses described by (Parish and Liew, 1972). Subsequent 
investigations of cytokine cross-regulation in vivo found that neutralising 
anti-IL-4 or anti-IFN-y mAb did not alter the immune response in mice 
with established L. major infection (Belosevic et al., 1989; Sadick et al., 
1990; Chatelain et al., 1992). Further studies demonstrated that CMI against 
L. major can be markedly downregulated by in vivo therapy with IL-4 and 
IL-10 (Powrie and Coffman, 1993b). In contrast, administration of IL-12 to 
mice with an established humoral (type 2) immune response did not alter 
expression of IL-4 (Wang et al., 1994). This phenomenon may be due to 
impaired IL-12 induced signalling in cells expressing type 2 factors (Szabo 
et al., 1995). These findings suggest that only in some situations cytokines 
may prove useful as therapeutic agents in the treatment of long term 
diseases by converting an ineffectual immune response into one that 
mediates protection. 
Type 1 and type 2 cytokines also act on non-CD4+ T cells and modulate 
their function. For example, IL-4 inhibits macrophage cytotoxicity by 
downregulating expression of nitric oxide (Bogdan et al., 1994), while IFN-y 
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activates macrophages and induces nitric oxide expression (Ding et al., 
1988). The role of cytokines in cross-regulating immune effector 
mechanisms is discussed in later sections. 
1.3.4 Cytokine responses in infectious disease 
The success of an immune response against an infectious organism 1s 
dependent on the activation of an appropriate set of immune effector 
responses. The inability to control a pathogen often results from the 
generation of an inappropriate immune response rather than a failure to 
generate an immune response at all (Bretscher et al., 1992; Powrie and 
Coffman, 1993a). A number of models of parasite infestation and bacterial 
infection exhibit marked polarisation of cytokine expression and type of 
immune response generated (Sher et al., 1992). Perhaps the model that 
best illustrates the marked exclusivity of type 1 and type 2 cytokine 
production in vivo is L. major infection of mice (reviewed in Reed and 
Scott, 1993). Infection of inbred mouse strains yields at least two distinct 
disease patterns. C3H/He or C57BL/ 6 mice produce a strong CMI response 
toward L. major that effectively clears the parasite. CD4 + T cells from these 
mice produce high levels of the type 1 cytokines IFN-y and IL-2 and low 
levels of type 2 factors such as IL-4 (Heinzel et al., 1989; Heinzel et al., 1991). 
In contrast, BALB/c mice produce a predominantly IgGl antibody response 
to infection with L. major and weak DTH responses which do not control 
infection. These mice eventually die from disseminated leishmaniasis. 
CD4 + T cells from infected BALB / c mice predominantly produce the type 2 
factors IL-4, IL-5 and IL-10 (Heinzel et al., 1989; Heinzel et al., 1991). 
Evidence that CD4+ T cells expressing type 1 factors mediate resistance to L. 
major was provided in adoptive transfer studies using T cell clones 
expressing different patterns of cytokines (Scott et al., 1988). 
Cytokine expression during viral infections also influences the 
development of an effective antiviral immune response. Resistance to 
viral infections with lymphocytic choriomeningitis virus (LCMVt 
ectromelia and vaccinia virus is dependent on the generation of antiviral 
CTL and the production of type 1 cytokines such as IFN-y (Klavinskis et al., 
1989; Leist et al., 1989; Ruby and Ramshaw, 1991; Karupiah et al., 1993a; 
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Carpenter et al., 1994). In sharp contrast, expression of IL-4 by recombinant 
vaccinia virus markedly impairs the generation of CTL and significantly 
delays viral clearance (Sharma et al., 1996). Furthermore, expression of 
type 1 cytokines IL-2, IFN-y and IL-12 are also downregulated. 
There are examples of immune responses where the pattern of cytokine 
expression is not highly polarised. For example, analysis of cytokine 
mRNA and protein production by T cells from the lungs and lymph nodes 
of mice infected with influenza virus demonstrate that both type 1 and 
type 2 factors are expressed during infection (Carding et al., 1993; Sarawar 
and Doherty, 1994). These data suggest that the preferential generation of a 
type 1 response is not essential to the clearance of some viral infections. 
A strong CMI response ( characterised by expression of type 1 cytokines) is 
thought to be important in the control of HIV infection (Clerici et al., 1992; 
Salk et al., 1993). Recently, Clerici and Shearer, (1993) proposed that the 
progression of HIV infected individuals to AIDS was due to the gradual 
loss of CD4 + T cells which produce type 1 cytokines and increased 
production of Th2 cytokines. Other investigations of cytokine expression 
during HIV infection have tended not to support this type 1-type 2 switch 
model. Using in situ hybridisation to detect cytokine expression in the 
lymph nodes of HIV infected individuals, Emile et al., (1994) found no 
evidence for elevated IL-4 expression at any stage of disease, while 
expression of IL-2 and IFN-y were markedly elevated. In a limited study, 
Graziosi et al., (1994) showed no increase in lymph node mRNA 
expression IL-4 mRNA. Furthermore, Maggi et al., (1994) failed to confirm 
that cytokine production by peripheral blood mononuclear cells to recall 
antigens switched from type 1 to a type 2 cytokine production pattern 
however, an increase in cells with a Th0 phenotype was observed. In a 
reappraisal of their original model, Clerici and Shearer, (1994) suggested 
that these observations which are inconsistent with their original 
hypothesis may reflect differences in experimental design and the material 
used. 
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1.4 CELLULAR ANTIVIRAL EFFECTOR MECHANISMS 
1.4.1 NK cells 
Natural killer (NK) cells are large, granular, CD2+, CD3-, TcR-, Ig-
lymphocytes which lyse a number of virus infected and tumour cells 
without prior stimulation (reviewed in Trinchieri, 1989). NK cells 
mediate antiviral effects in vivo by lysing infected cells and producing 
antiviral cytokines including IFN-y and TNF-a (Trinchieri, 1989). Natural 
killer cells also produce GM-CSF and IL-3 (Perussia, 1991) Together, these 
factors have roles in the activation of other immune cells, such as 
macrophages (Bancroft et al., 1987) to effector function and may promote 
the generation an adaptive immune response (Romagnani, 1992; Scharton 
and Scott, 1993). 
The _nature of the receptors used by NK cells to recognise tumour cells or 
cells infected with virus is unclear. A number of investigators have 
demonstrated that expression of MHC class I molecules protects tumour 
cells from lysis by NK cells (Karre et al., 1986; Liao et al., 1991). 
Furthermore, Storkus et al., (1991) showed that mutations in the peptide 
binding groove of MHC class I molecules could render tumour cells 
susceptible to lysis by NK cells. These observations suggest that NK cells 
recognise MHC class I molecules associated with peptides derived from self 
proteins and that loss of MHC class I expression or displacement of self 
peptides with mutant self or viral peptides could render such a cell 
susceptible to NK cell mediated lysis (Raulet, 1992). 
Viral infection can enhance NK cell cytotoxic activity and stimulated their 
proliferation of these cells. These effects can be induced by IFN-cx and 
IFN-P which is produced by infected cells and activated macrophages 
(Biron and Welsh, 1982; Biron et al., 1983; Biron et al., 1984; Bigda et al., 
1994). In addition, viral peptides and recognition of virus infected target 
cells activate NK cells (Welsh, 1986). Other cytokines, such as IL-12 
(Kobayashi et al., 1989) and IL-2 (Biron, 1990) activate NK cells and induce 
their proliferation, while factors such as IL-10 and TGF-P 1 inhibit NK cell 
function (Su et al., 1991). 
13 
The early activity of NK cells during virus infection permits them to act as 
a front line defence mechanism well before the generation of an adaptive 
immune response. Moreover, the rapid production of cytokines by NK 
cells may promote the generation of effective innate and adaptive 
immune responses. 
1.4.2 Macrophages 
Resident tissue macrophages and blood monocytes (referred to here as 
macrophages) are bone marrow derived mononuclear phagocytic cells. 
These cells are major anti-viral effectors of both the innate and adaptive 
immune responses and are integral to the induction and regulation of the 
latter (Blanden, 1982). During virus infections, macrophages mediate 
antiviral activity by direct actions on virus infected cells, or by promoting 
or down regulating various immune functions (Morohan et al., 1985). 
Activated macrophages can directly limit virus replication by producing 
antiviral cytokines such as IFN-~ and TNF-cx (Goldfield and Maniatis, 
1989) virucidal reactive oxygen intermediates (Chase and Klebanoff, 1992), 
reactive nitrogen intermediates (RNI; Croen, 1993; Karupiah et al., 1993b ); 
see also Section 1.5.4). Macrophages also phagocytose viral particles 
(reviewed in Kaufmann and Reddehase, 1989) and mediate antibody 
dependent cellular cytotoxicity against virus infected cells (see Section 
1.5.6). 
Macrophages promote the generation of antiviral immune responses in a 
number of ways. Their production of cytokines such as IFN-cx and IL-12 
enhances NK cell cytotoxicity and cytokine production (Biron et al., 1984; 
Kobayashi et al., 1989) and promotes generation of a CMI response 
(Finkelman et al., 1991; D'Andrea et al., 1992; Manetti et al., 1993). 
Macrophages also present phagocytosed extracellular antigens to CD4+ T 
cells 1n association with MHC class II molecules, thereby initiating 
antiviral immune responses. Following activation with IFN-y , 
macrophage expression of MHC class II molecules is upregulated (Wong et 
al., 1983) which, in turn, may increase antigen presentation to CD4+ T 
lymphocytes. 
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Activated macrophages can also modulate immune responses. Production 
of high levels of nitric oxide by macrophages can suppress T cell 
proliferation and antibody production (Albina et al., 1991; Al-Ramadi et al., 
1992). Other factors produced by macrophages, such as prostaglandins or 
steroid hormones impair B cell proliferation (Albina et al., 1991) or alter 
the production of cytokines by T cells (Daynes et al., 1991) respectively. 
The stimulation of macrophages to effector function is a multistep process 
requiring several signals. These signals can be delivered by cytokines, in 
particular IFN-y and TNF-a. IFN-y can provide the first signal to prime 
macrophages (Nathan et al., 1983; Pace et al., 1983). Primed macrophages 
do not exhibit cytotoxic activity and require a further signal to become 
activated and cytotoxic (Pace et al., 1983). Following priming with IFN-y, 
macrophages express TNF-a receptors (Ruggiero et al., 1986) and TNF-a 
whic!l stimulates the macrophage further (Philip and Epstein, 1986). 
Bacterial LPS can also prime macrophages to produce TNF-a and respond 
to secondary stimuli (such as TNF-a) and has been used as a convenient 
agent for macrophage stimulation. However, where bacteria are absent, as 
in viral infections, other mechanisms of macrophage activation occur. 
Activated T cells can provide the signals necessary for macrophage 
activation (reviewed in Stout, 1993), for example IFN-y and TNF-a 
produced by activated type 1 T cells. IFN-y primed macrophages may also 
be activated by antigen specific cell surface interactions with activated, but 
not resting, type 1 or type 2 T cells (Stout and Suttles, 1993; Tao and Stout, 
1993). Recently Tian et al., (1995), demonstrated that signalling occurs via 
ligation of CD40 and ICAM-1 (on the macrophage) by CD40L and LFA-1 (on 
the T cell). Fixed Th2 cells may activate IFN-y primed macrophages which 
indicates that cell surface interactions between type 1 and type 2 T cells and 
macrophages may be similar (Stout and Suttles, 1993). 
Macrophage activity is down-regulated by the cytokines IL-4, IL-10 and 
TGF-~. These cytokines inhibit macrophage effector functions including 
NO synthesis (Vodovotz et al., 1993; Bogdan et al., 1994) and the 
production of antiviral cytokines such as TNF-a (Bogdan et al., 1991; 
Gautam et al., 1992; Hausmann et al., 1994). Furthermore, IL-4, IL-10 or 
TGF-~, either alone or together, down-regulate macrophage cytotoxicity 
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(Oswald et al., 1992). In addition, IL-4 inhibits the ability of macrophage 
produced IL-12 to induce type 1 CD4+ T cell development (Hsieh et al., 
1993; Schmitz et al., 1994\ while IL-10 also suppresses the ability of 
macrophages to generate type 1 cells (Hsieh et al., 1992). 
1.4.3 Cytotoxic T cells 
The recognition and killing of virus infected cells by antigen specific, 
activated, cytotoxic T cells (CTL) is a major antiviral effector mechanism of 
the adaptive immune response (Blanden, 1974). Both CDS+ and CD4+ T 
cells exhibit cytotoxicity (Zinkernagel and Althage, 1977; Lukacher et al., 
1984; Lukacher et al., 1985) however MHC class I restricted (CDS+) CTL are 
thought to constitute the main antiviral CTL in most viral infections 
(Zinkernagel and Doherty, 1979). 
The _requirement of non-cytolytic CD4 + T helper cells for the generation of 
antiviral CDS+ CTL is variable. In vitro studies indicate that CD4 + T cells 
augment the development of CDS+ CTL responses to ectromelia, 
influenza, Sendai virus and vesicular stomatitis virus (Pang et al., 1976; 
Ashman and Miillbacher, 1979; Ciavarra, 1990). CD4+ T cells promote the 
generation of antiviral CDS+ CTL by providing cytokines active in CTL 
development (see Section 1.3.2.). CD4+ T cells may also be required for the 
generation of optimal CDS+ antiviral CTL responses in vivo, during 
infection with Sindbis virus (Kast et al., 1986) or mouse hepatitis virus 
(Williamson and Stahlman, 1990). In contrast, a number of studies have 
shown that mice lacking CD4+ T cells develop effective antiviral CDS+ CTL 
against vaccinia (Buller et al., 1987at influenza (Allan et al., 1990\ LCMV 
(Rahemtulla et al., 1991) or herpes simplex virus-1 (HSV-1; Nash et al., 
1987). These experiments suggest that CD4 + T cells are not essential for the 
generation of CDS+ CTL, however they do not preclude a role for CD4 + T 
cells in normal mice. It seems likely that CD4+ T cells play a role in the 
generation of CDS+ CTL, given that CDS+ T cell development is influenced 
by cytokines such as IL-2, IFN-y, IL-4 and IL-6 which are produced by 
activated CD4+ T cells (see Section 1.3.2). 
Once activated, CTL do not require co-stimulation by target cells to mediate 
lysis (Azuma et al., ·1993:; Harding and Allison, 1993). Lysis by activated 
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CTL is a sequential process beginning with their adhesion to the virus 
infected target cell. This is followed by T cell receptor ligation (recognition) 
by antigen associated with MHC on the target cell surface (reviewed in 
Berke, 1994). Following recognition, a 'lethal hit' is delivered to the target 
cell which leads to its death. The CTL then dissociates from the target cell 
and may carry out several more rounds of target cell lysis. 
The mechanism by which CTL lyse virus infected cells has been a topic of 
debate for many years. Two main models have been developed to explain 
CTL mediated lysis. It has been proposed that lysis of target cell 
membranes occurs via secreted pore-forming proteins such as perforin 
(analogous to complement proteins) as well as proteases (Squier and 
Cohen, 1994). Alternatively, CTL mediated lysis may be due to the 
triggering of apoptosis in target cells by ligation of the Fas molecule on the 
surfa~e of target cells (Rouvier et al., 1993; Stalder et al., 1994). Neither 
model is sufficient to fully explain the CTL mediated lysis observed in all 
systems, which implies that two mechanisms of lysis may be acting (Berke, 
1994). 
Following recognition of target cells, CTL also produce cytokines such as 
IFN-y and TNF-a (Morris et al., 1982; Fong and Mosmann, 1990; Carpenter 
et al., 1994). The antiviral activity of these factors, may directly limit virus 
replication within infected cells and also protect nearby cells from 
infection. Furthermore, IFN-y induces upregulation of MHC class I 
expression, which may enhance lysis of target cells (Bukowski and Welsh, 
1985). The importance of antiviral cytokines in CTL-dependent immunity 
to viral infection is illustrated by studies of immunity to vaccinia virus. 
Clearance of vaccinia virus is dependent on antiviral CDS+ T cells (Ruby 
and Ram.shaw, 1991). The generation of antiviral CTL was found to be 
unaffected by neutralisation of IFN-y in vivo using mAb, however 
resolution of infection was markedly impaired. These results indicate that 
antiviral CTL limit vaccinia virus replication by focussing the expression 
of antiviral cytokines at the site of virus replication (Ruby and Ram.shaw, 
1991; Ramsay et al., 1993). 
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1.4.4 B cells 
B cells mediate effector function by secreting antibodies. These molecules 
are globular proteins that bind to 3 dimensional shapes of antigens 
(epitopes) with high specificity and affinity. Antibodies mediate antiviral 
effects via a number of mechanisms which are discussed in sections 1.5.5 
and 1.5.6. 
The T cell-dependent activation of B cells is somewhat analogous to T cell 
activation, in that 2 signals are required. However, the process of 
activation is fundamentally different. The first event leading to B cell 
activation is the specific binding of antigen to surface immunoglobulin (lg; 
Signal 1). Following antigen binding, the antigen is endocytosed and 
proteolyticly degraded in endosomal compartments. Short peptide 
fragments of the degraded antigen are then expressed on the cell surface in 
association with MHC class II molecules (Hodgkin and Basten, 1995). The 
role of antigen binding to lg in B cell activation has long been a topic for 
debate (Langman and Cohn, 1991; Moeller et al., 1991). It appears that the 
strength of intracellular signalling by surface lg influences subsequent B 
cell responses. Multivalent antigens such as polysaccharides or high 
concentrations of monovalent antigens lead to the delivery of strong 
intracellular signalling by surface lg which, in turn, leads to T cell 
independent B cell responses (de Franco et al., 1987; Mangini et al., 1992). 
On the other hand, low concentrations of monovalent antigens are not 
sufficient to induce B cell proliferation and the B cell requires further 
signals to proliferate and produce antibody. 
T cell-dependent activation of B cells usually requires stimulatory signals 
or 'help' from activated CD4+ T cells (reviewed in Parker, 1993). The 
recognition of peptide associated with MHC class II molecules by the TcR 
of activated T cells (Signal 2) coupled with costimulation by CD40-CD40L 
receptor-ligand pairs (B cell-T cell; Armitage et al., 1992; Noelle et al., 1992) 
induce B cells to proliferate and differentiate. It would appear that ligation 
of CD40 by CD40L is essential for T cell dependent B cell activation as mice 
treated with anti-CD40L antibodies fail to generate antibodies toward a 
number of antigens (Foy et al., 1993). Furthermore, mice lacking CD40 
exhibit impaired lg class switching and germinal centre formation. 
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Moreover, X-linked hyper-IgM syndrome in humans, which is 
characterised by defective lg class switching and no germinal centre 
formation, is due to mutation in the CD40L gene (Allen et al. , 1993). CD4+ 
T cell clones have been shown to be able to provide costimulation to B 
cells via cell surface TNF-a, however it is unclear if this mechanism of 
costimulation is important in vivo (Aversa et al. , 1993; Macchia et al., 
1993). Activated CDS+ T cells that produce IL-4, IL-6 and IL-10 may also 
provide help for naive B cells (Erard et al., 1993). A recent study has 
shown that CD8+ T cells which produce type 2 cytokines also express 
CD40L and provide help for B cells via ligation of CD40 (Cronin et al., 
1995). 
Following activation, B cell development occurs under the influence of 
cytokines such as IL-4, IL-5, IL-6, IL-10, IFN-y and IFN-a, which modulate B 
cell proliferation, differentiation and the isotype of antibody produced 
(Snapper and Paul, 1987; Hodgkin et al., 1990; Finkelman et al., 1991). 
1.5 NON-CELLULAR ANTIVIRAL EFFECTOR MECHANISMS 
1.5.1 Interferon 
The IFNs are a family of cytokines produced during viral infections. IFNs 
exhibit direct antiviral activity in vitro via the induction of enzymatic 
pathways and the synthesis of proteins which limit viral replication and 
inhibit production of progeny virus (Samuel, 1991). In addition, IFNs 
promote the generation of antiviral immune responses via the activation 
and differentiation of immune cells to effector function. 
IFNs are classified into 2 separate groups. Type I IFN (IFN-a, IFN-~ , 
IFN-CD) are related proteins that bind to the same receptor. There are over 
20 distinct genes encoding IFN-a while there is only one IFN-~ and one 
IFN-CD. Type II IFN (IFN-y) is genetically and structurally distinct from 
Type I IFN and acts via a separate receptor (Samuel, 1991). Viral infection 
can induce the expression of Type I IFN by a wide range of cells including 
macrophages, T cells, B cells, fibroblasts and epithelial cells. In contrast, 
viral infection does not directly stimulate IFN-y production. Rather, IFN-y 
is expressed by NK cells following their activation by cytokines or by target 
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recognition and by T cells after antigenic or mitogenic stimulation (Banda 
et al., 1983; Sandvig et al., 1987). 
IFN-a, IFN-~ and IFN-y induce an antiviral state in uninfected cells which 
limits virus replication. IFNs mediate their antiviral effects by inducing 
expression of a number of proteins (reviewed in Staeheli, 1990; Samuel, 
1991). IFN induces the expression of 2',5 '-oligoadenylate synthetase which 
catalyses the formation of 2',5'-oligoadenylic acid in the presence of double 
stranded RNA which is formed during virus replication. The 2',5'-
oligoadenylic acid activates an endoribonuclease which degrades both 
cellular and viral RNA thus inhibiting virus replication (Kerr and Brown, 
1978; Baglioni, 1979). As well as 2',5'-oligoadenylate synthetase, IFN 
induce the expression of the protein kinase Pl/ eIF-2. When activated by 
autophosphorylation (in the presence of double stranded RNA) this kinase 
phosphorylates the a subunit of protein synthesis initiation factor eIF-2 
which inhibits protein synthesis by blocking the initiation of translation 
(Samuel, 1991). The induction of these enzymes and their effects on virus 
growth are dependent on the type of cell affected and the nature of the 
virus (Staeheli, 1990). The antiviral effects of each IFN species are often 
augmented by interactions with other types of IFN (Fleishmann and 
Schwarz, 1981) or cytokines such as TNF (Wong and Goeddel, 1986; Wong 
et al., 1988). 
The antiviral effects of IFN in vivo may be mediated by direct action on 
cells, as described above, or by activation of cellular effector functions. 
IFN-a,-~ 1 -y are involved in the activation of NK cells (Biron and Welsh, 
1982; Biron et al., 1983), while IFN-y induces macrophage activation (Pace 
et al., 1983; Ding et al., 1988) and generation of CTL (Maraskovsky et al ., 
1989). In addition, IFN-a and IFN-y modulate the isotype of antibody 
secreted by B cells, inducing the production of IgG2a while suppressing the 
production of IgE (Snapper and Paul, 1987; Sadick et al., 1990; Finkelman et 
al., 1991). 
IFNs have marked effects on the regulation of MHC expression. IFN-a, 
IFN-~ and IFN-y all induce MHC class I expression but only IFN-y 
promotes MHC class II expression (Wong et al., 1983; Bukowski and 
20 
Welsh, 1985). Treatment of virus infected cells with IFN renders them 
more susceptible to lysis by CTL (Bukowski and Welsh, 1985). This may be 
due to enhanced expression of MHC molecule-associated viral peptides on 
the surface of infected cells making these cells more recognisable by CTL. 
Furthermore, the induction of MHC class II by IFN-y may also increase the 
presentation of antigen to CD4 + T cells thereby promoting the generation 
of adaptive immune responses. 
The importance of Type I and Type II IFN in resistance to viral infection 
has been demonstrated using specific antibodies to block IFN activity 
(Gresser et al., 1976; Klavinskis et al., 1989; Leist et al., 1989; Ruby and 
Ramshaw, 1991; Karupiah et al., 1993b ), genetically altered mice that lack 
functional IFN or IFN receptor (Dalton et al., 1993; Huang et al., 1993) or 
administration of purified IFN protein (Hekman and Trapman, 1985; 
Schij~s et al., 1988; Ruprecht et al., 1990). Furthermore, recombinant 
vaccinia virus encoding murine IFN-y is markedly attenuated in both 
normal and athymic nude mice (Kohonen-Corish et al., 1990). The 
mechanism of virus attenuation is unclear, however the rapid clearance of 
virus is consistent with direct antiviral activity of IFN-y or activation of 
mononuclear phagocytes to antiviral effector function (Karupiah et al., 
1993a). It should be noted, however, that the course of infection with 
influenza virus was unaffected by treatment with antibodies to type I IFN 
(Gresser et al., 1976), while mice lacking functional IFN-y are no more 
sensitive to infection than wild type mice (Graham et al., 1993). These 
observations indicate that IFN mediate many antiviral effects in vivo, 
although IFN may not be essential for an effective immune responses in 
all viral infections. 
1.5.2 Tumour necrosis factor-a 
TNF-a is a pleotropic cytokine with a variety of effects in normal 
physiology and in immunity to a variety of infectious agents (Vassalli, 
1992). Activated macrophages are a major source of TNF-a in vivo, 
however NK cells, T cells and mast cells also produce this factor (Beutler 
and Cerami, 1989). TNF-a occurs as a soluble or cell surface membrane-
bound homotrimer and mediates its action through 2 distinct 55 kDa 
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(TNF-RI) and 75 kDa (TNF-RII) cell surf ace receptors (Tartaglia and 
Goeddet 1992). The role of each receptor is unclear, however there is 
some evidence for involvement of both receptors in TNF-a induced 
cytotoxicity and LPS induced toxic shock (Pfeffer et al., 1993; Bigda et al., 
1994). Studies by Wong et al., (1992) indicate that antiviral activity of 
TNF-a is signalled through TNF-RI. 
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TNF-a exhibits direct anti-viral activity against a wide range of RNA and 
DNA viruses in vitro (Mestan et al., 1986; Wong and Goeddel, 1986; Wong 
et al., 1988). These antiviral effects of TNF-a include the inhibition of viral 
replication in infected cells, protection of uninfected cells from infection 
and killing of infected cells. These effects are enhanced synergistically by 
IFN-y (Wong and Goeddel, 1986; Wong et al., 1988). The mechanism by 
which TNF-a mediates its direct antiviral effect is unclear. TNF-a 
mediates cytotoxicity toward tumour cells by inducing these cells to 
undergo apoptosis (Dealtry et al., 1987; Laster et al., 1988) or generate toxic 
free oxygen radicals (Wong and Goeddel, 1988). These mechanisms may 
also mediate the antiviral effects of TNF-a. In addition, TNF-a can inhibit 
viral gene transcription in vitro thereby impairing virus growth (Feduchi 
et al., 1989; Lucin et al., 1994). 
TN F- a has also been shown to exert antiviral effects in vivo. 
Administration of recombinant TNF-a limits the replication or pathology 
associated with Thieler's virus (Paya et al., 1990), HSV-1 (Rossol-Voth et 
al., 1991), Friend murine leukaemia virus (Johnson et al., 1988) and 
encephalomyocarditis virus (Sriram et al., 1991). In contrast, systemic 
administration of TNF-a or TNF-a neutralising antibodies had no effect 
on LCMV infection (Klavinskis et al., 1989; Leist and Zinkernagel, 1990). 
In vivo TNF-a may mediate its antiviral effects directly by inhibiting virus 
replication in cells as described above. Alternatively, TNF-a may activate 
NK cells, macrophages or T cells to effector function (reviewed in Vassalli, 
1992). Recombinant vaccinia virus encoding TNF-a was found to be 
markedly attenuated in vivo (Sambhi et al., 1991). This effect apparently 
occurred independently of lymphocytes, as SCID mice recover from 
infection with this virus (J. Ruby, JCSMR, personal communication). This 
finding suggests that the adapti e immune system may not be essential for 
the anti iral effect of T F-a therapy . 
1.5.3 L ymphotoxin (TNF-~) 
Lymphotoxin (LT) is a c tokine which has a major role in lymphoid cell 
de elopment and also exhibits antiviral activity. The expression of LT is 
largely restricted to activated lymphocytes (Paul and Ohara, 1988). 
Recently, mice lacking LT were found to lack secondary lymphoid tissues 
(Togni et al., 1994), indicating a role for this factor in lymphocyte 
de elopment. LT and TNF-a are related molecules exhibiting limited but 
significant sequence homology (Pennica et al., 1984). Despite the lack of 
high sequence conser ation, LT and T F-a bind to the same receptors 
(Aggar al et al., 1985) and appear to mediate similar effects in target cells 
(Ruddle, 1992). 
In light of these observations, it is not surprising that LT also exhibits 
antiviral acti ity against a number of RNA and D A viruses (Aderka et 
al., 1985; Wong and Goeddel, 1986). Furthermore, the antiviral activity of 
LT is augmented synergistically by IF -y (Wong and Goeddel, 1986). LT 
can also induce apoptosis (Schmid and Rouse, 1992) which may account 
for its direct antiviral activity. The in vivo relevance of LT in antiviral 
immune responses is unclear, however its role in lymphoid cell 
de elopment suggests that LT may be involved in the activation of T cells 
as well as acting as an effector molecule. 
1.5.4 N itric oxide 
itric oxide ( 0) has many functions in mammals, including neural 
signalling, maintenance of vascular tone and host defence against a variety 
of infectious organisms (re iewed in athan, 1992). 0 has been shown 
to limit tumour cell replication (Drapier and Hibbs Jr, 1986; Kwon et al., 
1991) and is toxic to a number of parasites (Adams et al., 1990; Green et al., 
1990), bacteria (Stuehr and arletta, 1987) and helminths Games, 1989). 
Recentl , TO has been shown to inhibit replication of a number of D A 
iruses such as ectromelia, accinia (Karupiah et al., 1993b; Harris et al., 
1995; Karupiah and Harris, 1995) and HSV-1 (Croen, 1993). 0 mediates 
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these effects by inactivating enzymes with iron-sulphur centres by forming 
nitrosyl-iron sulphur complexes (Lancaster and Hibbs, 1990; Pellat et al., 
1990). This process inhibits key enzymes in the Krebs cycle (cis-aconitase 
(Drapier and Hibbs Jr, 1986) and mitochondrial electron transport pathway 
(NADH: ubiquinone oxidoreductase and NADH: succinate oxidoreductase; 
(Granger et al., 1980; Granger and Lehninger, 1982; Stuehr and Nathan, 
1989). In addition, NO inhibits the activity of ribonucleotide reductase, a 
rate limiting enzyme in the synthesis of deoxynucleotides. Inactivation of 
this enzyme by NO prevents the replication of pathogens and tumour cells 
(Kwon et al., 1991; Lepoivre et al., 1991). NO may also mediate toxic effects 
by reaction with superoxide anion which generates the highly reactive and 
toxic hydroxyl radical (Ischiropoulos et al., 1992). 
NO is generated by the enzyme nitric oxide synthase (NOS). The enzyme 
catalyses the oxidation of L-arginine to L-citrulline and NO and is 
inhibited by L-arginine analogues such as NG-monomethyl-L-arginine 
(L-NMA) and amino guanidine (Hibbs et al., 1987; Marletta et al., 1988). 
Three isoforms of NOS have been described and these are categorised into 
two groups based on their mechanism of activation (Nathan, 1992). 
Macrophage derived NOS (iNOS) is inducible by LPS or IFN-y (Stuehr and 
Marletta, 1987) and is active independent of elevated intracellular calcium 
ion concentration (Cho et al., 1992). Other cytokines, such as TNF-a, 
IFN-a, IFN-~ and IL-1 alone do not stimulate macrophages to express 
iNOS, however these factors have been shown to synergise with IFN-y or 
LPS to enhance NO production (LDing et al., 1988n. Human monocytes or 
monocyte-derived macrophages also appear to produce NO in response to 
alternative stimuli including some tumour cells (Isobe and Nakashima, 
1993; Zembala et al., 1994) and viral peptides (Mollace et al., 1993; 
Pietraforte et al., 1994). In contrast, brain and endothelial cells express 
different forms of calcium dependent NOS which are expressed 
constitutively (cNOS). In general, cNOS activity is not augmented by 
agents such as LPS or cytokines, but rather by agents such as excitatory 
amino acids, bradykinin, leukotrienes, thrombin and calcium ionophore 
(Braciale et al., 1987; Moncada et al., 1991). 
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1.5.5 Antibody 
Antibodies exhibit antiviral activity by binding and neutralising infectious 
virus. Virus neutralisation by antibody is a complex phenomenon. It 
occurs via a number of mechanisms which may prevent virus attachment 
to, or entry of virus into, target cells, or subsequent events in virus 
replication (reviewed in Dimmock, 1993). In addition, antibody facilitates 
the specific recognition of virus infected cells by cytotoxic cells in a process 
described as antibody dependent cellular cytotoxicity (ADCC; Hashimoto et 
al., 1983; Alsheikhly et al., 1984; Ljunggren et al., 1987)). Cells expressing 
receptors for the Fe region of antibodies, such as activated macrophages, 
NK cells and some polymorphonuclear cells, are capable of mediating 
ADCC (Hashimoto et al., 1983). Interaction of these cytotoxic cells with 
virus infected cells via antibody - antigen ligation induces the lysis of 
target_ cells. 
The relative importance of antibody in resistance to primary viral 
25 
infection is variable. Resis~ance to primary infection with yellow fever, polio or 
coxsackie viruses requires circulating antibody, possibly to reduce viraemia 
(Mims, 1987). In contrast, the importance of antibody during primary 
infections with vaccinia or HSY is limited (Mims, 1987; Novembre et al., 
1989; Schmid and Rouse, 1992). In marked contrast, antibodies play an 
important role in the immune response to secondary or subsequent 
infections (Kris et al., 1985). The presence of antibody at the time of 
infection facilitates a very rapid response which occurs well before other 
immune effector functions (such as macrophages, CTL) are activated. 
1.5.6 Complement- Alternative and classical pathways 
The complement system is a multistep, multiprotein effector mechanism 
which, upon activation, leads to a breakdown in the integrity of cell 
surface membranes and the death of affected cells or to the inactivation of 
enveloped viruses (Liszewski and Atkinson, 1993). Two modes of 
complement activation have been described. In the classical pathway, 
complement is activated by IgM or IgG antibody bound to the surface of 
microorganisms or infected host cells. The antibody binds the first 
complement protein which leads to a cascade of proteolysis affecting the 
rema1n1ng complement proteins. The cascade culminates 1n the 
formation of the membrane attack complex (MAC) from several 
complement proteins which leads to lysis of affected cells. The 
complement cascade can also be activated at an intermediate step (the 
alternative pathway) which also leads to the formation of the MAC. In 
contrast to the classical pathway, the alternative pathway is activated in the 
absence of antibody. Rather, the deposition of the complement 3b (C3b) 
protein in an 'activating surface' such as the surface of an infecting bacteria 
or virus leads to the activation of the complement cascade and the 
formation of the MAC. A number of complement proteins have other 
roles in the immune system. Proteins such as C3b facilitate opsonisation 
of microorganisms by phagocytes while others including C3a and C5a act as 
leucocyte chemoatractants and promote inflammation (Frank and Fries, 
1991). 
Complement has been shown to be involved in the immune response 
toward a number of viruses. Mice depleted of complement by treatment 
with cobra venom factor suffer more severe infections with Sindbis or 
influenza viruses (Hicks et al., 1978; Hirsh, 1982). Complement may exert 
its antiviral effect by lysing infected cells. For example cells infected with 
Sindbis, VSV, measles or respiratory syncytia viruses activate complement 
via the alternative pathway which leads to their lysis (Hirsh, 1982). The 
binding of the C3b protein to viruses can also augment their uptake and 
destruction by macrophages (Frank and Fries, 1991). A number of viruses 
such as vaccinia and herpes simplex virus are able to evade the effects of 
complement by encoding proteins which inhibit the activation of the 
complement cascade (reviewed in Fishelson, 1994; Issacs and Moss, 1995). 
This finding suggests that evasion of the antiviral effects of complement 
may be important to the persistence of these viruses. 
Complement may also be involved in the pathogenesis of viral infections. 
For example, viruses such as HIV can utilise bound C3b to augment its 
uptake by macrophages and facilitate infection of these cells (reviewed in 
Marschang et al., 1994). Viruses may also use cell bound complement 
proteins as cellular receptors which allow infection of these cells. This 
mechanism is employed by Epstein Barr virus which uses C2 protein 
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present on B cells to bind to and subsequently infect these cells (Fishelson, 
1994). J 
1.6 THE RETROVIRUSES 
1.6.1 Definitions and taxonomy 
The retroviruses are small ( 60-120 nm) enveloped RNA viruses with a 
unique defining replicative cycle in which the RNA genome is transcribed 
into DNA and then integrated into the genome of the infected cell (Teich 
et al., 1982; Francki et al., 1991; Garfinket 1992; Poulet et al., 1994). 
Retroviruses are a ubiquitous family of viruses which have been isolated 
from a multitude of vertebrate animals including mammals, amphibians 
and fish as well as invertebrates such as molluscs and even fungi (Teich et 
al., 1982; Garfinkel, 1992; Poulet et al., 1994). Many of these viruses are 
exog~nous infectious agents, however a number exist as endogenous 
proviruses in the germ line and are inherited as Mendelian genes (Teich et 
al., 1982). 
Up until 1991, the family Retroviridae was divided into three subfamilies, 
Oncornavirinae, Lentiviranae and Spumaviranae, based on virion 
structure and pathogenicity (Murphy and Kingsbury, 1990). These 
classifications were not supported by analysis of retroviral genetic structure 
and nucleotide and amino acid sequence comparison, which led to a 
re-classification in 1991. The family Retroviridae was divided into seven 
genera which are Lentivirus, Spumavirus and five other as yet unnamed 
genera, which contain members of the former Oncornavirinae subfamily 
(Teich et al., 1982; Francki et al., 1991). Examples of retroviral genera and 
associated diseases are listed in Table 1.1. 
1.7 RETROVIRAL DISEASES 
1.7.1 Neoplasia 
A common outcome of many retroviral infections is the generation of 
neoplasia. Retroviral induced malignancies commonly occur as 
leukaemias, lymphomas, sarcomas, and liver, kidney or mammary 
carcinomas (Teich et al., 1982). Retroviruses can be divided into two 
classes based on the process of carcinogenesis. Non-acute transforming 
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Table 1.1 Classification of the family Retroviridaea 
Genusb 
Murine leukaemia virus-related 
group 
Mammalian type B oncornavirus 
group 
Type D retrovirus group 
Avian type C group 
Human T cell lymphotropic virus 
(HTL V) - Bovine leukaemia virus 
(BLV) group 
Len ti virus 
Spumavirus 
Speciesc Associated disease 
Murine leukaemia virus: Rauscher, Friend, Neoplasia, immunodeficiency, 
Moloney, Gross, LP-BMS neurological disorders, anaemia 
Mouse mammary tumour virus (MMTV) 
Mason-Pfizer monkey virus 
Squirrel monkey virus 
Avian leukosis virus 
Rous sarcoma virus 
HTLV-I, II 
Simian T cell lymphotropic virus 
BLV 
Human immunodeficiency virus-I, II (HIV-I,-II) 
Simian immunodeficiency virus (SIV) 
Caprine arthritis encephalitis virus (CAEV) 
Equine infectious anaemia virus (EIA V) 
Feline immunodeficiency virus (FIV) 
Human foamy virus 
Simian foamy virus 
Feline foamy virus 
Mammary carcinoma, T cell 
lymphoma 
Immunodeficiency 
Neoplasia, osteopetrosis, 
immunological disorders, 
Immunodeficiency 
T and B cell lymphomas, neurological 
disorders, immunodeficiency 
Immunodeficiency, autoimmune 
degenerative, neurological and other 
diseases 
None known 
Table 1.1 (cont) 
a) Adapted from Francki et al., (1991) and Coffin, (1994) 
b) A number of genera do not yet have approved international names. These genera are given English vernacular names and 
are written in normal text. Genera with approved names are shown in italics 
c) Examples of each genera are shown 
retroviruses induce neoplasia via insertional inactivation of cellular genes 
or insertional activation of proto-oncogenes. Carcinogenesis by acute 
transforming viruses involves the transduction of cellular 
proto-oncogenes, the transactivation of cellular genes by virus encoded 
peptides or the production of mitogenic viral peptides (reviewed in Bishop 
and Varmus, 1982; Kung et al., 1991; Tsichilis and Lazo, 1991; Fan, 1994). 
Central to the replicative cycle of retroviruses is the integration of the viral 
genome into the host genome. The insertion of retroviral sequences may 
lead to inactivation of host genes. The inactivation of genes involved in 
inhibiting cellular proliferation may lead to neoplasia. Insertional 
mutation of the cellular anti-oncogene p53 has been observed in tumours 
produced in mice infected with Abelson (Wolf and Rotter, 1984) or Friend 
murine leukaemia viruses (Mowat et al., 1985; Chow et al., 1987). 
Malignancies can also arise following retroviral provirus integration 
adjacent to cellular proto-oncogenes. The activation of these genes by 
promoter or enhancer elements in the retroviral L TR region is a major 
cause of malignancy associated with a wide range of retroviruses (Kung et 
al., 1991). Oncogenesis by non-acute transforming viruses via insertional 
inactivation or activation of cellular genes is a relatively long process and 
may take many months to years to occur. Furthermore, these viruses do 
not induce transformation in vitro. This may reflect the often random 
nature of proviral DNA integration (Shih et al., 1988) and the requirement 
for other events such as chromosomal translocation (Nottenburg et al., 
1987; Lazo and Tsichlis, 1988) to contribute to oncogenesis. 
On the other hand, acute transforming retroviruses induce transformation 
over a short period of time (days to weeks) by transduction of cellular 
oncogenes. This involves the capture of cellular genes by the retrovirus 
via recombination between the viral and host genomes (Tsichilis and 
Lazo, 1991). The transduction of host genes involved in the control of 
cellular proliferation (proto-oncogenes) often results in neoplasia, as the 
acquired genes are often refractory to host regulatory mechanisms. This 
may be due to mutations in the captured gene or the lack of host control 
over gene expression driven by the viral LTR promoter. 
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The spleen focus forming vuus of Rauscher and Friend rnur1ne 
leukaemia virus complexes encode a mutated viral envelope protein 
which induces a marked proliferation of cells expressing the 
erythropoietin receptor, such as progenitor erythroid cells (Ruta and Kabat, 
1980; Li et al., 1990). The viral protein alone is incapable of inducing 
transformation, however after 3 to 4 weeks, monoclonal erythroid 
tumours emerge. Events such as insertional activation of spi-1 
transcription factor (Moreau-Gachelin et al., 1988) and inactivation or 
deletion of p53 (Mowat et al., 1985; Chow et al., 1987) are also required for 
leukaemogenesis. 
Retroviruses may also induce carcinogenesis via transactivation of cellular 
genes by viral gene products. The tax protein produced by the human T 
lymphotropic virus I upregulates a number of genes involved in the 
proliferation of T cells. These genes include IL-2, IL-2 receptor, GM-CSP, 
and c-fos (reviewed in Green and Chen, 1994). Although the process of 
immortalisation by HTLV-I is not completely understood, tax is thought to 
play a role via the chronic stimulation of these genes (Yodoi and 
Uchiyama, 1992). 
1.7.2 Non-neoplastic retroviral diseases 
Many retroviral infections lead to disease without inducing 
transformation. These can be broadly categorised as immunosuppressive, 
neurological, anaemia and wasting diseases (Table 1.1). Perhaps the most 
widely studied of these disorders is immunosuppression. Infection with 
lentiviruses, MuLV, HTLV or Mason-Pfizer viruses induce various forms 
of impaired immune responses (reviewed in Dent, 1972; Bendinelli et al., 
1985; Specter and Friedman, 1985). Retroviral infections have been shown 
to impair a range of immune effector functions, such as lymphocyte 
proliferation, antibody production, cytokine production and CTL activity. 
As a result, infected animals exhibit impaired resistance to other infectious 
agents (Bendinelli et al., 1985; Levy, 1993). Retroviruses may induce 
immunosuppression in a number of ways. Envelope glycoproteins of 
MuLV, HTLV and HIV have all been shown to impair T cell function in 
vitro by inhibiting signal transduction by cell surface receptors, which may 
suppress proliferative or other signals (Ruegg et al., 1989b; Ruegg et al., 
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1989a; Kadota et al., 1991). Furthermore, some retroviral proteins, such as 
HTLV encoded tax or HIV encoded tat, may alter cellular responses to a 
range of stimuli (Rosenblatt et al., 1995). Alternatively, loss of immune 
cells, such as CD4 + T cells, as found in HIV infection, may lead to 
suppressed immune responses (Zinkernagel and Hengartner, 1994). 
A common occurrence in retrovirus infected animals is a wasting 
syndrome characterised by gradual, prolonged loss of weight and 
condition. Examples can be found in many retroviral genera, however this 
phenomenon is particularly common amongst animals infected with 
lentiviruses including HIV, SIV, EIA V, maedi-visna virus and CAEV 
(Narayan and Clements, 1989). The cause is largely unknown, however the 
symptoms are similar to the weight loss induced by chronic treatment 
with TNF (Vassalli, 1992). As TNF is overexpressed in some retroviral 
diseases such as HIV (Lahdevirta et al., 1988), it has been suggested that 
wasting associated with retroviral infection is due to TNF mediated effects 
(Matsuyama et al., 1991). 
Neurological disorders are also associated with retroviral infections. These 
include HIV-associated neuromuscular disease, encephalopathy and 
dementia (Wiley and Nelson, 1990), HTLV-I-induced tropical spastic 
paraparesis (Roman and Osame, 1988) and paralysis of mice infected with 
Cas-Br-E MuL V (Gardner et al., 1973). The mechanisms of 
neuropathogenesis in retroviral infections have not been clearly defined. 
These diseases may be due to inflammation of the central nervous system 
(CNS), neurotoxic effects of retroviral proteins or cytokines produced by 
cells within the CNS (Wiley and Nelson, 1990; Levy, 1993). 
Retroviruses such as EIAV, FeLV, ALV, R-MuLV and F-MuLV also induce 
anaemia, which can take several forms depending on the virus. Anaemia 
associated with FeL V infection is characterised by aplasia due to the 
destruction of erythroid stem cells (Hardy, 1993). Alternatively, anaemia 
may be hypoplastic, due to inefficient maturation of haematopoietic stem 
cells, as found during ALV, R-MuL V, F-MuLV infections (Teich et al., 
1982), or haemolytic, due to destruction of infected precursor or mature red 
blood cells by antiviral immune responses, as seen following EIA V 
infection of horses (Sentsui and Kono, 1987). 
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It is worth noting that not all retroviruses are associated with disease. 
Viruses in the genus Spumavirus, as well as some endogenous MuLV, are 
non-pathogenic (Kozak and Ruscetti, 1992; Loh, 1993). Endogenous MuLV 
replicate at very low levels and persist via vertical transmission (Kozak 
and Ruscetti, 1992). These viruses may be the perfect parasites, as they 
persist through generations with minimal cost to the host or their own 
propagation. 
1.8 THE MURINE LEUKAEMIA VIRUSES 
Murine leukemia viruses (MuLV) are a major species within the 
mammalian type C retrovirus group. Most MuLV occur as 
non-productive endogenous viruses incorporated in the mouse genome. 
Some inbred strains of mice, such as AKR and C58, spontaneously produce 
these viruses from very early in life (Pincus, 1980). In most other strains of 
mice, activation of endogenous viruses occurs at low incidence, however 
mutagenic agents such as X-rays or carcinogens can significantly increase 
the rate of activation (Ribacchi and Giraldo, 1966; Zilber and Postnikova, 
1966). 
MuLVs can be divided into different classes based on their ability to infect 
cells of different species (reviewed in Hunter and Swanstrom, 1990). 
Ecotropic MuLV efficiently infect mouse cells but poorly infect cells from 
other animal species (Levy, 1974). Xenotropic MuLV are able to infect and 
replicate in cells of non-murine animals but do not efficiently infect 
mouse cells (Levy, 1973; reviewed in Levy, 1978). Replication competent 
MuLV, which differ from ecotropic and xenotropic viruses in host range, 
are termed polytropic viruses. A number of these viruses form foci on 
mink cell monolayers and have therefore been called mink cell focus 
(MCF) forming viruses (Fischinger et al., 1975; Hartley et al., 1977). 
Amphotropic viruses have been isolated from wild mice but are not found 
in laboratory mice. These viruses replicate in both murine and non-
murine cells but differ from polytropic viruses in host range (Hartley and 
Rowe, 1976). The host range of MuLV is predominantly determined by the 
ability of major envelope glycoprotein (gp70) to bind to different cellular 
receptors (Kozak, 1983). The ecotropic MuLV receptor has recently been 
identified as an amino acid transporter (Kim et al., 1991). 
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A number of h ighly pathogenic MuL V have been isolated over the last 50 
years. These viruses were isolated by passage of leukaemic cells or cell-free 
leukaemic material in mice. Examples include Gross , Kirsten, 
Duplan-Laterjet (LP-BM5), Friend, Rauscher and Moloney MuLV viruses. 
Many of these have been found to be mixtures of ecotropic, polytropic and 
xenotropic viruses (reviewed in Kozak and Ruscetti, 1992). These viruses 
cause a wide range of diseases in mice, including T and B cell lymphomas, 
lymphoid, myeloid and erythroid leukaemias, neurological disorders, 
sarcomas and immunosuppression (Teich et al., 1982; Kozak and Ruscetti, 
1992). The relevance of these viruses in nature appears to be limited as 
they are difficult to transmit horizontally and may therefore may have 
disappeared with the death of the original animal. 
1.9 RAUSCHER MURINE LEUKAEMIA VIRUS 
1.9.1 R-MuL V and F-MuL V 
The experiments described in this thesis examined the effect of R-MuLV 
infection on the immune system of inbred mice. It is therefore important 
to review the mechanisms of resistance and susceptibility to R-MuLV 
infection, with particular emphasis on the role of the immune response to 
R-MuLV. While the pathogenesis of R-MuLV infection and disease has 
been investigated for over 30 years, the body of information gathered about 
this virus is dwarfed by studies of the closely related F-MuLV. Genetic, 
morphological and immunologic studies show that the anaemia strain of 
F-MuLV (F-MuLV-A) is closely related to R-MuLV. These viruses produce 
very similar disease patterns in mice (Teich et al., 1982). The 
polycythaemia strain of F-MuLV (F-MuLV-P) is also related to R-MuLV, 
however more distantly than F-MuLV-A (Wolf et al., 1983; Bestwick et al. , 
1984; Wolf et al., 1985; Kabat, 1989). Furthermore, the disease produced 
by F-MuLV-P is slightly different to R-MuLV, as it involves a 
hypervolaemic polycythaemia, as opposed to anaemia (Teich et al., 1982). 
Where studies of R-MuLV infection are lacking or inconclusive, studies 
using F-MuLV-A or the related F-MuLV-P will be described. 
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1.9.2 Pathogenesis of R-MuL V 
Rauscher MuLV is a murine type C oncorna virus discovered by (and 
named after) F.J. Rauscher in the early 1960's (Rauscher, 1962). Infection of 
susceptible mice, such as BALBI c, A/J, SJL/J or NIH inbred Swiss, results 
in a rapid, persistent viraemia, proliferation of progenitor erythroid cells, 
anaemia and splenomegaly (Rauscher, 1962; Boiron et al., 1965). 
Depending on the infecting dose, mice die from 4-6 weeks p.i., usually due 
to rupture of the grossly enlarged spleen. Surviving mice begin to develop 
B and T cell lymphomas 3-6 months p.i. (Rauscher, 1962; Reddy et al., 1980; 
de Both et al., 1983) In marked contrast, resistant C57BL/ 6 mice exhibit a 
transient viraemia, low level proliferation of progenitor erythroid cells 
and slight splenomegaly (Rauscher, 1962; Pluznik and Sachs, 1964; Boiron 
et al., 1965; Borella, 1969). Although these mice efficiently control 
R-MuLV infection, the appearance of lymphomas in infected mice indicate 
that the virus is not totally cleared (Boiron et al., 1965; McCoy et al., 1967). 
The major targets of R-MuLV are the progenitor erythroid cells (Rauscher, 
1962; Pluznik and Sachs, 1964), Infection of these cells augments the 
mitogenic signal delivered through the erythropoietin receptor which 
results in a marked increase in the erythroid stem cells ie. burst forming 
(BFU-e) and colony forming (CFU-e) units found in the bone marrow and 
spleen 7-14 days post infection (Okunewick and Phillips, 1973; Gallacchio 
and Murphy Jr, 1983). By three weeks post infection approximately 60% of 
the spleen of susceptible mice is comprised of progenitor erythroid cells ( de 
Both et al., 1978). These progenitor erythroid cells are dependent upon 
erythropoietin for replication in vitro (Gallacchio and Murphy Jr, 1983) 
and in vivo (Okunewick and Erhard, 1974), however they do not 
efficiently mature into red blood cells which results in the anaemia 
associated with R-MuLV infection (Brodsky et al., 1967). In the first 3-4 
weeks after infection these cells also have limited renewal capacity (Hess et 
al., 1984), however by 4 weeks post infection immortal oligoclonal 
leukaemias arise. 
Many other cells are targets of R-MuLV infection. Megakaryocytes are 
readily infected by R-MuLV resulting in thrombocytopoiesis through as yet 
undefined mechanisms (Grau et al., 1986). The role of lymphoid cells in 
33 
the pathogenesis of R-MuLV infection is unclear. In addition to being 
major contributors to anti-viral immune responses, lymphocytes may also 
act as targets of virus replication. The level of R-MuLV infection of B cells 
has not been formally demonstrated, however it interesting to note that 
F-MuLV replicates in spleen B cells and, to a lesser extent, in spleen T cells. 
Furthermore, F-MuL V replication is enhanced by stimulation of B cell 
proliferation (Isaak et al., 1979). B cells appear to be essential for F-MuLV 
disease as BALB / c mice depleted of B cells from birth are refractory to 
F-MuL V induced disease (Manning et al., 1974). Indirect evidence for 
R-MuLV infection of B cells is shown by the presence of virus particles 
near B cells very early in R-MuLV infection (from 24 h p.i. Hanna et al. , 
1970a). Also, pre-B cell lymphomas occur following R-MuL V infection 
(Reddy et al., 1980). Interestingly, germ-free mice were also found to be 
more resistant to R-MuL V than normal mice or germ-free mice 
challenged with antigen prior to infection. This suggests that lymphocytes 
(or lymphoid precursors) are targets of virus replication (Hanna et al ., 
1970b; Kouttab and Jutila, 1972). Early investigation of the role of T cells in 
R-MuLV infection was unclear as depletion of T cells from susceptible 
mice using polyclonal thymocyte antisera has been shown both to 
ameliorate (Siegel and Morton, 1970) or exacerbate (Hirsch and Murphy, 
1968) R-MuLV induced disease. Recently, Ruprecht and Bronson, 1994) 
showed that athymic nude BALBI c mice (which lack T cells) exhibit a 
disease similar to euthymic mice. This observation demonstrates that T 
cells are not essential for the pathogenesis of R-MuL V infection in BALB / c 
mice. 
1.9.3 R-MuLV genetics 
R-MuLV is a complex of at least 4 different viruses. Three of these viruses 
are replication competent, while the remaining virus is replication 
defective. Two of the replication competent viruses are ecotropic viruses 
(R-MuLV-eco) that differ in their ability to induce syncytia in the XC 
plaque assay (Vogt, 1982). These two viruses are thought to cause 
lymphatic leukaemia late in R-MuLV infection. The other replication 
competent virus is a polytropic mink cell focus forming virus (R-MCF; 
(van Griensven and Vogt, 1980). This virus has been shown to cause 
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erythroleukaemia with a latent period of 3-6 months . The rema1n1ng 
virus is a replication defective spleen focus forming virus (R-SFFV), 
which rapidly causes the generation of foci of proliferating cells when 
injected into mice (Hess et al., 1984; Bestwick et al., 1985). Rauscher-SFFV 
encodes a mutant envelope glycoprotein, gp52 (Ruta and Kabat, 1980), 
which is thought to bind to the erythropoietin receptor of haematopoietic 
progenitor cells, stimulating them to proliferate (Li et al., 1990). Whilst 
R-SFFV can induce splenomegaly and erythroproliferation when injected 
by itself, the R-MuLV-eco virus is also required for the transformation of 
progenitor erythroid cells (Hess et al., 1984; Bestwick et al., 1985). 
Retroviral insertional activation of cellular oncogenes occurs during 
R-MuLV infection. The R-SFFV and F-SFFV genomes integrate adjacent 
to the spi-l gene in a very high proportion of R-MuLV-induced tumours 
(Moreau-Gachelin et al., 1990). Furthermore, transcription of the spi- l 
gene is markedly upregulated in these tumours (Moreau-Gachelin et al., 
1990). The precise function of spi-l protein (independently isolated and 
referred to as PU.l; Klemsz et al., 1990) is unclear, however it has 
transcriptional activator activity and exhibits marked homology to the ets 
nuclear transcription factor (Klemsz et al., 1990). In vitro studies suggest 
that PU.l is involved in controlling the differentiation of Friend 
erythroleukaemia cells (Schuetze et al., 1992), which raise the possibility 
that PU.l may be involved in oncogenesis during R-MuLV infection. 
Recent studies indicate that the integration of F-MuLV-eco leads to 
activation of the Fli-1 gene in a large number of erythroleukaemias 
induced by F-MuLV-eco (Ben-David et al., 1991 ). The Fli-1 gene is also 
related to ets transcription factor and encodes a transcriptional activator 
(Zhang et al., 1993). Spi-1 and Fli-1 proteins are functionally distinct and 
bind different DNA sequences (Zhang et al., 1993). The role of Fli-1 in 
oncogenesis during R-MuLV infection remains to be demonstrated. 
1.10 RESISTANCE AND SUSCEPTIBILITY TO R-MuL V DISEASE 
Infection of mice with R-MuLV begins a complex interplay between the 
virus genome, host genetic factors and the host immune response. A 
number of autosomal mouse genes have been shown to control R-MuL V 
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infection and disease in vzvo. Toth et al., (1973) proposed that 2 genes, 
Rv-1 and Rv-2, control various aspects of R-MuLV replication. Although 
these genes were incompletely characterised, it is thought that the genes 
described were actually the Fv-1 and Fv-2 genes, which had been identified 
earlier as controlling F-MuLV induced disease (Steeves and Lilly, 1977). 
R v and Fv genes will be considered as identical in the following 
discussion. 
1.10.1 Fv-1 
The Fv-1 gene affects the ability of a range of MuL V to integrate into the 
genome of infected cells (reviewed in Teich et al., 1982). Cells expressing a 
resistant Fv-1 phenotype are 10-100 times less sensitive to infection by 
some MuLV (Pincus et al., 1971a; Pincus et al., 1971b). The nature of Fv-1 
restriction is unclear, however several studies indicate that the interaction 
between Fv-1 and the viral gag protein, p30, influence the integration of 
the viral genome into host genomic DNA (Gautsch et al., 1978; 
DesGroseillers and Jolicoeur, 1983). There are several Fv-1 alleles 
designated Fv-ln, Fv-lb and Fv-1nr. The Fv-ln and Fv-lb alleles are named 
after the prototypic strains of mice from whom they derive, NIH Swiss and 
BALB / c respectively (Pincus et al., 1971a). N-tropic viruses replicate more 
efficiently in cells of the Fv-1 n/n genotype while Fv-1 b/b cells support the 
replication of B-tropic viruses. Strains of mice which are Fv-1 n/n include 
NIH/N, DBA/2, C3H/He and AKR/N while strains such as A/J, C57BL/6 
and Bl0.BR/J are Fv-1 bib (Pincus et al., 1971a). A third Fv-1 allele, Fv-1 nr, 
was found in 129, NZW and NZB mice and was found to convey at least a 
four fold increase in resistance to N-tropic MuLV (Rowe and Hartley, 
reported in (Steeves and Lilly, 1977). Most strains of R-MuLV are N-B 
tropic and replicate equally well in cells from mice which are Fv-1n/n or 
Fv-lb/b (Hartley and Rowe, 1975). Thus it seems unlikely that Fv-1 
genotype would affect R-MuL V infection and subsequent disease in inbred 
mice, although Fv-1 nr 129 mice appear to be slightly more resistant than 
Fv-ln or Fv-lb mice. 
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1.10.2 Fv-2 
The replication and mitogenic effects of SFFV of Rauscher and Friend 
MuL V are under the control of the Fv-2 gene. The two alleles Fv-2r and 
Fv-2 5 confer resistance and susceptibility respectively (Odaka and 
Yamamoto, 1962; Lilly, 1970). Genetic studies have shown that the 
resistance mediated by Fv-2 is dominant over susceptibility at the Fv-1 
locus and that susceptibility is dominant in mice with heterozygous Fv-2 
alleles (Lilly, 1970). The Fv-2 protein is thought to control the proportion 
of progenitor erythroid cells actively progressing through the cell 
replication cycle (Suzuki and Axelrad, 1980). As retroviruses require cells 
to be actively replicating to integrate into the host genome (Luciw and 
Leung, 1992), this may explain why different patterns of progenitor 
erythroid cell replication affect R-MuLV and F-MuLV replication and 
disease. The Fv-2 gene product influences the mitogenic signal propagated 
by the erythropoietin receptor following ligation by erythropoietin or 
binding of gp55 F-SFFV (Hoatlin et al., 1990). Although similar studies 
have not been performed, it seems likely that R-SFFV activation of the 
erythropoietin receptor is also controlled by the Fv-2 protein. 
Resistance to F-MuLV conferred by Fv-2 was described by Stutman and 
Dupuy, (1972) as absolute, since treatment of Fv-2r/r mice (C57BL/10 and 
C57BL/ 6) with anti-lymphocyte antisera did not alter virus growth. In 
contrast, subsequent studies have shown that C57BL/6 mice depleted of T 
cells with Thy 1 specific mAb (van der Gaag and Axelrad, 1990) or athymic 
nu/nu C57BL/ 6 mice (Kitagawa et al., 1986; Kitagawa et al., 1993) exhibit 
marked sensitivity to F-MuLV infection and disease. These studies clearly 
demonstrate the requirement for T cells, and presumably T cell-dependent 
antiviral immune responses in the resistance to F-MuLV infection 
conferred by the Fv-2r/r genotype. 
1.10.3 Genes affecting the immune response to R-MuL V 
A number of other genes have been shown to control the pathogenesis of 
F-MuLV infection of mice including the H-2, Rfv-3 and Fv-3 genes. 
Although the function of these genes during R-MuLV infection is largely 
unexplored, the similarities between the disease induced by F-MuLV and 
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R-MuLV infection indicate that these genes may also play a role 1n 
resistance to R-MuL V infection and disease. 
Genes within the H-2 locus influence leukaemogenesis associated with 
F-MuLV infection. Susceptible mice (Fv-2r/s ) with a H-2b/b genotype have 
a high incidence of recovery from F-MuLV induced disease 10-14 days post 
infection. In contrast, congenic mice with the H-2d/b or H-2a/b genotype 
rarely recover when infected with high doses of F-MuLV. These 
heterozygous mice do however, recover from challenge with low doses of 
virus while congenic homozygous H-2a/a and H-2d/d do not. These effects 
are controlled by 2 genes within the MHC named Rfv-1 and Rfv-2 . 
(Chesebro and Wehrly, 1978). Rfv-1 has been mapped to the D region of 
the H-2 complex (Chesebro et al., 1974) and mediates its effect via the 
generation of antiviral CTL (Chesebro, 1990). The Rfv-1 gene is 
responsible for resistance to high doses of virus in susceptible H-2b/b mice. 
The Rfv-2 gene maps to the K and I region of the mouse H-2 locus and 
confers resistance to low doses of F-MuLV in H-2d/b or H-2a/b mice. The 
mechanism of resistance mediated by Rfv-2 has not been identified 
(Chesebro, 1990). 
The Rfv-3 gene also controls the ability of congenic susceptible mice to 
recover from F-MuLV induced disease (Chesebro and Wehrly, 1979). The 
presence of Rfv-3r genotype correlates with a high incidence of recovery 
from F-MuLV induced disease by the F-MuLV susceptible genotype 
Fv-2 515 , H-2a/a or H-2blb. The recovery mediated by the Rfv-3 locus is 
associated with the production of neutralising anti-F-MuLV antibodies 
10-14 days post infection (Chesebro and Wehrly, 1979; Doig and Chesebro, 
1979). It has been suggested that these antibodies act to prevent cycles of 
re-infection in these mice, however this remains to be shown (Chesebro, 
1990). 
The Fv-3 gene has been shown to regulate the immunosuppression 
associated with infection with F-MuLV virus (Kumar et al., 1978a; Kumar 
et al., 1978b ). Resistance is not absolute as large doses of virus (> 1500 focus 
forming units) appear to significantly reduce differences between Fv-3 s/s 
and Fv-3rlr mice (Kumar et al., 1978b). Studies by others have failed to 
show an effect of Fv-3 (Chesebro and Wehrly, 1979; Morrison et al. , 1986; 
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Chesebro, 1990) which has led to some scepticism as to the independence 
of Fv-3 from Fv-2 (Chesebro, 1990). Other studies have indicated that 
immunosuppression associated with F-MuLV is regulated by genes within 
the H-2 complex and that these genes map within H-2D subregion 
(Morrison et al., 1986; Morrison et al., 1987). Resistance or susceptibility to 
immunosuppression is conferred by the H-2Db or H-2Dd genotype 
respectively. 
1.11 THE IMMUNE RESPONSE TO R-MuL V 
Infection of susceptible mice with R-MuLV is characterised by a weak 
antiviral immune response. Toth et al., (1971a) showed that BALBI c mice 
generate only low levels of antiviral antibody following infection with 
R-MuL V. In addition, BALBI c mice challenged with low doses of live 
R-MuLV failed to generate a cellular immune response to R-MuLV 
antigens as measured by the macrophage migration inhibition test 
(Mortensen et al., 1973). The lack of an effective immune response in 
R-MuLV infected BALBlc mice is not due to an inherent inability of 
susceptible mice to recognise R-MuLV antigens, as seen in some other 
virus infections (Zinkernagel and Doherty, 1979; Bennink, 1988) since 
BALBI c mice generate strong immune responses toward R-MuLV 
following treatment with various vaccine preparations (Fink and 
Rauscher, 1964; Mortensen et al., 1973; Peters et al., 1975; Kello££ et al., 
1976). 
Passive transfer of spleen cells from R-MuL V-immune BALBI c mice 
showed that acquired immunity is dependent on CD4 + and CDS+ cells 
(Hom et al., 1991). It appears that CMI may be important in acquired 
immunity to R-MuL V as immune mice have been shown to express 
strong anti-R-MuL V DTH (Peters et al., 1975; Kelloff et al., 1976) or are 
positive in the macrophage migration inhibition test toward R-MuL V 
antigens (Mortensen et al., 1973). Moreover, passive serotherapy with 
hyperimmune anti.-R-MuLV sera only partially protects against R-MuLV 
infection (Fink and Rauscher, 1964; Ruprecht et al., 1990). 
Resistant C57BLI 6 mice generate a vigorous anti-R-MuLV immune 
response characterised by high, persistent levels of antibody (McCoy et al., 
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1972; Ishimoto and Ito, 1973) and strong induction of cell mediated 
immunity (Mortensen et al., 1973). The in vitro growth of R-MuLV in 
spleen cells from C57BL/ 6 and BALB / c mice are similar (Ishimoto et al., 
1971) which indicates that there is no significant inherent differences in 
virus productivity between susceptible and resistant mice. Infectious virus 
is rapidly lost from plasma and spleen of infected C57BL/ 6 mice (Pluznik 
and Sachs, 1964) which suggests that R-MuLV is cleared by anti-R-MuLV 
immune responses. Interestingly, the virus is not totally eliminated as 
cells expressing R-MuLV-eco have been detected in the spleen of infected 
mice at least 6 weeks post infection (Iwai et al., 1994). 
IFN-a and IFN-~ inhibit R-MuLV replication in vzvo. Significant 
reduction of splenomegaly and increased survival times have been 
demonstrated following multiple injection of these IFN-a/ ~ or IFN-~ 
however these treatments do not cure susceptible mice of R-MuLV 
(Gresser et al., 1968; Toth et al., 1971a; Hekman and Trapman, 1985). 
Susceptible, BALB / c mice can be cured of R-MuL V infection by treatment 
with IFN-a coupled with low dose AZT therapy (Ruprecht et al., 1990). 
This finding also suggests that treatment with IFN-a may be curative for 
mice given very low doses of virus as low dose AZT inhibits R-MuLV 
replication but does not lead to clearance of the virus (Ruprecht et al., 
1986). Several strains of mice that are resistant to R-MuLV produce high 
levels of IFN while susceptible mice produce only low levels (Glasgow and 
Friedman, 1969; Toth et al., 1971c). In addition, neutralisation of type I IFN 
with polyclonal rabbit anti-IFN a/~ antibodies augment R-MuLV induced 
splenomegaly in susceptible mice (Inglot and Chudzio, 1977) . 
Interestingly, high levels of IFN are produced by susceptible NZB mice 
following infection with R-MuLV which suggests that factors other than 
IFN are also involved in resistance to R-MuLV (Siegel et al., 1973). 
Type I IFN exert antiviral effects upon most MuLV. Early studies of the 
effects of IFN on AKR MuLV demonstrated that IFN prevented the 
production of infectious virus particles from chronically infected cell lines 
(Pitha et al., 1976). Examination of the antiviral effects of type I IFN on 
R-MuLV replication indicated that IFN treatment acted at a 
post-transcriptional level (Billiau, 1978) and that the processing of some 
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viral peptides and subsequent assembly of infectious virions was inhibited 
in IFN treated cells (Shapiro et al., 1977; Pitha et al. , 1979; Pitha et al. , 1980). 
In addition to direct antiviral effects on target cells, IFN may also stimulate 
a number of immune effector functions such as NK cell activity or MHC 
class I expression (see section 1.5.1). The relative importance of these 
effector mechanisms in R-MuLV infection remains to be elucidated. 
A feature of R-MuL V infection is a profound suppression of immune 
responses to a variety of stimuli. The generation of antibody to a variety of 
antigens such as bovine serum albumin, sheep red blood cells and 
influenza virus haemagglutinin have been shown to be suppressed in 
R-MuLV infected susceptible mice (Siegel and Morton, 1966; Ceglowski 
and Friedman, 1968; Millian and Schaeffer, 1968). In addition, the 
proliferation of spleen T cells following stimulation with 
phytohaemagglutinin (PHA) or allogeneic spleen cells were suppressed in 
R-MuLV infected BALB/c mice (Hayry et al., 1970). In contrast, the PHA 
stimulated proliferation of lymph node T cells is largely unaffected by 
R-MuLV infection (Hayry et al., 1970). Several studies have shown that 
R-MuL V infection also inhibits the ability of dendritic cells to migrate and 
provide costimulation in mixed lymphocyte reactions (Gabrilovich et al., 
1993; Gabrilovich et al., 1994). Resistant C57BL/ 6 mice (which are also 
H-2Db and Fv-3rlr) also exhibit suppressed antibody production following 
R-MuLV infection however the degree of suppression is small, transient 
and interestingly, correlates with the presence of virus in the plasma of 
infected mice (Borella, 1969; Seidel and Lauenstein, 1969). 
The cause of R-MuL V induced immunosuppression is largely unknown. 
It has been suggested that the accumulation of progenitor erythroid cells in 
the spleen may suppress immune responses, however many responses are 
suppressed before large numbers of these cells accumulate in the spleen 
(Ceglowski and Friedman, 1968; Hayry et al., 1970) . Furthermore, 
leukaemogenesis does not appear to be necessary for the development of 
immunosuppression associated with F-MuLV infection (Lopez-Cepero et 
al., 1988; Matteucci et al., 1989). Fowler et al., (1977) showed that disrupted 
R-MuLV was capable of suppressing PHA induced T cell proliferation in 
vitro. This observation suggests that virus infection is not required for 
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R-MuL V to suppress immune function. This finding is consistent with 
the report of Ruegg et al., (1989a) who showed that the R-MuL V p15E 
protein can inhibit T cell proliferation in vitro. 
R-MuL V infection of immune cells 1n 
immunosuppression is not known. 
The importance of 
R-MuLV induced 
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1.12 SCOPE OF THIS THESIS 
The replication of R-MuLV in inbred strains of mice is regulated by a 
number of autosomal genes. While some genes influence the ability of 
R-MuL V to replicate others modulate the antiviral immune response 
generated toward R-MuLV. The experiments in this thesis were designed 
to examine the role of the immune system in resistance or susceptibility to 
R-MuLV infection. For the purpose of comparison susceptible BALBI c 
and resistant C57BL/6 mice were used. 
Immunosuppression is associated with many retroviral infections and is a 
potential mechanism of evading host immune responses. Experiments in 
Chapter 2 were designed to investigate the effect R-MuLV infection had on 
immune function. BALB/c mice were more susceptible to R-MuLV 
infection and exhibited greater immunosuppression than R-MuLV 
infected C57BL/ 6 mice. A number of possible mechanisms which led to 
reduced immune responsiveness were investigated. 
Over the last 10 years it has become clear that cytokines play an integral 
role in the generation and effector phase of antiviral immunity. 
Experiments described in Chapter 3 examine cytokine expression during 
R-MuLV infection. The requirement of cytokines in resistance or 
susceptibility was determined using cytokine neutralising antibodies and 
mice lacking functional IFN-y receptors. Since T cells are major producers 
of cytokines and influence the type of immune response generated the 
requirement of T cell subsets in resistance or susceptibility to R-MuLV was 
examined. 
Nitric oxide has been shown to limit virus replication and inhibit the 
proliferation of rapidly dividing cells such as tumour cells and 
lymphocytes. The role of NO in R-MuL V infection was therefore 
examined. Experiments described in Chapter 4 showed that NO was 
produced during R-MuLV infection of both BALB/c and C57BL/6 mice. 
However, further experiments indicated that NO had little influence upon 
resistance or susceptibility to R-MuLV or upon immunosuppression 
associated with R-MuL V infection. 
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Chapter 2 
R-MuL V induced immunosuppression 
2.1 INTRODUCTION 
With the advent of the HIV pandemic the immunosuppression 
associated with virus infections has become a subject of increasing 
research interest. While the retroviruses are the predominant family of 
viruses that cause immunosuppression (for review see Dent, 1972; 
Bendinelli et al., 1985), many other viruses impair host immune 
responses. These include measles virus (Smithwick and Berkovich, 
1969), lactate dehydrogenase virus (LDV; Howard et al., 1969), LCMV 
(Mims and Wainwright, 1968) and human cytomegalovirus (Rinaldo et 
al., 1980). A wide range of immune functions have been shown to be 
suppressed, including the production of antibody, generation of cytotoxic 
T cells, lymphocyte proliferation, the generation of delayed type 
hypersensitivity, allograft rejection and production of cytokines 
(reviewed in Specter and Friedman, 1985; McChesney and Oldstone, 
1987). 
There are many potential mechanisms by which the immune system can 
be suppressed during virus infections, however it is often difficult to 
pinpoint defects in the cascade of events which occur during an immune 
response. Nevertheless, putative mechanisms of immunosuppression 
can be classified into 2 broad categories. Firstly, infection of a class of 
immune cells can lead to an intrinsic defect in the function of infected 
cells. This defect may be due to modified responses to stimuli such as 
ligation of antigen receptor on lymphocytes (Mizuochi et al., 1990). 
Alternatively, infected cells may be lost through a number of 
mechanisms including lysis, as in the case of lytic viruses such as LDV 
(Stueckemann et al., 1982). Immune cells may also be deleted by effective 
immune responses targeted toward virus infected cells, which occurs 
during LCMV infection (Zinkernagel and Hengartner, 1994) or apoptosis 
of infected cells which has been observed during HIV infection (Groux et 
al., 1992; Gougeon et al., 1993). Secondly, immunosuppression may be 
caused in an indirect manner. In this scenario, uninfected cells are 
affected due to the altered function of virus infected immune cells. 
Alternatively, the production of immunosuppressive factors such as 
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nitric oxide, prostaglandins or cytokines by dysregulated infected cells, or 
as part of antiviral immune responses, may lead to immunosuppression. 
The cellular events leading to suppressed immune function during 
retrovirus infection are largely unresolved. This is due, at least in part, to 
the replication of many retroviruses in immune cells which complicates 
the interpretation of observations of immune function during retrovirus 
infection. Retrovirus encoded proteins have been shown to alter a 
number of immune responses. The envelope components of murine 
leukemia viruses (p15E) and the human T lymphotropic virus (gp21E) 
have been shown to impair lymphocyte proliferation and chemotaxis of 
macrophages or monocytes (Snyderman and Ciancolo, 1984; Ruegg et al., 
1989a; Ruegg et al., 1989b). Studies by Kadota et al., (1991) indicate that 
these proteins downregulate protein kinase C signalling pathways which 
are required for signal transduction from the cell surface receptors. A 
number of studies have shown that addition of purified protein or 
UV-inactivated virus is capable of mediating these effects (Fowler et al., 
1977; Ruegg et al., 1989a; Ruegg et al., 1989b ). These observations suggest 
that immunosuppressive peptides do not have to be produced by infected 
cell to affect immune responses. 
Infection of mice with R-MuLV disrupts a number of immune functions 
(Ceglowski and Friedman, 1968; Dent, 1972; Bendinelli et al., 1985) . In 
order to examine the immunosuppression associated with R-MuLV 
infection in greater detail, lymphocyte proliferation by cells from 
R-MuLV infected mice was studied in vitro using strains of mice with 
differing susceptibility to infection. R-MuLV infection of highly 
susceptible BALBI c and relatively resistant C57BL/ 6 mice rapidly led to 
impaired in vitro T and B cell proliferative responses. Potential 
mechanisms of immunosuppression were investigated. 
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2.2 MATERIALS AND METHODS 
2.2.1 Mice 
Mice were obtained from the Animal Services Division at the Australian 
National University and were raised under specific pathogen-free 
conditions. BALB / c and C57BL/ 6J mice were used at 6-11 weeks of age. 
2.2.2 Virus 
Rauscher MuLV was obtained from Dr C. Birch (Fairfield Hospital, 
Victoria Australia). R-MuLV was passaged by i.p. injection of 104 pfu of 
R-MuL V into BALB / c mice. After 21 days the mice were sacrificed and a 
single cell suspension was prepared from pooled spleens (20% w / v in 
DMEM supplemented with 20% FCS). The cells were removed by 
centrifugation at 500g for 10 min at 4°C and the supernatant was aliquoted 
and stored at -70°C. The titre of the stock was determined by XC plaque 
assay (Section 2.2.5). Virus stocks were diluted with gelatin saline to 
contain 104 XC pfu/ ml before use. Mice were routinely infected with 104 
pfu of virus, administered by i.p. injection. 
2.2.3 Culture Media 
Cells were grown 1n Dulbecco's modified Eagle's media (DMEM) 
containing a number of supplements. H16 media is composed of DMEM 
(GIBCO BRL, Grand Island, NY, USA) supplemented with 10% heat-
inactivated FCS (Flow Laboratories, North Ryde, NSW, Australia), 10 
mM HEPES, 2 mM L-glutamine, penicillin (30 mg/1), streptomycin 
sulphate (50 mg/1), neomycin sulphate (50 mg/1) and 50 µM 
2-mercaptoethanol (Sigma Chemical Company, St. Louis, MO, USA). 
Mixed lymphocyte culture medium (MLCM) consisted of H16 
supplemented with glucose (4 g/1), folic acid (6 mg/ml), L-asparagine (36 
mg/1), L-arginine (116 mg/1), sodium bicarbonate (2 g/1) and 1 mM 
sodium pyruvate. 
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2.2.4 Cells 
SC-1 cells, a cell line derived from feral mouse embryos (Hartley and 
Rowe, 1975) and XC cells, a rat fibroblast tumour cell line (Svoboda et al ., 
1963) were maintained in Hl6. These cells were passaged every 2-3 days 
by diluting the cells 1:10 into a new culture flask. 
Spleen and lymph node cells were cultured in MLCM. 
2.2.5 Virus Titration 
Titration of R-MuLV used the XC plaque assay (Rowe et al., 1970). SC-1 
cells were seeded into each well of a 6 well plate (105 cells/well) and 
cultured for 24 h. Virus samples were serially diluted in H16 containing 
8 µg/ml polybrene (Sigma) and 2 ml of each dilution was overlayed onto 
SC-1 cells. The media was replaced 24 hours later and, after a further 2 
days, the cells were UV irradiated (15W lamp at 25 cm for 20 sec) and 
overlayed with 3.5x105 XC cells/well. The media was replaced 24 h later 
and, after a further 2-3 days, the monolayers were stained with 0.1 % 
crystal violet in 20% ethanol for 5 min and air dried. Plaques were 
counted using a dissecting microscope. 
Spleens removed from mice infected with R-MuL V were stored 
individually at -70°C. Cell free virus was assayed by homogenising frozen 
spleen in 1 ml ice cold gelatine saline containing 20 mM HEPES for 15 sec 
in a polytron homogeniser. The homogenate was diluted to 3 ml final 
volume with gelatin saline and assayed for infectious virus using the XC 
plaque assay described above. 
2.2.6 Infectious Centre Assay 
R-MuL V infected spleen cells were titrated using the XC infectious centre 
assay (Melief et al., 1975). Spleens from infected mice were aseptically 
removed and a single cell suspension was prepared in H16 containing 5% 
FCS. The cells were washed with Hl6/5% FCS adjusted to 5xl07 cells/ml 
and incubated with 25 µg/ml mitomycin C (Sigma) at 37°C for 30 min. 
The cells were washed, adjusted to 107 cells/ml and serially diluted in 
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H16 containing 8 µg/ml polybrene. Each dilution was overlayed onto SC-
1 cells which had been seeded 24 h earlier into 6 well plates 
(105 cells/well). The media was changed 24 h later and the assay 
developed as for the XC plaque assay above (Section 2.2.5). 
2.2.7 R-MuL V specific ELISA 
A capture ELISA was developed to detect R-MuLV antigen. The ELISA 
employed goat polyclonal anti-R-MuLV serum derived from goat 
immunised with intact R-MuLV (Lot # 75S000297; Quality Biotech, 
Camden, NJ, USA), polyclonal goat anti-R-MuLV antisera that had been 
biotinylated ( described below) and alkaline phosphatase conjugated 
streptavidin (Amersham Australia, North Ryde, NSW, Australia). 
Polyclonal goat anti-R-MuLV sera was biotinylated as described in Harlow 
and Lane, (1988). Briefly, goat serum was biotinylated as follows. Serum 
was diluted to 1 mg/ml total protein in bicarbonate buffer (4.2 g/1; pH 8.5) 
and for each mg of serum protein 120 µg of succinimidobiotin (Sigma) 
dissolved in dimethyl sulphoxide was added. Biotinylation was 
performed at room temperature for 2 h in the dark. Unreacted 
succinimidobiotin was removed by washing the mixture three times with 
cold PBS by centrifugation over a Centricon 10,000 column (Amicon, CT, 
USA) according to the instructions provided by the manufacturer. 
The R-MuL V ELISA used round bottomed 96 well ELISA plates 
(Dyantech Laboratories, VA, USA). Each well was coated with 50 µl of 
polyclonal anti-R-MuLV sera that had been diluted 1:800 in bicarbonate 
buffer (15 mM Na2CO3, 35 mM NaHCO3 pH 9.6) and allowed to bind to 
the plate overnight at 4°C. Unbound antibody was removed by washing 
with PBS/0.1 % Tween-20 (Sigma). Non-specific protein binding sites 
were blocked with 100 µl of 3% BSA (Sigma) for 1 hat 37°C. Plates were 
washed again and appropriate dilutions of virus containing samples were 
added to each well in 50 µl. Virus was allowed to bind for 2 h at room 
temperature and, after washing, 50 µl of 1:500 diluted biotinylated 
polyclonal goat anti-R-MuLV was added and allowed to bind for 90 min 
at room temperature. Bound biotinylated antibody was detected using 
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50 µl alkaline phosphatase conjugated streptavidin diluted 1:1000. The 
ELISA was developed using disodium p -nitrophenol phosphate (Sigma) 
at 1 mg/ml in 0.5 M diethanolamine (Fluka Chemika-Biochemika, 
Buchs, Switzerland), 25 mM MgCl2, pH 9.6. Optical density (OD) was 
measured after 30 min using a Thermomax plate reader (Molecular 
Devices, Menlo Park, CA, USA). The OD was read at 410 nm with a 
reference at 650 nm. Non-specific development of the ELISA was 
determined by running the ELISA using 1 % BSA in PBS instead of 
R-MuLV antigen. The endpoint of the ELISA was defined as the well 
with an OD greater than the mean background + (3x standard deviation 
of background). 
2.2.8 Plasma isolation 
Blood was obtained from mice via tail vein bleeding, collected, placed 
into a microcentrifuge tube containing heparin sulphate (5 U in 10 µl per 
500 µl blood) and stored on ice. Blood cells were collected by 
centrifugation at 12,000g for 5 min at 4°C. The plasma was removed, 
aliquoted and stored at -70°C until assay for viral antigen or infectious 
virus. 
2.2.9 Preparation of spleen and lymph node cells 
Single cell suspensions from spleens or pooled brachial and inguinal 
lymph nodes were obtained by gently pushing organs through stainless 
steel mesh with a glass rod into MLCM. Erythrocytes were removed from 
spleen cell suspensions by water lysis. Cells were washed twice with 
MLCM prior to use. 
2.2.10 Proliferation assays 
T cell proliferation was assayed by stimulating spleen or lymph node cells 
with anti-CD3 antibody, clone 145-2Cll (Leo et al., 1987), which was 
bound to round bottomed 96 well plates (Linbro, ICN Biomedicals, Irvine, 
CA, USA). The plates were previously coated with 125 ng of anti-CD3 
antibody /well in 40 µl of PBS for 90 min at 37°C, washed twice with cold 
PBS. Plates were used either immediately or after storage in 100 µl 
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PBS/well at 4°C. Cells were cultured at 2x105 /well in 200 µl of MLCM. 
Replicate cultures were incubated for 72 h at 37°C and then labelled with 
1 µCi of [3H]-TdR (ICN Biomedicals) for a further 18 h. The cultures were 
harvested using an automatic plate harvester and counted using a 
betaplate liquid scintillation counter (Pharmacia LKB, Uppsula, Sweden). 
Spleen B cell proliferation was determined by stimulation with LPS 
(E. coli strain 0128:B12, water-phenol extracted; Sigma). Cells were 
cultured at 2x105 cells/well in 200 µl of MLCM containing 10 µg/ml LPS at 
37°C. After 72 h incubation the cultures were labelled with 1 µCi of [3H]-
TdR for a further 18 h and harvested as above. 
In some experiments 5x104 spleen cells from uninfected or infected mice 
were added to an equal number of spleen cells from uninfected mice. 
The cells were cultured in MLCM and stimulated with immobilised anti-
CD3 antibodies for 72 h at 37°C. Proliferation was measured by TdR 
incorporation following addition of 1 µCi of [3H]-TdR (ICN Biochemicals) 
and culture for a further 18 h and harvested as above. 
2.2.11 Antibodies 
The following antibodies were used to determine the proportions of 
splenocytes expressing specific cell surface antigens: FITC conjugated anti-
B220, clone RA3-6B2 (Coffman, 1982) was kindly supplied by Dr Philip 
Hodgkin (Division of Cell Biology, JCSMR) and used at a 1:100 dilution in 
PBS; biotinylated anti-Thyl.2, clone 30-H12 (Ledbetter and Herzenberg, 
1979) was purchased from Becton Dickinson (Mountain View, CA, USA) 
and was used at 1:25, Streptavidin fluorescein (Amersham) was used at 
1:40. 
Supernatants of the hybridoma Jlld (Bruce et al., 1981) were generously 
provided by Dr Janet Ruby (Division of Cell Biology, JCSMR). The 
supernatants were used to lyse spleen cells expressing heat stable antigen 
(CD 24) using methods described in Section 2.2.14. 
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2.2.12 Immunofluorescence staining 
5-10 x 10s cells were collected by centrifugation at 200g for 5 min at 4°C. 
Supernatants were aspirated and the cells were resuspended in 50 µl of 
diluted antibody. After 20-30 min incubation on ice, unbound reagents 
were removed by adding 500 µl of ice cold PBS and collecting cells as 
above. The cells were incubated on ice for a further for 20-30 min in 50 µl 
of diluted antibody or streptavidin fluorescein. Unbound reagents were 
removed by washing the cells with 500 µl of ice cold PBS. Cells were 
resuspended in 500 µl of cold PBS and stored on ice until assayed by flow 
cytometry. If flow cytometry was not performed until the next day, the 
cells were collected, resuspended in 500 µl of fixing buffer (16.83 g/1 
NaH2PO4.2H2O, 3.85 g/1 NaOH, 0.95% formaldehyde, 20 g/1 glucose and 
0.03% NaN3) and stored at 4°C overnight in the dark. 
2.2.13 Flow cytometry 
Fluorescent labelled cells were analysed using a Becton Dickinson 
FACScan. FITC was excited using 100 mW laser light at 488 nm with 
FITC fluorescence emissions detected through a 530 nm band pass filter. 
10,000 events were collected for each sample. Data was analysed using the 
Lysis II or Cell Quest programs (Becton Dickinson). 
Side and forward scatter were used as criteria for gating of live cells. The 
proportion of brightly stained live cells was calculated relative to control 
cells stained with fluorochrome reagents. Calculations are based on data 
from 10,000 events. 
2.2.14 Enrichment of T cells 
Splenocytes were enriched for Thy 1.2+ cells using the following protocol. 
1-2x108 spleen cells prepared as in Section 2.2.9 were adjusted to a volume 
of 5 ml in cold MLCM and carefully layered onto 10 ml cold isotonic 32% 
Percoll (Pharmacia). The gradients were centrifuged for 25 min at 2500g at 
4°C. Low density cells were removed using a Pasteur pipette and pelleted 
cells were washed in MLCM. These higher density cells were 
resuspended in 7 ml MLCM and incubated at 37°C with 2 ml Jlld culture 
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supernatant for 15 min. Jlld+ cells were lysed by the addition of 1 ml 
rabbit complement (Cedar Lane Laboratories, Ontario, Canada) followed 
by incubation for a further 45 min at 37°C with gentle shaking every 15 
min. Viable cells were isolated by centrifugation of the cells over a 
ficoll/metrizoate density gradient p=l.803 g/1 (Davidson and Parish, 1975) 
at room temperature, 1500g for 20 min. The cells at the interface were 
removed, washed and resuspended in MLCM. 
The enriched cells were then used in proliferation assays as described in 
Section 2.2.10. The proportion of Thy 1.2+ cells was assayed using flow 
cytometry as described in Sections 2.2.12 and 2.2.13. 
2.2.15 Statistical analysis 
The relationship between different groups was determined using 
unpaired Student's t test. All quoted probabilities of significance use this 
test unless otherwise stated. As Student's t test is invalid where the 
standard deviations of two different samples are significantly different, 
Welch's t test was used in these instances. The difference between two 
groups was considered significant different if the probability of 
relatedness was less than 5% ie. p<0.05. 
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2.3 RESULTS 
2.3.1 Growth of R-MuL V in BALB/c and C57BL/6 mice 
In this thesis, R-MuL V infection of susceptible (BALBI c) and resistant 
(C57BLI 6) strains of mice was studied. Although the growth of R-MuL V 
and disease pathology in these two strains has been described previously 
(Rauscher, 1962; Rauscher and Allen, 1964; Boiron et al., 1965; Ishimoto et 
al., 1971; Iwai et al., 1994) it was necessary to determine the growth of 
R-MuLV and the resulting disease, using the conditions and virus 
available at the JCSMR. 
Groups of BALBlc and C57BLl6 mice were injected i.p. with 104 pfu 
R-MuLV and a variety of parameters of virus growth were measured at 
1, 2 and 3 weeks p.i. These included spleen weight, numbers of virus 
producing spleen cells, infectious virus in plasma and viral antigen in 
plasma and cell-free spleen extracts. 
Infection of BALBI c mice with R-MuLV led to a rapid and marked 
increase in spleen weight which reached 10 times that of uninfected mice 
by 3 weeks p.i. (Table 2.1). Large numbers of virus-producing spleen cells 
were detected at 1, 2 and 3 weeks p.i. In contrast, infection of C57BLI 6 
mice induced a slight splenomegaly with a 2-3 fold increase in spleen 
weight at 2 and 3 weeks p.i. (Table 2.1). The numbers of virus expressing 
cells in spleens of infected C57BLI 6 mice peaked at 1 week p.i., decreased 
thereafter and were much lower at all time points compared to BALBI c 
mice. 
Infectious virus was readily detected in the plasma and cell-free extracts 
from spleens of infected BALBI c mice (Table 2.2). High levels of virus 
were recovered at 1, 2 and 3 weeks p.i. Viral antigen in plasma from 
infected BALBI c mice rapidly increased over the time points at which 
samples were taken. In marked co1:1-trast, the levels of infectious virus in 
plasma or cell-free spleen extracts from infected C57BLI 6 mice were below 
the limit of detection of the XC assay (100 pfulml plasma or 100 pful g 
spleen respectively) at any time p.i. (Table 2.2). Low levels of v iral 
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Table 2.1 Splenomegaly and virus expressing cells during R-MuL V infection 
Mouse Strain Weeks Post 
Infection 
BALB / c Uninfected 
C57BL/6 
1 
2 
3 
Uninfected 
1 
2 
3 
Mean Spleen 
Weight (mg)a 
120 + 6 
200 + 8C 
615 + 63d 
1285 + 73d 
94+6 
144 + 35 
219 + 2oe 
208 + 26e 
Spleen Infectious 
Centresb 
ND 
5.72 + 0.06 
5.65 + 0.10 
5.60 + 0.06 
ND 
3.88 + 0.09 
1.49 + 0.16£ 
1.97 + 0.60g 
Groups of 4 BALB / c or C57BL/ 6 mice were given 104 pfu R-MuL V i.p. 1, 2 or 
3 weeks previously. The spleen was taken from each mouse and weighed in 
tared sterile tubes containing 5 ml of H16 5% FCS. Single cell suspensions 
were prepared from each spleen and the numbers of virus expressing cells 
were assayed using the XC infectious centre assay described in Section 2.2.6. 
a) Mean spleen weight of 4 mice + SEM 
b) Log10 infectious centres producing ecotropic R-MuLV/107 nucleated 
spleen cells. Data shown is mean + SEM of 4 mice 
c) p<0.001, versus spleen weight of uninfected BALB / c mice 
d) p<0.005, versus spleen weight of uninfected BALBI c mice (Welch's t test) 
e) p<0.02, versus spleen weight of uninfected C57BL/6 mice (Welch's t test) 
f) p<0.02, versus number of virus producing spleen cells from C57BL/ 6 mice 
at 1 week p.i. (Welch's t test) 
g) p=0.05, versus number of virus producing spleen cells from C57BL/ 6 mice 
at 1 week p.i. (Welch's t test) 
Table 2.2 Infectious virus and virus antigen recovered from R-MuL V infected mice 
Mouse Strain Weeks Post Infection Plasma R-MuLVa Plasma an ti gen b Spleen R-MuL ye 
BALB/c Uninfected ND 40 ND 
1 4.51 + 0.16 160 + 44 6.39 + 0.14 
2 4.70 + 0.18 704 + 157 6.28 + 0.14 
3 4.67 + 0.16 2048 + 313 6.10 + 0.18 
C57BL/6 Uninfected ND 40 ND 
1 <2 120 + 55 <2 
2 <2 80 + 10 <2 
3 <2 40 <2 
Groups of 5 BALB / c or C57BL/ 6 mice were given 104 pfu R-MuL V i.p. on the appropriate week prior to virus assay. Each mouse 
was anaesthetised with 400 µl of avertin i.p. Blood was taken by cardiac puncture and placed in heparinised tubes. Plasma was 
separated from blood cells by centrifugation and assayed for viral antigen by ELISA or infectious virus by XC assay. A cell-free 
extract of each spleen was prepared and assayed for ecotropic virus using the XC assay described in Section 2.2.5. 
a) Log10 pfu of ecotropic R-MuL V per ml of plasma. Data represent mean + SEM of 5 mice 
b) Endpoint of R-MuL V ELISA of R-MuL V antigen in plasma. Data represent mean + SEM of 5 mice 
c) Log10 pfu of ecotropic R-MuL V per gram of spleen. Data represent mean + SEM of 5 mice 
antigen were detected in plasma at 1 and 2 weeks p.i. which suggests that 
virus replication occurred at these times. 
2.3.2 Proliferation of immune cells from R-MuL V infected mice 
It has been known for some time that in vitro proliferative responses of 
immune cells from mice infected with R-MuL V are suppressed (Hayry et 
al., 1970), however the mechanism of this immunosuppression has not 
been fully elucidated. In order to examine this further, an in v itro model 
was established to examine the proliferation of T or B cells from R-MuL V 
infected mice. Spleen and lymph node cells were prepared from mice 
infected with R-MuLV and their ability to proliferate in response to 
stimulation with anti-CD3 (T cells) or LPS (B cells) was determined. 
Infection with R-MuLV had a marked effect of the proliferation of spleen 
T and B cells from both BALBI c and C57BLI 6 mice. The proliferation of 
BALBI c spleen T and B cells was significantly depressed at 1 week p.i. and 
almost completely suppressed after infection for 3 weeks (Figure 2.la, b ). 
Spleen cells from infected C57BLI 6 mice also exhibited decreased 
proliferative responses at 1 week p.i. At later time points, C57BLI 6 spleen 
T cells proliferated to a greater extent than BALBI c T cells. At 2 weeks p.i. 
C57BLI 6 T cell proliferation was approximately 35% of normal responses, 
while at 3 weeks p.i. proliferation was approximately 50% that of 
uninfected cells (Figure 2.lb ). C57BLI 6 spleen B cell proliferation was also 
suppressed by 1 week p.i. and remained so up to week 3 p.i. (Figure 2.lb). 
In marked contrast to spleen cells, lymph node cells from R-MuL V 
infected mice exhibited unaltered proliferative responses to immobilised 
anti-CD3 antibodies (Figure 2. lc). Cells from both strains of mice 
proliferated to levels comparable with uninfected controls. 
2.3.3 Proportion of T and B cells in cultured spleen cells 
A feature of R-MuLV infection in BALBI c mice is a rapid accumulation 
of progenitor erythroid cells in the spleen (de Both et al., 1978). 
Suppressed proliferative responses of spleen lymphocytes may thus 
reflect a decrease in the proportion of responsive cells rather than a defect 
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Figure 2.1 Proliferation of spleen cells and lymph node from R-MuL V infected mice 
Spleens and lymph nodes were removed from BALB / c f-o- ) or C57BL/ 6 ( • ) mice which were either uninfected or 
infected with 104 pfu R-MuL V 1, 2 or 3 weeks previously. Single cell suspensions were prepared from pooled spleens or 
lymph nodes which were taken from mice at each time point. Cells were cultured with immobilised anti-CD3 antibodies 
or LPS for 72 hand labelled with 0.5 µCi [3H]-TdR for a further 16 h. Data points indicate the mean cellular proliferation 
of 6 replicate culture (+ SEM) as measured by [3H]-TdR incorporation. [A] anti-CD3 stimulated spleen cells, [B] LPS 
stimulated spleen cells, [C] anti-CD3 stimulated lymph node cells. Data shown is representative of 3 experiments. 
in their ability to proliferate. It was therefore necessary to determine the 
proportion of cells among cultured splenocytes from R-MuLV infected 
mice with the capacity to respond to stimulation with anti-CD3 or LPS. 
This was achieved by flow cytometric analysis of water lysed spleen cells 
for expression of Thy 1.2 (T cells) and B220 (B cells). 
The proportion of Thy 1.2+ cells among spleen cells prepared from 
BALBI c mice gradually decreased with time post-infection (Table 2.3). 
Approximately 40% of spleen cells from uninfected BALBI c mice were 
Thy 1.2+ and this decreased to between 20-25% by 3 weeks p.i. In marked 
contrast, the proportion of Thy 1.2+ spleen cells prepared from C57BLI 6 
mice was largely unaltered following R-MuL V infection (Table 2.3). 
The proportion of B22Q+ cells among BALBI c splenocytes following 
R-MuL V infection increased slightly from approximately 48% to over 
60% of live cells (Table 2.3). In contrast, the proportion of B22Q+ cells 
from infected C57BLI 6 mice was unaltered during the course of infection 
(Table 2.3). 
The majority of nucleated cells from the spleen of R-MuLV infected 
BALBI c mice are of the erythroid lineage (de Both et al., 1978). The flow 
cytometric data presented here indicate that a majority of live, water lysed 
spleen cells expressed either Thy 1.2 or B220. There have been no reports 
of Thy 1.2 or B220 expression by progenitor erythroid cells which suggests 
that few progenitor erythroid cells are present after hypotonic shock of 
spleen cells. Therefore, it seems unlikely that reduced numbers of T or B 
cells are the major cause of suppressed lymphocyte proliferation. 
2.3.4 Spleen cells from infected mice suppress normal spleen cell 
proliferation 
The suppressed proliferation of splenocytes stimulated with anti-CD3 
reported above may reflect the production of a suppressive factor by 
spleen cells from infected mice. In an attempt to resolve this question, 
equal numbers of spleen cells from uninfected and infected mice were 
mixed and stimulated with anti-CD3. 
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Table 2.3 Proportion of Thy 1.2+ or B220+ cells in the spleen of R-MuL V 
infected BALB/c or C57BL/6 mice 
Weeks Post Infection % Thy 1 + cells % B220+ cells 
BALB/c 
Uninfected 38.8 + 6.7 47.9 + 1.4 
1 34.3 + 4.1 55.9 + 9.6 
2 28.8 + 6.0 57.9 + 9.2 
3 23.9 + 1.7a 62.7 + 4.4c 
C57BL/6 
uninfected 40.8 + 6.7 57.3 + 6.0 
1 39.9 + 2.7 54.4 + 5.3 
2 40.4 + 6.6 56.9 + 3.6 
3 40.7 + 8.9 54.3 + 8.1 
Groups of 4 BALB/c or C57BL/6 mice were infected with R-MuLV 1, 2 or 3 
weeks previously. Single cell suspensions were made from pooled spleens 
in each group. The cells were subjected to hypotonic shock to remove red 
blood cells. 5-10x105 cells were stained with either biotinylated anti-Thy 1.2 
mAb followed by FITC conjugated streptavidin or FITC conjugated 
anti-B220 mAb. The proportion of cells expressing Thy 1.2 or B220 was 
measured by flow cytometry. Forward and side scatter were used to gate for 
live cells. Results are expressed as the percentage of live cells positively 
stained for Thy 1 or B220 expression. 
Data represents mean of three independent experiments + SD 
a) significantly less than uninfected mice p=0.02 
b) significantly greater than uninfected mice p<0.05 
c) significantly greater than uninfected mice p<0.01 
Addition of cells from infected BALBI c mice did not alter (1 week p.i.) or 
markedly inhibited T cell proliferation (2 and 3 weeks p.i.; Table 2.4). 
Similarly, cells from C57BLI 6 mice slightly increased (1 week p .i.) or 
suppressed (2 or 3 weeks p.i.; Table 2.4) proliferation of uninfected cells 
however, due to the range in the data this difference was not statistically 
significant (p>0.05, Table 2.4). As expected, addition of uninfected BALB I c 
or C57BLl6 spleen cells to an equal number of uninfected cells resulted in 
a large increase in proliferative responses to anti-CD3 stimulation. 
2.3.5 Effect of T cell enrichment on anti-CD3 stimulated proliferation 
The decrease in Thy 1.2+ spleen cells observed in BALBI c mice infected 
with R-MuL V may account at least in part for the observed decrease in T 
cell proliferation. Virus infected progenitor erythroid cells and cell debris 
may also suppress T cell proliferation. To test these propositions, spleen 
cells from infected mice were enriched for Thy 1.2+ cells in an attempt to 
obtain approximately equal numbers of Thy 1.2+ cells among infected and 
uninfected spleen cell populations used in in vitro culture. To enrich for 
Thy 1.2+ cells, a Percoll density gradient was used to remove 
contaminating low density erythroid progenitor cells (Faxvaag et al., 
1993), while B cells were removed using Jlld antibody (Bruce et al., 1981) 
plus complement mediated lysis (Section 2.2.8). 
This enrichment protocol left a population of spleen cells from 
uninfected BALBI c mice that were approximately 60% Thy 1.2+ 
(Table 2.5). The proportion of Thy 1.2+ cells from spleen cells of infected 
BALBI c mice following enrichment was between 40 and 55%. Spleen 
cells from C57BLI 6 mice which were enriched for Thy 1.2 expressing cells 
were approximately 70% Thy 1.2+ (Table 2.5). 
The proliferation of BALBI c T cell enriched spleen cells from infected 
mice was similar to that of T cell enriched splenocytes from uninfected 
mice (Table 2.6). This is in marked contrast to proliferation of whole 
splenocytes which was suppressed in infected mice. The enrichment of 
Thy 1.2+ cells did not alter the suppressed proliferation of spleen cells 
from R-MuLV infected C57BLl6 mice (Table 2.6). The anti-CD3 
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Table 2.4 Spleen cells from infected mice suppress uninfected spleen cell 
proliferation 
Mouse Strain 
BALB/c 
C57BL/6 
Uninfected 
Cells 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Cells Added 
None 
Uninfected 
1 
2 
3 
None 
Uninfected 
1 
2 
3 
Proliferation a 
(cpm x l0-3) 
149.1 + 14.2 
376.5 + 7.7b 
165.8 + 20.4 
83.3 + 10.4C 
73 .5 + 20 .5d 
61.5 + 9.1 
98.0 + 9.5e 
73.9 + 10.8 
53.8 + 9.8 
42.2 + 4.5 
5x104 spleen cells from uninfected mice were cultured alone or with 5x104 
spleen cells from uninfected mice or mice infected 1, 2 or 3 weeks earlier. 
Cells were stimulated with immobilised anti-CD3 mAb for 72 h. 
Proliferation was estimated by [3H]-TdR incorporation for the next 18 h. Data 
shown is representative of 2 similar experiments. 
a) Mean+ SEM proliferation of 4 wells 
b) Significantly greater proliferation compared to 5x104 uninfected cells 
(p<0.001) 
c) Significantly less proliferation compared to 5xl04 uninfected cells (p<0.01) 
d) Significantly less proliferation compared to 5xl04 uninfected cells (p=0.02) 
e) Significantly greater proliferation compared to 5xl04 uninfected cells 
(p=0.03) 
Table 2.5 Proportion of cells expressing Thy 1.2 in Thy 1.2+ enriched spleen 
cells from R-MuL V infected BALB/c or C57BL/6 mice 
Strain of mouse 
BALB/c 
C57BL/6 
Weeks Post Infection 
Uninfected 
1 
2 
3 
uninfected 
1 
2 
3 
% Thy 1.2+ cells 
61.2 + 4.0 
51.5 + 3.4a 
41.5 + 4.5b 
47.4 + 2.9b 
74.1 + 8.6 
67.8 + 1.5 
72.4 + 7.5 
67.2 + 11.2 
Groups of 4 BALB/c or C57BL/6 mice were infected with R-MuLV 1, 2 or 3 
weeks previously. Single cell suspensions were made from pooled spleens 
in each group. The cells were enriched for Thy 1.2+ cells as described in 
section 2.2.13. 5-10x105 cells were stained with either biotinylated anti-
Thy 1.2 mAb followed by FITC conjugated streptavidin. The proportion of 
cells expressing Thy 1.2 was measured by flow cytometry. Forward and side 
scatter were used to gate for live cells. Results are expressed as the 
percentage of live cells positively stained for Thy 1.2. Data represent the 
mean of three independent experiments+ SD. 
a) significantly less than uninfected mice p=0.03 
b) significantly less than uninfected mice p<0.01 
Table 2.6 Effect of T cell enrichment on spleen T cell proliferation 
Weeks Post Infection 
BALB/c 
Uninfected 
1 
2 
3 
C57BL/6 
Uninfected 
1 
2 
3 
Proliferation (cpm xl0-3 + SEM) 
Whole Spleen 
267.8 + 6.8 
244.2 + 4.6 
68.5 + 11.7a 
9.7 + 1.2a 
222.4 + 19.8 
175.9 + 7.7 
93.6 + 6.3a 
193.3 + 6.6 
T Cell Enriched 
216.9 + 23.1 
271.3 + 8.3 
185.1 + 12.3 
184.1 + 12.3 
291.5 + 17.6 
307.1 + 1.0 
146.5 + 8.8a 
134.7 + 4.7a 
Groups of 4 BALB/c or C57BL/6 mice were infected with R-MuLV 1, 2 or 3 
weeks previously. Single cell suspensions were made from pooled spleens 
in each group. The cells were enriched for Thy 1.2+ cells as described in 
section 2.2.13. 2x105 whole spleen or Thy 1.2+ enriched cells were stimulated 
with immobilised anti-CD3 antibodies for 72 h and labelled with 0.5 µCi 
[3H]-TdR for a further 16 h. Data represents the mean + SEM proliferation of 
6 replicate cultures as indicated [3H]-TdR incorporation. Results are 
representative of 2 similar experiments. 
a) Significantly lower proliferation compared with proliferation by cells 
from uninfected mice (p<0.001) 
stimulated proliferation of enriched splenocytes was similar to 
unfractionated spleen cells. These observations raise the possibility that 
suppression of BALBI c spleen T cell proliferation is due to suppressive 
factors and not to an intrinsic defect in the capacity of T cells to 
proliferate. In contrast, these findings are consistent with the impaired 
capacity of C57BL/ 6 T cells to proliferate being due to an intrinsic defect. 
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2.4 DISCUSSION 
Initial experiments in this chapter were designed to examine the growth 
of R-MuLV in BALB/c and C57BL/6 mice. R-MuLV grew well in BALB/c 
mice with high levels of infectious virus and virus expressing cells found 
in spleen and high titres of infectious virus in plasma at all times 
examined. Levels of viral antigen in plasma increased with time 
following infection. In contrast, C57BL/ 6 mice were relatively resistant to 
R-MuLV infection. Infectious virus was not detected in plasma or cell 
free spleen homogenates, however virus expressing cells were present in 
the spleen at all times examined p.i. Peak numbers of virus producing 
cells were found at 7 days p.i. and declined thereafter. These data agree 
with numerous reports of R-MuL V replication in BALB / c and C57BL/ 6 
mice. (Rauscher, 1962; Rauscher and Allen, 1964; Boiron et al., 1965; 
Seidel and Lauenstein, 1969; Ishimoto et al., 1971; McCoy et al., 1972; Iwai 
et al., 1994). Furthermore, the data in Tables 2.1 and 2.2 are similar to the 
reported growth of the closely related F-MuLV in these two strains of 
mice (Odaka and Yamamoto, 1962; Ceglowski et al., 1974; Isaak et al., 
1979). 
The degree of splenomegaly at 2-3 weeks p.i. is proportional to the dose of 
virus given (Chirigos, 1964). This is thought to be due to infection of 
progenitor erythroid cells and the subsequent mitogenic effect of R-SFFV 
upon these cells. Indeed, the titre of R-SFFV in a virus sample can be 
measured by counting the number of colonies of proliferating cells that 
appear in the spleen of infected mice at day 7-9 p.i. (Pluznik and Sachs, 
1964). There have been many reports which use spleen weight (measured 
either by direct weighing or, for long term studies, palpation of the spleen 
in anaesthetised mice) to measure the efficacy of vaccine preparations, 
drug therapies or cytokine treatments in both R-MuLV and F-MuLV 
model systems (Johnson et al., 1988; Chesebro, 1990; Hom et al., 1991; 
Robertson et al., 1992; Ruprecht et al., 1992). In agreement with these 
reports, data in Table 2.1 and 2.2 show that spleen weight increases with 
time in R-MuLV infected BALB/c mice. Furthermore, virus antigen in 
plasma also increases with time p.i. In contrast, infectious virus in 
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plasma and spleen reach high levels early on in infection and remain so 
at all time points examined. As the spleen weight of R-MuLV infected 
C57BL/ 6 mice increased only slightly with time p.i. it may be argued that 
splenomegaly is not be a valid measure of R-MuLV induced disease in 
these mice. However, C57BL/ 6 nude mice or mice depleted of T cells 
(with anti-Thy 1.2 antibodies) developed significant splenomegaly 
following F-MuLV infection (Kitagawa et al., 1986; van der Gaag and 
Axelrad, 1990; Kitagawa et al., 1993). These observations suggest that in 
the absence of effective anti-R-MuLV immune responses C57BL/ 6 mice 
would also develop significant splenomegaly. Spleen weight was 
therefore used in some experiments to measure the outcome of R-MuL V 
infection in both BALE/ c and C57BL/ 6 mice in Chapter 3 and 4. 
The proliferation of splenic T cells from R-MuL V infected BALB / c mice 
was markedly suppressed. The proliferation of these cells was inhibited 
as early as 1 week p.i. and was almost completely ablated by week 2 p.i. 
These observations are similar to those of Hayry et al., (1970) who showed 
that proliferation by PHA-stimulated spleen cells from infected mice was 
suppressed early during infection. The proliferation of splenic B cells 
from BALB / c mice was also markedly inhibited over the times examined. 
These observations are consistent with a number of reports of suppressed 
B cell function (antibody production) during R-MuLV infection of 
susceptible mice strains such as BALBI c (Ceglowski and Friedman, 1968; 
Millian and Schaeffer, 1968), SJL/J (Meredith et al., 1978), DBA/2 (Toth et 
al., 1971b; T6th et al., 1971c). 
C57BL/ 6 mice also exhibited immunosuppression following R-MuL V 
infection. The proliferation of both splenic T and B cells was found to be 
inhibited as early as 1 week p.i and was suppressed until 3 weeks p.i. The 
magnitude of suppressed T cell proliferation appeared to be greatest at 
week 2 p.i. while B cell proliferation was suppressed at all time points 
examined. Antibody production is also suppressed in R-MuLV infected 
C57BL/ 6 mice however the degree of suppression is lower than that 
found in susceptible mice (Borella, 1969; Seidel and Lauenstein, 1969). 
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In contrast with the suppressed proliferation exhibited by B cells from 
R-MuLV infected BALBI c mice, Meredith et al., (1978) showed that LPS 
induced proliferation by spleen cells from highly susceptible SJLI J mice 
not suppressed following R-MuL V infection. In addition, R-MuL V 
infection of C57BLl10 mice was found to have little effect on proliferation 
of spleen T and B cells (Meredith et al., 1978) . The cause of the 
discrepancy between the data presented here and the findings of Meredith 
et al., (1978) is unclear, however it may be due to genetic differences 
between the mice used here (BALBI c and C57BLI 6) and those used by 
Meredith et al., (1978; SJLIJ and C57BLl10). 
The proliferation of lymph node T cells from BALBI c and C57BLI 6 mice 
was unaffected by R-MuLV infection. These findings are similar to those 
of Hayry et al., (1970) who showed that R-MuLV infection of BALBI c 
mice had no effect on the proliferation of PHA stimulated lymph node 
cells. Furthermore, Gabrilovich et al., (1993) showed that R-MuL V 
infection of BALBI c or C57BLl10 mice had little effect on the capacity of 
lymph node T cells to proliferate in response to allogeneic stimulation. 
The data presented here are also similar to those of Genovesi et al., (1982), 
who showed that F-MuLV infection of susceptible DBAl2 mice had little 
effect on Con A stimulated proliferation of lymph node T cells. 
The causes of suppressed lymphocyte proliferation in spleens of R-MuL V 
infected mice are unclear. As there is a large increase in the number of 
progenitor erythroid cells in the spleen of R-MuL V infected BALBI c mice 
it has been postulated that the suppressed proliferation may due to a 
decrease in the proportion of lymphoid cells in the spleen (Hayry et al., 
1970). Analysis of spleen cells by FACS showed that the proportion of 
cells expressing the T cell marker Thy 1.2+ in R-MuLV infected BALBI c 
mice became progressively reduced with time p.i. While this reduction 
appears to be significant, it may not be sufficient to explain the near total 
suppression of T cell proliferation in these mice. Furthermore, 
proliferation by spleen T cells from C57BLI 6 mice was suppressed 
without a reduction in the proportion of Thy 1.2+ cells. Similarly, 
proliferation by spleen B cells from infected mice was impaired but the 
proportion of B220+ cells in spleens of both strains of mice was unaltered 
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or only slightly increased following infection. Together, these data argue 
against changes in the proportion of splenic T or B cells as the 
predominant mechanism of immunosuppression. 
Flow microfluorometry of splenocytes from infected BALB / c mice 
demonstrated that at least 90% of cells were Thy 1.2+ or B220+ cells (Table 
2.3). Based on this finding it would appear that less than 10% of spleen 
cells used in culture were progenitor erythroid cells as neither Thy 1.2 or 
B220 markers have been shown to be expressed by progenitor erythroid 
cells. This conclusion is in marked contrast to previous reports which 
estimated that 3 weeks p.i. progenitor erythroid cells comprise over 60% 
of spleen cells in BALBI c mice (de Both et al., 1978). On the data 
presented in this chapter it is difficult to satisfactorily explain this 
inconsistency. It may be that progenitor erythroid cells were vulnerable 
to lysis by exposure to hypotonic conditions which were used to lyse red 
blood cells prior to culture. May-Grunwald Giemsa staining of cytospin 
preparations of water lysed spleen cells would readily resolve this 
contention by showing the proportion of progenitor erythroid cells and 
lymphocytes following removal of red blood cells. At present it is not 
possible to determine the proportion of progenitor erythroid cells within 
the spleen by FACS analysis due to a lack of specific antibodies. To date 
the only antibody specific for erythroid cells is produced by the clone Ter 
119 (Ikuta et al., 1990). This antibody is specific for highly differentiated 
erythroid cells (normoblast stage; Ikuta et al., 1990) but not BFU-e and 
CFU-e (which are major targets of R-MuLV; see Section 1.9.2) and would 
therefore appear to be of limited value here. 
An alternative possible explanation of the discrepancy between the data 
described here and that by de Both et al., (1978) is the coexpression of 
Thy 1 and B220 by spleen lymphocytes following R-MuL V infection. 
Snapper et al., (1988) found that B cells stimulated with LPS or antigen in 
the presence of IL-4 were induced to express surface Thy 1. This 
hypothesis seems unlikely as cytokine expression analysis (see Chapter 3) 
indicated that IL-4 synthesis is not induced following R-MuLV infection, 
however at this time it is premature to dismiss this possibility. Further 
experiments designed to examine splenocyte expression of other T and B 
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cell markers such as CD3, CD4, CDS and surface IgM during R-MuLV 
infection may clarify the proportion of lymphocytes in the spleen of 
R-MuL V infected mice. 
Addition of spleen cells from infected BALB / c mice to was found to 
markedly suppress the proliferation of spleen T cells from uninfected 
mice. Spleen cells from R-MuL V infected C57BL/ 6 mice also inhibited 
the proliferation of spleen T cells from uninfected mice although this 
effect was not as pronounced. This effect was more pronounced when 
cells from mice infected 2 and 3 weeks earlier were used. These data 
indicate that an immunosuppressive factor was produced by spleen cells 
from infected mice. The identity of this suppressive factor was not 
characterised, however this is clearly an interesting finding which 
requires further study. The possible nature of this suppressive factor is 
discussed below. 
Perhaps the most likely source of this suppression is R-MuLV itself. 
Mixing experiments similar to those described here have shown that 
F-MuL V infected spleen cells inhibit the ability of uninfected splenocytes 
to generate antibody producing cells (Kately et al., 1974). The inhibition of 
proliferation was independent of cell contact and was blocked by 
anti-F-MuLV antibodies which suggests that the immunosuppressive 
factor was associated with F-MuLV. Similar experiments using 
anti-R-MuLV antibodies in the mixing experiments described in Section 
2.3.4 would determine if R-MuLV was responsible for the observed 
suppression. Alternatively, addition of supernatants from cultured 
spleen cells of infected mice to uninfected cells with or without 
anti-R-MuL V antibodies would clarify the role of virus in suppressed 
T cell proliferation. If R-MuL V was found to be the suppressive factor 
described in Section 2.3.4, subsequent experiments may then determine 
whether infectious virus was required to mediate this effect. This may be 
achieved by inactivation (by heat or UV irradiation) of R-MuL V present 
in supernatants from cultures of cells from infected mice prior to 
addition to normal cells. 
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The suppressive effect reported in Section 2.3.4 may be mediated by virus 
encoded peptides. A number of investigators have demonstrated that 
purified, inactivated retrovirus virions (Orosz et al., 1985) and some 
retroviral proteins such as p 15E encoded by MuL V (Snyderman and 
Ciancolo, 1984; Ruegg et al., 1989a) inhibit a range of immune responses . 
Moreover, disrupted R-MuLV particles were found to inhibit PHA 
induced proliferation by BALB/c spleen cells (Fowler et al., 1977), while 
plSE protein of R-MuLV inhibits T cell proliferation in vitro (Ruegg et 
al., 1989a). Addition of antibodies which bind specific viral proteins 
during m1x1ng experiments may resolve their role 1n 
immunosuppression associated with R-MuLV infection. 
The level of R-MuLV infection in each immune cell populations found 
within the spleen and lymph nodes of infected mice was not determined. 
This information is of interest as infection of immune cells by R-MuL V 
may alter their function leading to suppressed responses. Furthermore, 
this data may help to explain the correlation of the degree of 
immunosuppression associated with R-MuL V infection with the level of 
virus replication in BALB / c and C57BL/ 6 mice. Determination of virus 
levels and targets of virus infection in spleen and lymph node may also 
shed light on how R-MuLV infection markedly suppresses spleen but not 
lymph node T cells function. 
In another attempt to clarify the nature of suppressed T cell proliferation, 
efforts were made to obtain purified population of T cells from the spleen 
cells from infected mice. Removal of low density cells, Jlld+ cells and 
debris from spleen cells of R-MuLV infected BALBI c mice restored T cell 
proliferation to levels similar to those of cells from uninfected mice 
treated in a similar manner. These data suggest that the suppressed T cell 
proliferation is not due to defects intrinsic to spleen T cells but is 
mediated by other factors. In contrast, similar treatment of spleen cells 
from R-MuLV infected C57BL/6 mice did not ameliorate the impaired 
T cell proliferation exhibited by untreated spleen cells. This observation 
raises the possibility that a different mechanism may be involved in 
suppression of C57BL/ 6 T cell proliferation. Clearly further investigation 
of the mechanisms of R-MuLV associated immunosuppression in 
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C57BL/ 6 mice is required before definitive statements can be made 
concerning this issue. Indeed, isolation of highly pure populations of 
immune cells eg. T cell subsets, B cells, macrophages would allow the 
function of each population to be assessed without the complicating 
presence of other cells. 
The protocol employed to obtain similar levels of T cells in splenocyte 
populations from uninfected and infected mice was found to give 
relatively poor enrichment of T cells ie. 50-70%. It is unclear why these 
levels were so low. The protocol used was based on reports which 
showed that Percoll gradients could successfully separate T cells from 
progenitor erythroid cells in spleen cells from F-MuLV infected mice 
(Lopez-Cepero et al., 1988; Faxvaag et al., 1993). Furthermore treatment of 
splenocytes from normal or vaccinia infected mice with Jlld antibody 
plus complement has been successfully used to remove B cells in our 
laboratory (Carpenter et al., 1994). It is a possibility that the density of 
progenitor erythroid cells which accumulate during R-MuL V infection 
may be different to those found in F-MuLV infected mice, however there 
is no data to support this contention. In the light of the inefficiency of the 
enrichment protocols used here, alternative methods may have yielded 
better levels of purification. Positive selection of lymphocyte 
subpopulations using specific antibodies coupled to magnetic beads may 
be a more satisfactory method. An alternative approach would be to use 
fluorescence activated cell sorting of spleen cells to obtain relatively pure 
populations of cells. 
Activated macrophages have been shown to inhibit lymphocyte 
proliferation in a wide range of infectious disease models including 
parasite infestations (Wellhausen and Mansfield, 1979) as well as bacterial 
(Al-Ramadi et al., 1992) and viral infections (Rowland et al., 1994; Pertile 
et al., 1995). A number of soluble molecules produced by activated 
macrophages, such as NO, prostaglandins, H202 or the cytokine TGF-~ 
have been shown to mediate these effects (Albina et al., 1991). Clearly, 
activated macrophages are a potential source of immunosuppression 
associated with R-MuLV infection. The removal of macrophages from 
spleen cells of infected mice or the addition of activated macrophages to 
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splenocytes from normal mice may clarify the role of activated 
macrophages in the immunosuppression associated with R-MuLV 
infection. Alternatively, inhibition of the suppressive factors produced 
by activated macrophages may also clarify the importance of these 
molecules in R-MuLV induced immunosuppression. The role of two of 
these molecules (NO and prostaglandins) 1n R-MuL V 
immunosuppression is examined in Chapter 4. 
Suppression of IL-2 production by T cells has been found in a number of 
retroviral infections such as F-MuLV (Lopez-Cepero et al., 1988; Soldaini 
et al., 1991t LP-BMS MuLV (Gazzinelli et al., 1992) and HIV (Murray et al., 
1984). As IL-2 acts as a growth factor for stimulated T cells (Swain, 1991t 
impaired IL-2 synthesis may be integral to the suppressed spleen T cell 
proliferation observed following R-MuLV infection. This hypothesis is 
examined in Chapter 3. 
In summary, the results in this chapter show that the capacity of spleen 
but not lymph node lymphocytes to proliferate is suppressed following 
R-MuLV infection. This effect is more pronounced in susceptible 
BALBI c mice compared with resistant C57BL/ 6 mice. Analysis of 
lymphocyte populations in the spleen indicated that suppressed in vitro 
lymphocyte proliferation may not be due to changes in the proportions of 
different lymphocyte subgroups in the spleen. 
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Chapter 3 
The role of cytokines and T cell subsets in 
resistance or susceptibility to R-MuL V 
3.1 INTRODUCTION 
The failure to control or resolve infectious disease often results from the 
generation of inappropriate immune responses, rather than the lack of 
immune responses (Bretscher et al., 1992; Powrie and Coffman, 1993a). 
The observation that cytokine production by Th2 CD4+ T cell clones can 
be cross-regulated by cytokines produced by Thl clones (and vice versa) 
raised the possibility that in vivo CMI and humoral immune responses 
were regulated by cytokines (Mosmann et al., 1986b; Mosmann and 
Coffman, 1989). Parasite infestation of inbred mice with differing 
susceptibilities to disease clearly demonstrated the role of cytokines in the 
generation of protective or non-protective immune responses (reviewed 
in Sher et al., 1992). In the context of virus infections, the expression of 
strong CMI responses is often associated with the generation of protective 
immune responses (Blanden, 1974). This is well illustrated by pox virus 
infections of mice, where viral clearance is dependent on the generation 
of cytotoxic T cells (Blanden, 1971b; Blanden, 1971a) and the production of 
IFN-y (Ruby and Ramshaw, 1991; Karupiah et al., 1993a). In contrast, the 
expression of the type 2 factor, IL-4, by recombinant vaccinia viruses 
inhibits the generation of CTL and markedly delays clearance of infection 
(Andrew and Coupar, 1992; Sharma et al., 1996). 
The anti-R-MuL V immune response differs quite markedly between 
strains of inbred mice. BALB / c mice produce only small amounts of 
anti-R-MuLV antibodies following infection, while C57BL/ 6 mice 
generate high titres of R-MuLV specific antibodies (Toth et al., 1971c; 
McCoy et al., 1972). In addition, BALB/c mice generate weak 
anti-R-MuL V CMI responses, while resistant C57BL/ 6 mice produce a 
relatively strong CMI response (McCoy et al., 1972; Mortensen et al., 1973). 
The failure of BALB/c mice to generate a protective anti-R-MuLV 
immune response does not reflect a lack of recognition of R-MuL V 
antigens, as mice are protected following administration of a variety of 
vaccine preparations (Fink and Rauscher, 1964; Peters et al., 1975; Kelloff 
et al., 1976). These observations suggest that the failure of BALBI c mice 
to control R-MuLV infection reflects the lack of a vigorous immune 
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response rather than the generation of an inappropriate immune 
response. As discussed above, the production of certain patterns of 
cytokines are associated with the generation of particular types of 
immune responses. The lack of markedly polarised anti-R-MuLV 
immune responses in resistant or susceptible mice make it unlikely that 
resistance or susceptibility to R-MuL V stems from the mutually exclusive 
production of type 1 or type 2 cytokines as found in other model systems 
(reviewed in Mosmann and Sad, 1996). 
Nevertheless, the marked differences in anti-R-MuLV immune response 
generated by C57BL/ 6 and BALE/ c mice may be a major determinant of 
the resistance or susceptibility exhibited by these strains. As cytokines are 
integral to the generation and regulation of immune responses, the 
expression and activities of cytokines and T cell subsets in resistant or 
susceptible strains infected with R-MuL V were investigated. 
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3.2 MATERIALS AND METHODS 
3.2.1 
Virus and infection of mice As described in Section 2.2.2 
Culture media As described in Section 2.2.3 
R-MuLV ELISA As described in Section 2.2.7 
Statistical analysis As described in Section 2.2.15 
3.2.2 Mice 
BALB / c, C57BL/ 6, were used as described in Section 2.2.1. CBA/J and 
athymic nude Swiss mice were raised under specific pathogen-free 
conditions and were used at 8-12 weeks of age. 
IFN-y receptor gene knock out (IFN-y R0 1°) and isogenic wild type (IFN-y 
R+I+) mice were obtained from Dr M. Aguet (Genentech, CA, USA) and 
generously provided by Dr A. Ramsay (Division of Cell Biology, JCSMR). 
Both strains were generated on a homozygous 129 /Sv /Ev background 
(Huang et al., 1993). 129 /Sv /Ev mice have the genotype H-2bc, Fv-]nr/nr, 
Fv-2s/s. Male mice were raised under specific pathogen free conditions 
and used at 8-10 weeks of age. 
3.2.3 RNA extraction from spleen cells 
RNA was extracted using the guanidinium thiocyanate/ acid phenol 
extraction method (Chomczynski and Sacchi, 1987). Briefly, 2-5x107 
freshly isolated spleen cells (Section 2.2.9) were collected, snap frozen in a 
dry ice ethanol bath and stored at -70°C until further processing. Frozen 
cells were denatured in guanidinium isothicyanate followed by extraction 
of DNA and proteins using acid phenol/ chloroform. Following 2 rounds 
of isopropanol precipitation, the RNA was washed with ice cold 70% 
ethanol, dried and resuspended in diethyl pyrocarbonate (DEPC) treated 
water (Sambrook et al., 1989). Total RNA was quantified 
spectrophotometrically using absorbance at 260nm. RNA integrity was 
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determined by electrophoresis of 3 µg total RNA through a denaturing, 
formaldehyde, 1 % agarose gel (Sambrook et al., 1989) followed by staining 
with ethidium bromide (10 µg/ml) for 20 min and destaining for at least 
1 h. Intact RNA had a typical 2:1 ratio of 28S to 18S ribosomal RNA 
bands. 
3.2.4 cDNA synthesis 
1 µg of total RNA was diluted in 8 µl of DEPC treated water, denatured at 
80°C for 5 min and then chilled on ice for 5 min. A master mix of cDNA 
synthesis reagents was prepared and added to the denatured RNA in a 
12 µl volume. Each cDNA reaction had a final volume of 20 µl and 
contained 2 mM of dATP, dCTP, dGTP and dTTP (Pharmacia), 50 mM 
Tris-HCl pH 8.3 (at 42°C), 50 mM KCl, 10 mM MgCb, 10 mM DTT, 0.5 mM 
spermidine, 8 U AMV reverse transcriptase, 20 U RNasin and 0.5 µg oligo 
dT1s (Promega, Madison, WI, USA). The oligo dT was allowed to anneal 
at 23°C for 10 min followed by cDNA synthesis for 45 min at 42°C. The 
reaction was terminated by heating the reaction mixture at 95°C for 5 
min. 
3.2.5 PCR amplification of cDNA 
PCR amplification was used to detect cDNA encoding cytokines and the 
'housekeeping gene' hypoxanthine phosphoribosyl transferase (HPRT). 
Primer sequences were taken from previously published reports and 
synthesised by the Biomolecular Resources Facility of the JCSMR or 
purchased from commercial sources. Primers used for PCR are listed in 
Appendix 1. All primers were selected to span at least one intron to allow 
differentiation between amplification of cDNA and genomic DNA. 
The cDNA prepared in Section 3.2.4 was diluted to a volume of 100 µl 
with water so as to have the equivalent of 50 ng of cDNA per 5 µl. 
Aliquots of 7 µl were stored at -20°C until amplification. A PCR master 
mix was prepared and 15 µl of the mix was added to 5 µl of cDNA. Each 
reaction contained 0.2 U Supertaq polymerase (Stehelin & CIE AG, Basel, 
Switzerland), 10 mM Tris-HCl pH 9 (25°C), 50 mM KCl, 0.01 % gelatin, 1.5 
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mM MgCl2, 0.1% Triton X-100, 0.2 mM dATP, dCTP, dGTP and dTTP 
(Pharmacia) and 10 pMol of each appropriate forward and reverse primer. 
PCR amplification of cDNA was conducted using a FTS-1 Capillary 
Thermal Sequencer (Corbett Research, Mortlake, NSW, Australia). After 
incubation for 3 min at 94°C the cDNA was amplified using the following 
conditions. Denaturation at 95°C for 5 sec, primer annealing at 55°C for 5 
sec (IFN-y, TNF-a, HPRT), 60°C for 5 sec (IL-2) or 53°C for 10 sec (IL-4) 
followed by primer extension at 72°C for 1 min. Between 20 and 35 cycles 
were used to amplify each cDNA. 
RNA was derived from cells known to express desired genes and used as 
positive controls for reverse transcription and PCR amplification. 1 µg of 
RNA from each source was handled as described in Section 3.2.4 and 3.2.5. 
RNA extracted from the T cell cone HDK-1, was used as a positive control 
for IFN-y and TNF-a analysis (Cher and Mosmann, 1987). The T cell 
clone Dl0, was used as source of RNA encoding IL-4 (Rojo and Janeway 
Jr, 1988). Both T cell clones were stimulated with Con A (10 µg/ml; 
Pharmacia) for 16 h prior to RNA extraction. HDK-1 and Dl0.G4.l cells 
were generously provided by Dr P. Hodgkin (JCSMR) and maintained as 
described in (Hodgkin et al., 1990). RNA from a-6310 cells transfected 
with an expression plasmid encoding IL-2 (Section 3.2.8) was used as a 
positive control for IL-2 expression. 
PCR products were analysed by electrophoresis through 1.5% 
agarose /TAE gel and visualised by ethidium bromide staining and UV 
illumination (Sambrook et al., 1989). 
3.2.6 Recombinant cytokines 
Recombinant standard murine TNF-a and IFN-y were kindly provided by 
Boehringer Ingelheim, Vienna, Austria; TNF specific activity was 
1.2 x 107 U /mg, IFN-y specific activity was 1 x 107 U /mg. Recombinant 
standard murine IL-6 and IL-4 were prepared by F. Lee and R. Kastelein 
(DNAX, Palo Alto, CA, USA) and provided by Dr P. Hodgkin (JCSMR). 
The IL-6 preparation was calibrated against the International Standard 
reference preparation of recombinant human interleukin-6 (88/ 514; 
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National Institute of Biological Standards and Control, Herts, U.K.) and 
therefore all titres have been given in arbitrary units (AU). The specific 
activity of the 88/514 preparation was 5x106 AU /mg using a bioassay 
which employed the EBY-transformed B cell lines CESS or SKW6-CL4. 
Recombinant standard IL-2 was purchased from Genzyme Diagnostics 
(MA, USA) and had a specific activity of 2.5 x 106 U / mg. 
3.2.7 Antibodies 
Hybridomas were used to generate a variety of antibodies. Hybridomas 
were grown in MLCM and kept in log phase by adjusting cell 
concentration to 105 /ml every 2 days. Antibodies were either used as 
ascites or culture supernatants. 
Culture supernatants containing antibodies were generated by culturing 
hybridoma cells for 5-7 days. Cells were removed from the exhausted 
media by centrifugation at 500g for 10 min. The antibody containing 
supernatant was filtered and stored at -20°C. 
Swiss outbred mice were used to generate antibody containing ascites. 
These mice were primed for hybridoma growth 10-14 days previously by 
i.p. injection of 500 µl of pristane (Sigma) and injected with 5xl06 
hybridoma cells. After a further 10-14 days, the mice were killed and the 
ascites removed. The ascites was allowed to clot at room temperature for 
1 hand then clarified by centrifugation at 500g for 10 min. Some batches 
of ascites were extracted with CCl2FCClF2 (Sigma) to remove lipids. An 
equal volume of CCl2FCClF2 was added to ascites followed by gentle 
mixing. The two phases were separated by centrifugation at 500g for 
5 min. The upper, aqueous phase was removed, aliquoted and stored at 
-20°C until required. 
Cytokine neutralising mAb used in this study were derived from the 
following hybridomas: S4B6 (anti-IL-2, Rat IgG2a; Mosmann et al., 1986a), 
llBll (anti-IL-4, rat IgGl; Ohara and Paul, 1985), 20F3 (_Anti-IL-6, rat IgGl; 
Starnes Jr et al., 1990), JES5-2A5 (anti-IL-10, rat IgGl; Abrams et al., 1992), 
R4-6A2 (anti-IFN-y, rat IgGl; Spitalny and Havell, 1984), XT22 
71 
(anti-TNF-a, rat IgGl; Abrams et al., 1992), GL113 (anti-~-galactosidase, rat 
IgGl; kindly provided by Dr. J. Abrams, DNAX). 
Mice were depleted of cells expressing CD4 or CDS using the monoclonal 
antibodies produced by hybridomas GKl.5 (Dialynas et al., 1983) or D9 
(Fazekas de St Groth et al., 1986) respectively. Clone GKl.5 produces rat 
IgG 2b antibody, while clone D9 secretes mouse IgG 2a antibody. Antibody 
produced by clone SFR8-B6 (anti human HLA-Bw6; rat IgG 2b; Radka et 
al., 1982) was used as a control antibody in depletion experiments. 
Hybridomas were grown and were used to generate antibody containing 
ascites as described above. 
The concentration of antibody in various preparations was determined 
using an antibody specific capture ELISA system as described by (Coffman 
and Carty, 1986). The ELISAs used unlabelled and biotinylated polyclonal 
rabbit antisera specific for mouse IgG2a and Rat IgGl, IgG2b antibodies 
(Southern Biotechnology Associates Inc, Alabama, USA). Each ELISA 
used 96 well, round bottomed plates (Dynatek) and were developed and 
measured as described for the R-MuLV specific ELISA in Section 2.2.7. 
Known amounts of purified antibody were used to determine the 
absorbance produced by given amounts of antibody. A curve of best fit 
was used to calculate the levels of antibody in ascites or culture 
supernatant. Purified mouse antibodies from the clones UPC 10 (IgG2a; 
Sigma) and purified rat antibodies from clones GL113 (IgGl) and 30-H12 
(IgG2b; generously provided by Dr P Hodgkin, JCSMR) were used as 
standards. 
3.2.8 Cells used in cytokine bioassays 
The IL-6 responsive cell line, B9, a B-cell hybridoma cell line, (Aarden et 
al., 1 987) was obtained from Dr L.A. Aarden (University of Amsterdam, 
Amsterdam, The Netherlands). B9 cells were maintained in H16 media 
supplemented with 10% of a Con A supernatant source of IL-6. The IL-2 
or IL-4 dependent cell line HT-2 (Watson, 1979) was obtained from 
Dr P. Hodgkin (JCSMR) and was maintained in MLCM containing 50 
72 
U/ml murine IL-2. The IL-2 was prepared as a supernatant from a-6310 
cells as described below. 
The Con A supernatant source of IL-6 was generated by stimulating 
CBA/H mouse spleen cells with Con A. Single cell suspensions were 
made from spleens aseptically removed from 15 CBA/H mice. After 
washing, these cells were resuspended in 200 ml H16 containing 1 % FCS 
and 5 µg/ml Con A (Pharmacia) and incubated at 37°C in a humidified 
atmosphere of 5% CO2 for 3 days. Cells and debris were removed by 
centrifugation at 500g for 10 min. Con A was precipitated with a-methyl-
D-mannoside (2 g/100 ml; Sigma) and collected at 11,000g for 10 min at 
4°C. The supernatant was sterilised by filtration through a 0.22 µm 
membrane and stored at -70°C. 
Recombinant IL-2 was generated using a-6310 cells stably transfected with 
a plasmid expressing the IL-2 gene (Karasuyama and Melchers, 1988). 
Cells were grown in MLCM containing 1 mg/ml geneticin (GIBCO BRL) 
and kept in log phase by adjusting cell concentration to 105 / ml every 2 
days. To obtain supernatants containing IL-2, cells were washed with 
MLCM and cultured in the absence of geneticin. After 48 h, the cells were 
removed by centrifugation and the supernatant was aliquoted and stored 
at-20°C. 
3.2.9 Cytokine biological assays 
3.2.9.1 IL-2 Bioassay 
The HT-2 cell line was used to determine the concentration of IL-2 in 
culture supernatants. Supernatant samples and recombinant IL-2 
standard were serially diluted 1:2 across a 96 well flat-bottomed plate 
(Nunc, Kamstrup, Denmark) in a volume of 50 µl. HT-2 cells were 
washed twice with MLCM containing no IL-2 and 2xl03 cells were added 
to each well in 50 µl of MLCM. The cultures were incubated at 37°C in a 
humidified atmosphere of 5% CO2.for 24 h. Proliferation was quantified 
using [3H]-TdR incorporation (lµCi/well; ICN Radiochemicals) during 
the last 4 h of culture and was measured using a 96 well automatic 
harvester and a betaplate liquid scintillation counter (Pharmacia). IL-2 
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titres in culture supernatants were determined by comparison of the 
dilution giving half maximal proliferation of HT-2 cells with that of a 
concurrently run standard recombinant murine IL-2. As HT-2 cells also 
proliferate in response IL-4, IL-2 specific proliferation was determined by 
neutralising IL-4 in culture supernatants with anti-IL-4 mAb (llBll) 
which was generously provided by Dr P. Hodgkin CTCSMR) and was used 
at 10 µg/ml. 
3.2.9.2 IL-6 Bioassay 
IL-6 was measured using the IL-6-responsive cell line, B9. A 50 µl sample 
of culture supernatant or recombinant human IL-6 was serially diluted in 
H16 medium across a 96 well flat bottomed plate (Nunc) and cultured 
with 104 washed B9 cells in a total volume of H16 media. The cells were 
incubated at 37°C in a humidified atmosphere of 5% CO2 for 44 h. 
Proliferation was determined by [3H]-TdR incorporation over the last 4 h 
of culture as described in Section 3.2.9.1. The concentration of IL-6 
supernatants was determined by comparison of the dilution producing 
half maximal proliferation of B9 cells with that of proliferation generated 
by standard recombinant human IL-6 
3.2.10 Cytokine ELISAs 
3.2.10.1 TNF-a and IFN-y ELISA 
TNF-a and IFN-y in culture supernatants were measured by indirect 
ELISA methods (Sheehan et al., 1989) and were performed as described in 
Carpenter et al., (1994). Anti-IFN-y and anti-TNF-a antibodies were 
generously provided by Dr E. Carpenter and Mrs S. Fordham (Division of 
Cell Biology, JCSMR). Briefly, the IFN-y ELISA used protein A purified 
R4.6A2 hybridoma cell ascites fluid (American Type Culture Collection, 
Rockville, MD, USA), polyclonal rabbit anti-Mu-IFN-y antisera and 
alkaline phosphatase conjugated sheep anti rabbit antisera (Silenus, 
Parkeville, Victoria, Australia). The TNF ELISA employed immobilised 
hamster anti-mouse TNF mAb, TN3-19.12, (Sheehan et al., 1989; kindly 
provided by Celtech, Berkshire, U.K.) polyclonal rabbit anti-Mu-TNF-a 
antisera and alkaline phosphatase conjugated anti-rabbit lg (Silenus). 
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Both ELISAs utilised 96 well, flat bottomed ELISA plates (Titertek, Flow 
Laboratories, The Netherlands). The developed ELISAs were measured 
using conditions described for the R-MuLV specific ELISA in Section 
2.2.7. A standard amount of recombinant cytokine was used to determine 
optical densities for given amounts of IFN-y or TNF-a. A curve of best fit 
was determined and used to calculate the levels of cytokine in culture 
supernatants. The lower limit of the assays were routinely found to be 
0.3 ng/ml (IFN-y) and 160 pg/ml (TNF-a) 
3.2.10.2 IL-4 ELISA 
IL-4 in culture supernatants was assayed using indirect capture ELISA. 
Antibody reagents were generously provided by Ms K. Doherty (Division 
of Cell Biology, JCSMR). The coating antibody (llBll, 5 µg/ml) was 
diluted in 15 mM Na2CO3, 35 mM NaHCO3 coating buffer (pH 9.6) and 
was bound to 96 well, round bottomed ELISA plates (Dynatech) by 
incubation overnight at 4°C in 50 µI/well. Unbound llBll was removed 
by washing each well 3 times with phosphate-buffered saline (PBS) 
containing 0.1 % Tween (Sigma; PBS-Tween). Protein binding sites in 
each well were blocked by the addition of 100 µl 3% BSA PBS-Tween 
followed by incubation for 1 h at 37°C. After washing three times in PBS-
Tween, 50 µl of diluted sample or recombinant murine IL-4 was added to 
each well and allowed to bind for 2 h at room temperature. The plates 
were washed again and 50 µl of biotinylated anti-IL-4 antibody (BVD6; 625 
ng/ml) was added to each well and allowed to bind for 1 h at room 
temperature. After washing, 50 µl of streptavidin conjugated-alkaline 
phosphatase (Amersham; diluted 1:1000) was added to each well and 
incubated for 1 h at room temperature. The plates were washed, 
developed and measured as described in Section 2.2.7. A standard curve 
was generated for each ELISA and a curve of best fit applied. The 
equation describing the curve was used to determine the cytokine levels 
in supernatant samples. The lower limit of the assay was routinely found 
to be 1.5 U /ml. 
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3.2.11 Preparation of spleen cell culture supernatants for cytokine assay 
Supernatants from spleen or lymph node cells were produced by 
stimulation with plate bound anti-CD3 as described for proliferation 
assays (Section 2.2.10). Plates were centrifuged at 200g for 2 min prior to 
removing supernatants. Supernatants for IL-2 assay were taken after 24 h 
culture. After 72 h, supernatants were taken and frozen at -20°C until 
assayed for IFN-y, IL-6, IL-4 or TNF-a content. 
3.2.12 Removal of adherent spleen cells. 
Adherent cells were removed from spleen cells (prepared in Section 2.2.9) 
by incubating 5x107 cells at 107 /ml in a 60 x 15 mm petri dish (Nunc) for 
1 h at 37°C. Non-adherent cells were removed by washing the petri dish 
with warm MLCM and were allowed to adhere to a second petri dish for a 
further 30 min at 37°C. Non-adherent cells were again removed by gentle 
washing, collected by centrifugation at 200g for 5 min and resuspended in 
5 ml MLCM. The cells were subsequently treated as being 107 cells/ml 
and used to produce culture supernatants as described in Section 3.2.11 
Adherent cells were collected by scraping with a rubber policeman, 
washed and counted. The proportion of Thy 1.2+ cells was determined 
using flow cytometry as described in Section 2.2.12 and 2.2.13. 
3.2.13. In vivo neutralisation of cytokines during R-MuL V infection 
Monoclonal antibodies which were specific for a given cytokine were 
used to neutralise cytokines in vivo. Groups of BALB/c and C57BL/6 
mice were treated with ascites diluted in PBS to 2.5 mg/ml antibody and 
was given at 0.5 mg/ dose in 200 µl i.p. Antibody was given on days -1, 1, 
3, 7, 10 and every 3 days thereafter. Half the mice in each group were 
infected with 104 pfu R-MuLV i.p. on day 0. After 14 days, mice were 
sacrificed and spleen weight of each mouse was determined as an 
indicator of disease progression as described by (Chirigos, 1964). 
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3.2.14 R-MuLV infection of IFN-y R+I+ and IFN-y R 010 mice 
Groups of IFN-y R+I+ and IFN-y R0 1° mice were inoculated with 104 pfu 
R-MuL V. A number of parameters of virus growth were examined 
including spleen weight, viral antigen in plasma and in vitro 
proliferation of spleen T and B cells. 
3.2.14.1 Virus growth 
Blood was obtained from mice via tail vein bleeding and was placed in 
heparinised tubes (Section 2.2.8). Plasma was separated from blood cells 
by centrifugation at 12000g for 5 min. Plasma was isolated and stored at 
-20°C. Viral antigen in plasma was assayed by ELISA as described in 
Section 2.2.7 
Spleens were taken from uninfected and infected mice and weighed. Half 
of each spleen was used to prepare single cell suspensions (Section 2.2.9) 
while the other half was fixed in 10% neutral buffered formalin prior to 
processing and embedding in paraffin. Serial, 4 µM sections were taken, 
stained with May-Grunwald Giemsa and mounted in mounting fluid. 
3.2.14.2 Proliferation assays 
Single cell suspensions were prepared from pooled spleens from BALB / c 
or C57BL/ 6 mice as described in Section 2.2.9. Spleen B and T cell 
proliferation was assayed as described in Section 2.2.10. 
3.2.15 In vivo depletion of cells expressing CD4 or CDS 
Groups of BALB / c and C57BL/ 6 mice were depleted of cells expressing 
CD4 and/ or CDS using GK 1.5 (anti-CD4) or D9 (anti-CDS) ascites. As a 
control, ascites from SRFS-B6 (anti-human HLA-Bw6) was used. 
Appropriate antibody was diluted to 2.5 mg/ml antibody with PBS and 
given on days -1, 1, 3, 7, 10 and every 4 days thereafter. Half the mice 
from each group were infected with R-MuL V i.p. on day 0. After 21 days, 
mice were sacrificed and spleen weight of each mouse was determined as 
an indicator of disease progression as described by (Chirigos, 1964). 
Depletion of the appropriate cell type was assayed using fluorescence 
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microfluorometry as described in Section 3.2.16. Depletion resulted in 
loss of >90% of target cells from lymph nodes. 
3.2.16 Immunofluorescence staining and flow cytometry 
The efficiency with which CD4 or CDS expressing cells were depleted was 
assayed using flow cytometry. The following mAb and antisera were used 
to determine the proportion of cells expressing specific cell surf ace 
antigens. Anti-CD4 , clone RL 172.4 (rat IgM; Ceridig et al., 1985) and 
anti-CDS, clone 31M (rat IgG; Sarmiento et al., 1980) were used as 
hybridoma supernatants and were generously provided by Dr J. Ruby 
(JCSMR). The supernatants were used undiluted. Rabbit polyclonal 
anti-rat K chain (Immunotech S.A., Marseille, France) was used to detect 
cells which had bound either of the two rat mAb and was used at a 
dilution of 1:40 in PBS. 
At the end of each depletion experiment the efficacy of cell depletion was 
determined by flow microfluorometry of single cell suspensions prepared 
from pooled brachial and inguinal lymph nodes (CD4 and CD8) from 2-3 
mice. Staining of lymph node or spleen cells was performed on 106 cells 
using reagents described above (CD4, CD8). Cells were stained as 
described in Section 2.2.12 and analysed by flow cytometry as described in 
Section 2.2.13. 
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3.3 RESULTS 
3.3.1 Qualitative analysis of cytokine mRNA expression in spleens of 
R-MuLV infected mice 
Cytokines are integral to the generation and mediation of adaptive 
immune responses. It was therefore of interest to determine cytokine 
expression during R-MuLV infection. The expression of mRNA 
encoding IL-2, IL-4, IFN-y, TNF-cx and the 'housekeeping' gene HPRT in 
spleen cells during R-MuLV infection was examined by reverse 
transcriptase-PCR (RT-PCR). Cytokine expression was determined 1n 
both BALB / c and C57BL/ 6 mice at various stages of infection. 
Figure 3.1 illustrates the expression of mRNA encoding IL-2 or IL-4 in the 
spleens of R-MuL V infected mice. R-MuL V infection of either BALB / c or 
C57BL/6 mice led to a slight reduction of IL-2 mRNA expression in the 
spleen. In BALB / c mice the effect was most marked at 21 days p.i. while 
in C57BL/6 mice expression was reduced at day 14 and 21. In contrast, IL-4 
expression was largely unaltered following R-MuL V infection of mice of 
either strain. 
The expression of IFN-y and TNF-cx mRNA by spleen cells was also 
examined (Figure 3.2). Production of IFN-y mRNA was induced at low 
levels following R-MuLV infection of BALBI c mice and peaked at 2 
weeks p.i. Expression of IFN-y mRNA in spleen cells from infected 
C57BL/ 6 mice were also slightly elevated with levels being similar at all 
time p.i. examined. Slightly elevated levels of TNF-cx mRNA were also 
found in the spleens of infected BALB / c mice, with peak levels observed 
at 2 weeks p.i. In contrast, R-MuL V TNF-cx expression in the spleen cells 
from C57BL/ 6 mice was reduced at 2 weeks p.i. 
The consistency of the RT-PCR procedure was demonstrated by RT-PCR 
amplification of HPRT mRNA (Figure 3.1) and equivalent ethidium 
bromide staining of 3 µg total RNA run through a formaldehyde gel 
(Figure 3.1). 
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Figure 3.1 Cytokine and HPRT mRNA expression by spleen cells from 
R-MuLV infected BALB/c and C57BL/6 mice 
Total RNA was extracted from spleen cells taken from BALBI c or 
C57BL/ 6 mice which were either uninfected or infected with R-MuL V 1, 2 
or 3 weeks earlier . cDNA, equivalent to 50 ng of total RNA, was 
amplified by PCR through the number of cycles indicated (cycles) using 
cytokine specific primers. PCR products were run through 1.5 % agarose 
gels and stained with ethidium bromide. To confirm RNA integrity, 3 
mg of total RNA was run through a 1 % agarose-formaldehyde gel and 
stained with ethidium bromide. Data shown is representative of 2 
batches of RNA and at least 1 cDNA synthesis and PCR amplification 
from each batch of RNA. 
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Figure 3.2 RT-PCR analysis of IFN-yand TNF-a mRNA 
RNA was extracted from spleen cells of BALB / c and C57BL/ 6 mice which 
were uninfected or infected with R-MuLV 1, 2 or 3 weeks earlier. mRNA 
encoding IFN-y or TNF-a was detected by RT-PCR amplification. RT-PCR 
of cDNA equivalent to 50 ng of total RNA was amplified through 22 or 25 
cycles of PCR. PCR products were electrophoresed through 1.5% agarose 
and stained with ethidium bromide. Data shown is representative of 2 
batches of total RNA and at least 1 cDNA/PCR amplification from each 
batch of RNA. 
22 cycles 25 cycles 
BALB/c C57BL/6 BALB/c C57BL/6 
0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 + 
IFN-y 
22 cycles 25 cycles 
BALB/c C57BL/6 BALB/c C57BL/6 
+ 0 1230123012301 2 3-
TNF-a 
To demonstrate that the amplification of cytokine cDNA was 
proportional to the amount of input cDNA and to the number of cycles of 
amplification, serial 10 fold dilutions of cDNA known to contain cytokine 
sequences were amplified through 25, 30 and 35 cycles of PCR. The data 
shown in Figure 3.3 clearly demonstrates that by increasing the number 
of cycles of amplification low levels of cytokine cDNA (equivalent to 5 pg 
total RNA) were readily detected. The data also shows that amplification 
of high levels of input cytokine cDNA (equivalent 5 ng total RNA) 
rapidly becomes non-proportional and yields no further increases in 
amplified DNA. 
3.3.2 Production of cytokines by spleen cells following in vitro 
stimulation with anti-CD3 antibodies 
Next, the capacity of spleen cells from R-MuLV infected mice to produce 
cytokines was examined as it was important to confirm that changes in 
cytokine mRNA expression resulted in altered cytokine synthesis. Spleen 
cells were isolated, stimulated with immobilised anti-CD3 antibodies 
(anti-CD3) and the accumulation of cytokines in culture supernatants was 
assayed. 
3.3.2.1 Effect of R-MuLV infection on IFN-y production by spleen cells 
Anti-CD3 stimulated spleen cells from uninfected mice produced 
substantial levels of IFN-y. Supernatants collected from stimulated 
C57BL/ 6 cells consistently contained more IFN-y than from BALB / c mice 
(p<0.01; Table 3.1). Anti-CD3 stimulated spleen cells from infected 
C57BL/ 6 mice produced 2-3 fold less IFN-y compared to levels produced 
by cells from uninfected mice. BALBI c spleen cells initially produced 
increased levels of IFN-y, while IFN-y production was markedly 
suppressed (p<0.01) at 3 weeks p.i. Supernatants from unstimulated 
spleen cells from uninfected or infected mice contained less than 1 ng/ml 
IFN-y (data not shown). 
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Figure 3.3 Qualitative RT-PCR analysis of cytokine mRNA expression by 
cytokine expressing cell line 
cDNA was prepared from total RNA derived from cytokine producing 
cell lines. Serial 10 fold dilutions of cDNA, equivalent to between 5 ng 
and 5 pg of total RNA were amplified through 25, 30 or 35 cycles of PCR 
using cytokine specific primers. PCR products were run through 1.5% 
agarose gels and stained with ethidium bromide. 
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Table 3.1 Cytokine production by anti-CD3 stimulated spleen cells 
Weeks Post 
Infection 
Uninfected 
1 
2 
3 
IFN-y (ng/ml) 
BALB/c 
17.1 + 2.3 
57.1 + 2.2b 
12.8 + 2.1 C 
2.3 + 0.2d 
C57BL/6 
139 + 18.0 
84.2 + 10.Sd 
58.7 + 8.0d 
50.7 + 5.3d 
IL-2 (U /ml) 
BALB/c 
2.36 + 0.17 
3.15 + 0.40b 
1.07 + 0.16d 
<0.5d 
C57BL/6 
1.90 + 0.23 
1.96 + 0.27 
1.69 + 0.46 
1.23 + 0.27C 
IL-6 (AU /ml) 
BALB/c 
3.53 + 0.75 
4.65 + 0.9oa 
4.95 + o.ssa 
2.02 + 0.21b 
C57BL/6 
5.34+ 0.48 
5.29 + 1.07 
19.3 + 2.16b 
9.22 + 0.27b 
Spleen cells from R-MuLV infected or uninfected BALB / c or C57BL/ 6 mice were stimulated with anti-CD3 antibody in vitro. 
After 72 h culture, supernatants were taken and assayed for cytokine content. Cytokine levels are expressed as mean of 3 wells 
assayed in duplicate (+ SD) and are representative of 2 (IL-2) or 3 (IFN-y, IL-6) experiments. Cytokine levels found in 
supernatants from unstimulated cultures were as follows: IFN-y <1 ng/ml; IL-2 <0.5 U /ml; IL-6 <0.25 AU /ml 
a) Significantly greater (p<0.05) than levels in supernatants from cells of uninfected mice 
b) Significantly greater (p<0.001) than levels in supernatants from cells of uninfected mice 
c) Significantly less (p<0.05) than levels in supernatants from cells of uninfected mice 
d) Significantly less (p<0.001) than levels in supernatants from cells of uninfected mice 
3.3.2.2 IL-2 production by spleen cells from R-MuLV mice 
Spleen cells derived from uninfected mice produced low levels of IL-2 
following stimulation with anti-CD3. Supernatants from stimulated 
BALBI c splenocytes at 1 or 2 weeks p.i. were largely similar to levels 
produced by cells from uninfected mice (Table 3.1). In marked contrast, 
IL-2 was not detected in the supernatants from spleen cells at 3 weeks. 
The levels of IL-2 in supernatants from stimulated C57BLI 6 spleen cells 
were largely unaltered at 1, 2 and 3 weeks p.i. (Table 3.1). IL-2 levels in 
supernatants from unstimulated spleen cell cultures were below the 
levels of detection in the HT-2 assay ie. less than 0.5 U I ml ( data not 
shown). 
3.3.2.3 Production of IL-6 by spleen cells from R-MuLV infected mice 
IL-6 was also found in supernatants of spleen cells stimulated with 
anti-CD3. Cells from uninfected mice of either strain produced 
approximately the same levels of IL-6 (Table 3.1). Spleen cells from 
C57BLI 6 mice initially produced unaltered levels of IL-6, however at 2 
weeks p.i. IL-6 production was at markedly greater levels compared to 
production by cells from uninfected mice (p<0.001). At 3 weeks, IL-6 
levels were still elevated over uninfected controls but significantly less 
than at week 2 p.i. (p<0.001). In contrast, IL-6 production by spleen cells 
from BALBI c mice was largely unaltered following R-MuLV infection. 
Unstimulated spleen cells also produced IL-6 but was at levels less than 
10% of those found in stimulated cultures (data not shown). 
Carpenter et al., (1994) demonstrated that IL-6 production by spleen cells 
from vaccinia virus infected mice was independent of T cells but 
dependent on adherent cells. The role of adherent cells in IL-6 
production by spleen cells from R-MuLV infected mice was therefore 
examined. Results in Table 3.2 show that adherent cells were required for 
peak IL-6 production by spleen cells from uninfected mice of either strain. 
Adherent cells comprised less than 2% of cells applied to the petri dishes. 
Flow cytometry of adherent cells demonstrated that less than 20% 
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Table 3.2 IL-6 production by anti-CD3 stimulated non-adherent spleen 
cells 
Mouse R-MuLV 
BALB / c 
+ 
+ 
C57BL/ 6 
+ 
+ 
Spleen cells 
Whole 
Non-adherent 
Whole 
Non-adherent 
Whole 
Non-adherent 
Whole 
Non-adherent 
IL-6 (AU / ml) 
2.03 + 0.33 
1.12 + 0.13a 
1.96 + 0.90 
1.07 + 0.35b 
0.91 + 0.30 
0.52 + o.05a 
5.31 + 0.75 
2.81 + 0.9oa 
Whole or non-adherent spleen cells from uninfected mice or mice 
infected with R-MuLV 14 days earlier were stimulated with anti-CD3 
antibodies. After 72 h culture supernatants were taken from 3 wells and 
assayed for cytokine content using the B9 /IL-6 bioassay. Data expressed as 
mean IL-6 concentration of 3 wells assayed in duplicate (+ SD). Data 
representative of two experiments. IL-6 levels found in supernatants 
from unstimulated cultures were less than 0.25 AU /ml. 
a) p<0.01 versus whole spleen 
b) p<0.05 versus whole spleen 
expressed Thy 1.2 which suggests that the majority of these cells were not 
T cells and were presumably macrophages and monocytes (Mosier, 1984). 
3.3.2.4 Cytokine production by anti-CD3 stimulated lymph node cells 
from R-MuLV infected mice 
It was of interest to examine cytokine expression by lymph node cells 
since R-MuL V infection has markedly different effects on the capacity of 
spleen and lymph node cells to proliferate following stimulation with 
anti-CD3 ( chapter 2). At various times p.i., cells from systemic lymph 
nodes were obtained, stimulated with immobilised anti-CD3 and the 
level of cytokines in culture supernatants were determined. 
Lymph node cells derived from uninfected C57BL/6 and BALB/c mice 
produced significant levels of IFN-y following stimulation with anti-CD3. 
Levels of IFN-y produced by BALB / c lymph node cells were largely 
unaltered at 7 days p.i. (Table 3.3). At 14 and 21 days p.i. IFN-y production 
was slightly elevated- compared to uninfected mice. Lymph node cell 
culture supernatants from R-MuL V infected C57BL/ 6 mice also contained 
elevated amounts of IFN-y compared to uninfected controls with peak 
production occurring at 14 days p.i. (Table 3.3). Culture supernatants 
from unstimulated lymph node cells contained levels of IFN-y which 
were below limits of detection (0.3 ng/ml; data not shown). 
Anti-CD3 stimulated lymph node cells from R-MuLV infected mice 
produced elevated amounts of IL-6 compared to uninfected controls 
(Table 3.3). Cultures of cells from BALB / c mice produced increasing 
amounts of IL-6 with time p.i. which reached peak levels at 21 days p.i. In 
a pattern similar to IL-6 production by anti-CD3 stimulated spleen cells, 
IL-6 production by C57BL/ 6 cells reached peak levels at 14 days p.i. and 
was still elevated 21 days p.i. although at concentrations less than 14 days. 
Levels of IL-6 in supernatants of unstimulated cultures were below limits 
of detection ( <0.1 AU /ml; data not shown). 
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Table 3.3 Interferon-y and interleukin-6 production by anti-CD3 stimulated lymph node cells 
Interferon-y (U /ml) Interleukin-6 (AU /ml) 
Weeks Post Infection 
Uninfected 
1 
2 
3 
BALB/c 
14.9 + 1.3 
10.3 + 0.4C 
23.8 + 1.2a 
24.9 + 1.sa 
C57BL/6 
5.8 + 0.7 
9.1 + 0.6a 
38.3 + 6.8b 
21.1 + 1.2a 
BALB/c 
0.12 + 0.01 
0.37 + 0.04b 
0.78 + 0.06b 
1.84 + 0.29b 
C57BL/6 
0.13 + 0.02 
1.46 + 0.09b 
2.16 + 0.32b 
1.26 + 0.30b 
Lymph node cells from R-MuL V infected or uninfected BALB / c O! C57BL/ 6 mice were stimulated with anti-CD3 antibody in 
vitro. After 72 h culture, supernatants were taken and assayed for cytokine content. Data expressed as mean cytokine 
concentration of 3 wells assayed in duplicate (+ SD) and are representative of 2 experiments. Cytokine levels found in 
supernatants from unstimulated cultures were as follows: IFN-y <1 ng/ml ; IL-6 <0.1 AU /ml 
a) Significantly greater (p<0.001) than levels in supernatants from cells of uninfected mice 
b) Significantly greater (p<0.001, Welch's t test) than levels in supernatants from cells of uninfected mice 
c) Significantly less (p<0.001) than levels in supernatants from cells of uninfected mice 
IL-2 a not detected in culture supernatants of anti-CD3 stimulated 
1 mph node cells (data not sho n ). The limit of detection of the IL-2 
assa used as 0.5 U / ml. IL-2 was not detected in supernatants from 
cultured cells from uninfected or infected BALB / c or C57BL/ 6 mice. 
3.3.2.6 Production of IL-4 and TNF-a by immune cells from R-MuL V 
infected mice 
Culture supernatants from anti-CD3 stimulated spleen and lymph node 
cells were also assayed for IL-4 and TNF-a. Stimulated spleen cells from 
uninfected BALB / c mice produced detectable levels of IL-4 
(approximately 10 U / ml). In contrast, IL-4 was not detected in 
supernatants from spleen cells of infected BALB I c mice. IL-4 was not 
found in culture supematants from uninfected or infected C57BL / 6 mice 
(data not shown). In addition, IL-4 was not found in supernatants from 
anti-CD3 stimulated cultures of lymph node cells from BALB / c or 
C57BL/ 6 mice (data not shown). T F-a was not detected in culture 
supernatants of stimulated spleen or lymph node cells from either strain 
of mice (data not shown). 
3.3.3 In vivo neutralisation of cytokines with monoclonal antibodies 
So far in this chapter, experiments have been designed to examine 
cytokine expression during R-MuLV infection. In order to demonstrate a 
functional role for these cytokines in resistance or susceptibility to 
R-MuLV, mice were treated with cytokine neutralising mAb. 
Groups of BALB /c or C57BL/6 mice were treated with anti-cytokine mAb 
on days -1, 1, 3, 7 and 10 p.i. Half the mice in each group were infected 
with R-MuLV on day 0. Spleen weight on day 14 was used as a measure 
of disease progression and virus growth (Chirigos, 1964). 
The treatment of R-MuL V infected BALB / c or C57BL/ 6 mice with 
neutralising antibodies to the cytokines IL-2, IL-4, IL-6 or to an irrelevant 
antigen had no significant effect on R-MuLV induced increases in spleen 
weight after 14 days (Table 3.4). Although there was an increase in mean 
spleen weights of BALB / c mice treated with anti-IL-6 mAb this was not 
3 
Table 3.4 In vivo neutralisation of cytokines with mAb during R-MuLV 
infection 
Cytokine Neutralising 
Antibody 
BALB/c 
None 
Anti-~-Gal 
Anti-IL-2 
Anti-IL-4 
Anti-IL-6 
None 
Anti-~-Gal 
Anti-IL-2 
Anti-IL-4 
Anti-IL-6 
C57BL/6 
None 
Anti-~-Gal 
Anti-IL-2 
Anti-IL-4 
Anti-IL-6 
None 
Anti-~-Gal 
Anti-IL-2 
Anti-IL-4 
Anti-IL-6 
R-MuLV 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Spleen weight (mg) 
99 + 7 
101 5 
104 + 10 
110 + 11 
87+4 
300 + 10 
291 + 18 
318 + 31 
279 + 20 
456 + 70 
92 + 7 
77+ 2 
73 +8 
78 +5 
75 +4 
178 + 14 
233 + 24 
165 + 14 
167 + 17 
188 + 18 
Groups of 8 BALB / c or C57BL/ 6 mice were treated with PBS or mAb to 
~-galactosidase, IL-2, IL-4 or IL-6 on days -1, 1, 3, 7 and 10 p.i. Each dose 
was 0.5 mg of antibody in ascites diluted in PBS and given i.p. Half the 
mice from each group were infected with 104 pfu R-MuLV i.p. on day 0 
while uninfected mice received PBS. After 2 weeks, the spleen was taken 
from each mouse and weighed in tared tubes. Data expressed as mean 
spleen weight of 4 mice + SEM. 
significant (p=0.06). eutralisation of TNF or IFN-y also had no 
significant effect on R-MuL V induced splenomegaly in either strain of 
mouse (Table 3.5). The slightly increased mean spleen weight of 
anti-TNF-cx mAb treated C57BL/ 6 mice (Table 3.5) was not statistically 
significant (p=0.08) nor was it reproducible in subsequent experiments 
(Table 3.6). 
TNF-cx and IFN-y have been shown to synerg1se 1n direct antiviral 
activity and activation of cells such as macrophages (Wong and Goeddel, 
1986; Ding et al., 1988). In order to examine the role of these two factors in 
resistance to R-MuLV infection, anti-TNF-cx and anti-IFN-y mAb were 
administered to mice together during R M uL V infection. Data in 
Table 3.6 indicate that treatment with mAb against IFN-y or TNF-cx either 
alone or together had no effect on R-MuLV induced splenomegaly. 
3.3.4 R-MuLV infection of IFN-y R0 l0 and IFN-y R+I+ mice 
Selective inactivation of the IFN-y or IFN-y receptor gene in mice has 
been shown to markedly alter the immune response to viruses and other 
pathogens (Dalton et al., 1993; Huang et al., 1993; Muller et al., 1994). Mice 
with the IFN-y receptor gene disrupted were used to further investigate 
the role of IFN-y in the immune response during R-MuLV infection. 
The growth of R-MuLV in IFN-y R+I+ and IFN-y R0 1° mice as well as the 
ability of immune cells to proliferate in vitro was determined. 
3.3.4.1 Growth of R-MuLV in mice lacking functional IFN-y receptor 
Groups of IFN-y R0 1° or IFN-y R+I+ mice were infected with R-MuLV 
and spleen weight and plasma viral antigen were determined as a 
measure of virus growth at 1, 2 and 3 weeks p.i. 
Infection of IFN-y R0 1 ° mice led to an increase in mean spleen weight 
which was approximately 4 times that of normal spleens at 1 week p.i. 
Splenomegaly persisted at 2 and 3 weeks, but at lower levels than at 1 
week (Table 3.7). In contrast, elevated spleen weights were not found in 
IFN-y R+ I+ mice until week 3 p.i. At this time there was a marked 
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Table 3.5 In vivo neutralisation of cytokines with mAb during R-MuL V 
infection 
Cytokine Neutralising 
Antibody 
BALB/c 
None 
Anti-TNF-a 
Anti-IFN-y 
Anti-IL-10 
None 
Anti-TNF-a 
Anti-IFN-y 
Anti-IL-10 
C57BL/6 
None 
Anti-TNF-a 
Anti-IFN-y 
Anti-IL-10 
None 
Anti-TNF-a 
Anti-IFN-y 
Anti-IL-10 
R-MuLV 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Spleen weight (m g) 
117+4 
111 + 6 
109 + 3 
107+5 
408 + 32 
457 + 57 
382 + 53 
470 + 64 
90+ 3 
74+ 2 
68+ 6 
76+4 
219 + 10 
328 + 51 
148 + 23 
153 + 17 
Groups of 10 BALB / c or C57BL/ 6 mice were treated with PBS or mAb to 
TNF-a, IFN- y or IL-10 on days -1, 1, 3, 7 and 10 p.i. Each dose was 0.5 mg 
of antibody in ascites diluted in PBS and given i.p. Half the mice from 
each strain were infected with 104 pfu R-MuLV i.p. on day 0 while 
uninfected mice received PBS. After 2 weeks, the spleen was taken from 
each mouse and weighed in tared tubes . Data expressed as mean spleen 
weight of 5 mice + SEM. 
Table 3.6 In vivo neutralisation of TNF-a and IFN-y during R-MuL V 
infection of C57BL/ 6 mice 
Cytokine neutralising R-MuLV Spleen weight 
antibody 
PBS 78 +3 
TNF-a 74 + 11 
IFN-y 75+5 
TNF-a + IFN-y 68 + 2 
PBS + 198 + 28 
TNF-a + 127+ 7 
IFN-y + 172 + 21 
TNF-a + IFN-y + 139 + 11 
Groups of 10 C57BL/ 6 mice were treated with PBS or mAb to TNF-a, 
IFN-y or both TNF-a and IFN-y on days -1, 1, 3, 7 and 10 p.i. Each dose 
was 0.5 mg of antibody in ascites diluted in PBS and given i.p. in a 200 µl 
volume. Half the mice from each group were infected with 104 pfu 
R-MuLV i.p. on day 0 while uninfected mice received inert carrier alone. 
After 2 weeks, the spleen was taken from each mouse and weighed in 
tared tubes. Data expressed as mean spleen weight of 5 mice+ SEM. 
Table 3.7 Growth of R-MuLV in IFN-y R+I+ or IFN-y R 0 1° mice 
Mouse Strain Weeks Post Infection Plasma An ti gen a Spleen Weight (mg) Mean Spleen Weightb 
IFN-yR+/+ Uninfected 32,32,32,32 169, 144, 82, 80 118 + 22 
1 512,256,128,128 175,149,133,131 145 + 11 
2 128,64,32,32 131, 119, 118, 117 121 + 3 
3 512,256,256,32 414,365,243, 78 275 + 75 
IFN-yR0 1° Uninfected 32,32,32,32 55,54,51,46 51 + 2 
1 512,256,256,256 264,234,231,146 219 + 25d 
2 64,64,32C 141,131,109 127 + lQd 
3 128, 128,64,64 123, 119, 109, 96 112 + 6d 
Groups of 4 IFN-y R+I+ or IFN-y R0 1° mice were given 104 pfu R-MuLV i.p. 1, 2 or 3 weeks previously. Blood was collected 
from each mouse by tail vein puncture. Plasma was separated from blood cells and was stored at -20°C until assayed for viral 
antigen. The spleen was taken from each mouse and weighed in tared, sterile tubes. 
a) Endpoint of R-MuL V ELISA of R-MuLV antigen in plasma 
b) Mean spleen weight of 4 mice + SEM 
c) One mouse died 13 days p.i. from unknown causes 
d) Significantly different (p<0.001) when compared to spleen weight of uninfected 1nice 
increase in spleen weight in 3 out of 4 mice, however due to range of the 
data this difference is not statistically significant (p=0.09, Welch's t test) . 
Levels of viral antigen in the plasma of IFN-y R+ I+ mice was biphasic: 
High levels plasma viral antigen were found at 1 and 3 weeks p.i. while 
somewhat lower levels were found at week 2 (Table 3.7). The patterns of 
plasma viral antigen levels in IFN-y R 0 / 0 mice were similar to those 
found in IFN-y R+ / + mice at 1 and 2 weeks. In contrast, levels of viral 
antigen titres in plasma at 3 weeks p.i. were lower in IFN-y R0 1° mice 
compared with IFN-y R+I+ mice. 
3.3.4.2 Histological analysis of spleen from IFN-y R 0 l 0 and IFN-y R+I+ 
mice following R-MuL V infection 
R-MuLV infection had significant effects on the cellular composition of 
the spleen of IFN-y R0 1° and IFN-y R+I+ mice. Early in infection of IFN-y 
R+I + mice, small pockets of progenitor haematopoietic cells appeared in 
the red pulp, however spleen architecture was largely unaltered (Figure 
3.4). At 3 weeks p.i. the areas of progenitor haematopoietic cells in the red 
pulp were extensive and there was significant disruption of splenic 
architecture. In contrast, there were large areas of progenitor 
haematopoietic cells in the spleen and moderate disruption of normal 
spleen morphology at 1 week p.i. in IFN-y R0 1 ° mice (Figure 3.5). The 
area of progenitor haematopoietic cells in the red pulp was reduced at 2 
weeks p.i. and at 3 weeks these progenitor haematopoietic cells were 
largely absent. The identity of the haematopoietic cells mentioned above 
is unclear (Dr A. Hapel, Division of Clinical Sciences, JCSMR, personal 
communication), however it seems likely that they are progenitor 
erythroid cells (Rauscher, 1962; Hanna et al., 1970a). 
3.3.4.3 Effect of R-MuL V infection· on spleen cell proliferation of 
IFN-y R 0 l0 and IFN-y R+I+ mice 
A feature of R-MuLV infection is the marked suppression of spleen 
lymphocyte proliferation. It was therefore of interest to determine if 
R-MuLV induced immunosuppression was dependent upon IFN-y 
activity. The ability of spleen cells from IFN-y R0 1° and IFN-y R+ I+ mice 
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Figure 3.4 Histology of spleens from R-MuLV infected IFN-y R+I+ mice 
Spleens were taken from groups of 4 uninfected IFN-y R+I+ mice or mice 
which had been infected for t 2 or 3 weeks with R-MuL V. The spleens 
were collected and fixed in neutral buffered formaldehyde. Sections were 
prepared and stained with May Grunwald Giemsa. Sections shown are 
representative of 4 spleens. Magnification x40 is shown. White pulp 
(WP), Red pulp (RP) and Haematopoietic progenitor cells ( •) are 
indicated. 
Normal spleen morphology is illustrated in micrograph of spleen from 
uninfected mice. White and red pulp are well delineated. At 1 and 2 
weeks post infection pockets of progenitor haematopoietic cells were 
found in the red pulp. At 3 weeks p.i. progenitor haematopoietic cells 
had infiltrated large areas of red pulp. The photomicrograph of spleen at 
3 weeks shows white pulp surrounded by red pulp largely comprised of 
progenitor haematopoietic cells. 
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Figure 3.5 Histology of spleens from R-MuLV infected IFN-y R 0 l0 mice 
Spleens were taken from groups of 4 uninfected IFN-y R0 1° mice or mice 
which had been infected for 1, 2 or 3 weeks with R-MuLV. The spleens 
were fixed for histology in neutral buffered formaldehyde. Sections were 
prepared and stained with May Grunwald Giemsa. Sections shown are 
representative of 4 spleens. Magnification x40 is are shown for all 
sections. White pulp (WP), Red pulp (RP) and Haematopoietic 
progenitor cells ( ~) are indicated. 
The micrograph of spleen from uninfected mice shows normal spleen 
morphology. At 1 week p.i. progenitor haematopoietic cells were 
widespread throughout the red pulp. At 2 weeks p.i. there were only 
several pockets of progenitor haematopoietic cells in the red pulp, while 
at 3 weeks these cells were largely absent from the spleen. 
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to proliferate 1n response to stimulation with anti-CD3 or LPS was 
investigated. 
The proliferation of anti-CD3 stimulated spleen cells from IFN-y R+ I+ 
mice was unaltered at 7 and 14 days p.i. but was markedly suppressed at 
day 21. The proliferative response of spleen cells from wild type mice to 
LPS stimulation was also rapidly suppressed follow ing R-MuLV 
infection. The suppression persisted and was greatest at 21 days p.i. In 
sharp contrast, the response of spleen cells from IFN-y R0 1 ° mice was 
largely unaltered at all times p.i. examined (Figure 3.6). In addition, LPS 
induced proliferation by spleen cells from IFN-y R 0 1 ° mice was also 
unaffected by R-MuLV infection (Figure 3.6) . These data suggest that 
suppressed lymphocyte proliferation associated with R-MuLV infection 
may be dependent upon IFN-y activity. 
3.3.5 Effect of in vivo depletion of CD4+ or CDS+ cells on R-MuLV 
induced splenomegaly 
In adoptive transfer studies it was demonstrated that both CD4 + and CDS+ 
spleen cells from R-MuLV immunised mice were required to confer 
maximal protection against R-MuLV to naive BALBI c mice (Hom et al., 
1991). To extend this further, the role of cells expressing CD4 or CD8 in 
mediating resistance or susceptibility to R-MuL V infection was 
investigated by depleting mice of these cell subsets during virus 
challenge. Spleen weight on day 21 was used as a measure of virus 
growth and disease progression (Chirigos, 1964). 
The efficiency with which T cell subsets were depleted was determined by 
flow microfluorometry of lymph node cells stained for CD4 or CD8 
expression. The depletion protocol routinely eliminated greater than 
90% of cells expressing CD4 or CD8 (data not shown). The proportion of 
cells expressing CD4 or CD8 in lymph nodes of mice given ascites from 
the rat IgG2b control were similar to those of mice receiving PBS alone 
(data not shown). 
Treatment with anti-CD4 antibody decreased R-MuLV induced 
splenomegaly (p<0.015) in infected C57BL / 6 mice (Table 3.8). In contrast, 
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Figure 3.6 Proliferation of spleen cells from IFN-y R 010 IFN-y R+I+ following R-MuL V infection 
Spleens were removed from IFN-y R0 1° ( - ) and IFN-y R+I+ (-a-) which were uninfected or infected with 104 pfu 
R-MuLV 7, 14 or 21 days. The spleens taken at each time point were pooled and single cell suspensions were prepared 
as described in section 2.2.8. Spleen cells were cultured with immobilised anti-CD3 antibodies or LPS for 72 h and 
labelled with 0.5 µCi [3H]-TdR for a further 16 h. Data points indicate the mean proliferation of 4 replicate culture (+ 
SEM) as measured by [3H]-TdR incorporation. Data shown is from a single experiment. 
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Table 3.8 R-MuL V disease in mice depleted of cells expressing CD4 or CD8 
Groups of 8 or 10 BALB / c or C57BL/ 6 mice were treated with PBS or 
ascites containing mAb against CD4 (GK 1.5) or CDS (D9). In experiment 2 
ascites containing rat IgG 2b antibody reactive with an irrelevant antigen 
(SFR8-B6) was used as an ascites control. Mice were given 0.5 mg of each 
antibody on days -1, 1, 3, 7 and 10 and then every 4 days until day 21. 
Ascites was diluted in PBS and given i.p. in 200 µl. Half the mice in each 
group were given 104 pfu/ ml i.p. on day 0. Spleen weight at day 21 p.i. 
was used as an estimate of disease progression. 
a) Mean spleen weight of 5 mice (experiment 1) or 4 mice (experiment 2) 
+SEM 
b) Significantly greater (p<0.05) than spleen weight of infected mice given 
PBS 
c) Significantly less (p<0.001) than spleen weight of mice given PBS 
d) Significantly less (p<0.05) than spleen weight of infected mice given 
PBS 
Table 3.8 (cont) 
Antibody 
BALB/c 
PBS 
Rat IgG 2b 
Anti-CD4 
Anti-CDS 
PBS 
Rat IgG 2b 
Anti-CD4 
Anti-CDS 
C57BL/6 
PBS 
Rat IgG 2b 
Anti-CD4 
Anti-CDS 
PBS 
Rat IgG 2b 
Anti-CD4 
Anti-CDS 
R-MuLV 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Mean Spleen weight (mg)a 
Experiment 1 
95+3 
ND 
102 + 4 
95 +4 
843 + 97 
ND 
467 + 175 
1202 + 74b 
78 +5 
ND 
75 +3 
74+5 
174 + 11 
ND 
121 + 11 d 
295 + 24b 
Experiment 2 
134+ 7 
159 + 17 
131 + 14 
132 + 11 
983 + 30 
1052 + 68 
541 + 32C 
948 + 53 
97.5 + 11 
102 + 7 
88 + 13 
82+4 
223 + 35 
219 + 17 
109 + 9d 
310 + 23b 
depletion of CDS+ cells during R-MuLV infection led to increased spleen 
weight (p<0.05). These data indicate that CD4+ and CDS+ cells either 
promote or limit R-MuLV induced splenomegaly, respectively, in 
C57BL/6 mice. 
Splenomegaly in BALB / c mice depleted of CD4 + cells compared with 
mice receiving PBS alone was reduced in both experiments (Table 3.8). 
However, due to the range of the data, the difference was statistically 
significant only in experiment 2 (p<0.001). These results suggest that 
Cp4 + cells may be required for optimal development of disease associated 
with R-MuLV. Virus induced splenomegaly was elevated in BALB/c 
mice which were depleted of CDS+ cells (p=0.02, experiment 1), however 
in experiment 2 there was no difference in spleen weight compared to 
R-MuLV infected PBS treated mice (p>O.l). This variability in spleen 
weight limits the conclusions which may be drawn about the role of CDS+ 
cells in R-MuLV pathogenesis in BALBI c mice. 
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3.4 DISCUSSION 
The type of immune responses generated toward an infectious agent 
often correlate with resistance or susceptibility to infection. Cytokines 
play an integral role in determining the class of the immune response 
which is induced (Ramshaw et al., 1992; Powrie and Coffman, 1993a). 
Thus, the cytokines produced following infection of C57BL/6 or BALBI c 
mice may be expected to influence the type of antiviral immune response 
generated toward R-MuL V and therefore the resistance or susceptibility of 
each strain of mice. The experiments in this chapter were designed to 
determine the patterns of cytokine expression as well as the role of 
cytokines in resistance or susceptibility to R-MuLV induced disease. As 
T cell subsets regulate immune responses via the cytokines they produce 
(Mosmann and Coffman, 1989; Seder and Paul, 1994) the role of these 
cells in resistance or susceptibility to R-MuL V infection was also 
examined. 
Expression of IFN-y mRNA was slightly elevated in the spleens of 
infected BALE/ c and C57BL/ 6 mice. Despite this increase, spleen cells 
from R-MuLV infected C57BL/6 mice and BALB/c mice with established 
disease produced decreased levels of IFN-y following anti-CD3 
stimulation. These observations indicate that in vitro production of 
IFN-y does not directly correlate with the expression of IFN-y mRNA in 
vivo. One interpretation of this result is that IFN-y may be produced in 
vivo by cells that do not respond to anti-CD3 stimulation, such as NK 
cells. It is therefore notable that IFN-y mRNA expression by splenocytes 
was induced following LP-BMS MuL V infection of C57BL/ 6 mice, while 
Con A stimulated IFN-y protein synthesis was progressively reduced 
(Pitha et al., 1988; Gazzinelli et al., 1992; Uehara et al., 1994). Recent 
studies have suggested that NK cells may be the source of elevated IFN-y 
expression in LP-BMS infected mice as LPS induced IFN-y production by 
K cells was increased in LP-BMS infected mice (Uehara et al., 1994; 
Morse et al., 1995). Interestingly, IFN-y mRNA expression by splenocytes 
was also elevated during murine cytomegalovirus (MCMV) infection, 
while Con A stimulated IF -y protein synthesis was progressively 
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reduced. In addition, LPS stimulated IFN-y production by splenocytes was 
increased following MCMV infection (G. Karupiah, JCSMR personal 
communication). Similar experiments using spleen cells from R-MuLV 
infected mice may clarify the contribution of NK cells to the levels of 
IFN-y mRNA which were detected in vivo. 
Post transcriptional regulation of IFN-y expression may also explain the 
disagreement between IFN-y mRNA levels and IFN-y production in 
vitro. Regulation of IFN-y expression is thought to occur primarily at the 
levels of transcription (Farrar and Schrieber, 1993), however it is notable 
that IFN-y mRNA is found at high levels in draining lymph nodes of 
mice infected with ectromelia while IFN-y protein was not detected 
(G. Karupiah, JCSMR personal communication). It is not known at this 
time how this effect is mediated. 
In vitro IL-2 production by spleen cells from BALBI c mice at 1 and 2 
weeks p.i. was similar to that of uninfected controls. IL-2 production by 
spleen cells from infected C57BL/ 6 mice was also largely unaltered 
following R-MuLV infection. However, IL-2 production by BALB/c mice 
at 3 weeks p.i. was markedly suppressed which may lead to reduced T cell 
proliferation at this time (Figure 2.1). Interpretation of this data is 
complicated by the fact that IL-2 is a growth factor for many cells (Swain, 
1991) and therefore the lower levels found may reflect increased 
adsorption of IL-2. This possibility may be examined by determining IL-2 
receptor expression by spleen cells _or assessing the ability of these cells to 
bind IL-2. 
As IL-2 is central to the activation and proliferation of T cells (Swain, 
1991) decreased IL-2 production may be integral to the suppressed 
response of spleen T cells found in R-MuLV infected mice (see Figure 
2.1). However, in vitro IL-2 production by spleen cells from infected 
BALB/c mice was not markedly suppressed until 3 weeks p.i. while T cell 
proliferation was significantly impaired at 1 and 2 weeks p.i. 
Furthermore, spleen cells from infected C57BL/ 6 mice produced IL-2 at 
levels similar to those produced by spleen cells from uninfected mice 
while proliferation of T cells from infected mice was reduced (Figure 2.1). 
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These data suggest that suppressed T cell proliferation may not be due to 
insufficient IL-2 production. Indeed, lower levels of IL-2 may reflect 
impaired responses by T cells following ligation of the T cell receptor or T 
cells receiving weak costimulatory signals. 
IL-2 mRNA expression by spleen cells from infected BALB/c and C57BL/6 
mice was suppressed at 3 weeks p.i. IL-2 production by anti-CD3 
stimulated spleen cells from R-MuLV infected BALB/c mice was also 
reduced at 3 weeks p.i. In contrast, in vitro IL-2 production by spleen cells 
from C57BL/ 6 mice was largely unaltered at 3 weeks p.i. The reason for 
this difference is unclear, however as IL-2 transcription occurs following 
the stimulation of T cell it may be that T cell activation is reduced in 
R-MuLV infected C57BL/ 6 mice. That T cell stimulation in vitro is 
provided by anti-CD3 antibodies raises the possibility that reduced IL-2 
transcription in vivo may be due to defective antigen presentation in 
these mice. It may therefore be interesting to assess the ability of cells 
such as macrophages and dendritic cells from C57BL/ 6 mice to present 
antigen following R-MuLV infection. 
IL-6 production by spleen cells from C57BL/6 mice was elevated following 
R-MuLV infection. IL-6 expression has been shown to be induced during 
infection with a number of viruses, including vaccinia virus (Carpenter 
et al., 1994), Sendai virus (Sehgal et al., 1988) and HIV (Nakajima et al., 
1989). As IL-6 has been shown to activate T cells, promote CTL generation 
and augment antibody production by B cells (van Snick, 1990) the 
increased IL-6 production in resistant mice is consistent with a role of this 
factor in the generation of antiviral immunity in these animals. Peak 
IL-6 production by spleen cells from uninfected and infected BALB / c or 
C57BL/ 6 mice was found to be dependent on adherent cells (Table 3.2). 
The exact identity of the adherent cells was not determined, however a 
majority did not express Thy 1.2 which indicates that they were not T 
cells. These data do not demonstrate which cells produce IL-6, however it 
is notable that plastic adherent cells in human peripheral blood or 
spleens of vaccinia infected mice are the major source of IL-6 produced 
following in vitro stimulation (Aarden et al., 1987; Carpenter et al., 
1994). 
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The pattern of in vitro IL-2 and IFN-y production by spleen cells from 
R-MuLV-infected BALBI c mice (Table 3.1) is similar to that produced by 
phorbol ester and calcium ionophore stimulated spleen cells from 
F-MuLV infected BALB / c mice (Soldaini et al., 1991). In contrast, the 
capacity of splenocytes from F-MuLV infected BALBI c mice to produce 
IL-2 and IFN-y following Con A stimulation was suppressed as early as 1 
week p.i. and completely inhibited by week 3 (Lopez-Cepero et al., 1988; 
Matteucci et al., 1989; Shen et al., 1991; Soldaini et al., 1991). In addition, 
Con A stimulated IL-6 production by spleen cells from F-MuLV infected 
BALB/c mice was markedly suppressed (Faxvaag et al., 1993) while data 
presented in this thesis showed that R-MuL V infection had little effect on 
IL-6 production by anti-CD3 stimulated spleen cells from BALB / c mice. 
These cytokine expression data may reflect differing effects of R-MuLV 
and F-MuL V on the signalling pathways induced by each stimulus. 
IL-4 was not detected in supernatants from anti-CD3 stimulated spleen or 
lymph node cells from infected mice, however stimulated spleen cells 
from uninfected BALB / c mice produced low levels of IL-4. These data 
suggest that spleen and lymph node cells are not primed to produce high 
levels of IL-4 following R-MuLV infection. These data however, do not 
exclude the possibility that IL-4 may be produced at low levels nor the 
possibility that IL-4 may have been consumed by spleen cells during 
culture. An alternative strategy for determining the frequency of IL-4 
secreting T cells by limiting dilution analysis or IL-4 specific ELISPOT 
assay may further clarify IL-4 expression during R-MuLV infection. 
TNF-a was not detected in supernatants from cultured spleen or lymph 
node cells from uninfected or infected mice. These data suggest that 
R-MuLV infection does not prime spleen and lymph node cells to secrete 
high levels of TNF-a following T cell restimulation in vitro. This 
finding is surprising given that T cells secrete TNF-a following in vitro 
stimulation (Beutler and Cerami, 1989). Furthermore, macrophages have 
been shown to produce TNF-a following exposure to IFN-y and/ or 
interaction with activated T cells (Stout, 1993) both of which are present 
in anti-CD3 stimulated cultures. It is possible that membrane bound 
TNF-a represented a significant component of TNF-a production. 
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Further experiments which examine the level of membrane bound 
TNF-a or the TNF-a production by immune cells in response to other 
stimuli known to induce TNF-a synthesis eg. LPS (Beutler and Cerami, 
1989) may examine the effect of R-MuLV infection upon TNF-a 
synthesis. 
In contrast to spleen cells anti-CD3 stimulated lymph node cells from 
R-MuLV infected C57BL/6 or BALB/c mice were found to produce 
elevated levels of IFN-y and IL-6 compared to uninfected controls. The 
dissimilarity between the patterns of cytokine production in spleens and 
lymph nodes may be explained by the differing cellular composition of 
these organs. Moreover, a number of studies have demonstrated that 
lymphocytes from different sites produce different cytokines. Hoiden and 
Moller, (1991) reported that Con A stimulated IFN-y production by spleen 
cells was greater than that produced by lymph nodes. Plastic adherent 
cells were found to regulate cytokine secretion by spleen or lymph node 
cells (Hoiden and Moller, 1991). Daynes et al., (1990) postulated that 
macrophages mediate these effects by local activation of steroid hormones 
which modulate cytokine production by lymphocytes. Virus infection 
introduces a number of other possible regulatory mechanisms. 
Retroviral peptides may serve as immunogenic antigens and as 
immunosuppressive molecules (Snyderman and Ciancolo, 1984). The 
relative levels of R-MuL V in spleen and lymph node was not assessed, 
however viral replication in the spleens of F-MuLV infected mice exceeds 
that in the lymph nodes (Isaak et al., 1979) and therefore R-MuLV levels 
may play a significant role in influencing the expression of cytokines. As 
discussed in Chapter 2, identification of immune cell populations which 
are infected with R-MuLV may shed light on the role of the virus in 
different responses exhibited by spleen and lymph node cells. 
Cytokine production by spleen and lymph node cells from uninfected and 
R-MuLV infected mice was induced in vitro using anti-CD3 antibodies. 
As anti-CD3 antibodies stimulate T cells polyclonally (Maraskovsky et al., 
1991), the cytokines produced reflect the result of stimulating virtually all 
T cells in the lymph node or spleen cultures. This is in contrast to 
antigen stimulated cultures where cytokine production follows 
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stimulation of antigen specific T cells. During an immune response the 
number of antigen specific T cells which are activated and primed to 
express cytokines are increased compared with levels found in naive 
animals (Morris et al., 1992). It may therefore be postulated that changes 
in cytokine production between polyclonally activated immune cells 
from naive mice and mice undergoing an immune response reflect the 
nature of that immune response. Indeed, there are many examples 
where similar cytokines are produced by immune cells which have been 
restimulated in vitro with either antigen or polyclonal T cell stimuli such 
as- anti-CD3 antibodies or Con A during immune responses to viruses 
( iemialtowski and Rouse, 1992; Carpenter et al., 1994) and parasites (Gryzch et 
al., 1991). Moreover, (Kelso et al., 1994) found that in vitro cytokine 
production by lymph node T cells from mice immunised with keyhole 
limpet haemacyanin depended upon the in vivo history of these cells 
rather than the conditions of in vitro restimulation. It seems likely 
therefore, that similar patterns of cytokines may be produced by 
R-MuLV-antigen or anti-CD3 stimulated spleen or lymph node cells from 
R-MuLV infected mice. 
It is notable however, that antigen specific immune responses may 
influence the cytokines produced by non-antigen specific T cells (Kullberg 
et al., 1992; Coyle et al., 1995). For example, mice infested with 
Schistosoma mansoni exhibit marked deviation of immune responses to 
non-5. mansoni antigens toward type 2 cytokine production and down 
regulation of CMI responses (Kullberg et al., 1992; Actor et al., 1994). In 
this context, it is conceivable that the cytokines produced by non-antigen 
specific T cells following polyclonal activation in vitro may influence 
cytokines produced by antigen specific T cells. In light of this possibility it 
is clear that antigen dependent restimulation of immune cells is required 
to clarify T cell dependent cytokine production during R-MuLV infection. 
A wide spectrum of cytokines may be expressed during an immune 
response. There are a number of examples where the pattern of cytokines 
expressed are markedly polarised towards either type 1 or type 2 cytokines 
(Sher et al., 1992; Romagnani, 1994). Examination of cytokine expression 
following R-MuL infection indicated that both susceptible and resistant 
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mice predominantly expressed type 1 cytokines. These observations 
suggest that the susceptibility exhibited by BALBI c mice is not due to a 
bias towards type 2 cytokine production which may be inappropriate for 
responses favouring virus clearance. Similar observations have been 
made by (Brenner et al., 1994) who showed that HSV-1 resistant and 
susceptible mice produce type 1 cytokines following infection. 
Interestingly, in this present study, spleen cells from BALBI c mice 
consistently produced lower levels of IFN-y upon restimulation 
compared with levels produced by splenocytes from C57BLI 6 mice. 
Furthermore, the difference was more pronounced as infection 
progressed. These observations raise the possibility that resistance to 
R-MuL V infection exhibited by C57BLI 6 mice may be due to expression of 
high levels of IFN-y and that BALBI c mice fail to produce sufficient IFN-y 
to resist R-MuLV infection. These hypotheses are consistent with the 
relatively poor anti-R-MuLV immune response generated by BALBI c 
mice compared with C57BLI 6 mice (see Section 1.10). 
That certain cytokines are integral to the generation and effector activities 
associated with an immune response and therefore resistance or 
susceptibility to infectious agents may be demonstrated using cytokine 
neutralising antibodies. For example, mice infected with ectromelia 
(Karupiah et al., 1993a), vaccinia (Ruby and Ramshaw, 1991) or herpes 
simplex (Smith et al., 1994) viruses exhibit a diminished ability to resolve 
infection when treated with anti-IFN-y antibodies. Recent studies with 
mice lacking functional cytokine or cytokine receptor genes have also 
demonstrated the role of cytokines in immunity to a wide range of 
pathogens (Pfeffer et al., 1993; Biron, 1994; Kaufmann, 1994). However, 
administration of IL-2, IL-4, IL-6, IL-10, IFN-y or TNF-a neutralising 
antibodies had little effect on R-MuL V induced disease in either BALBI c 
or C57BLI 6 mice. These observations suggest that, individually, these 
cytokines may not be essential for the pathogenesis of R-MuLV infection 
in susceptible BALBI c. These findings also suggest that the resistance to 
R-MuL V infection exhibited by C57BL/ 6 mice may not be dependent 
upon the expression of type 1 cytokines such as IFN-y or IL-2. 
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A number of studies have shown that IFN-y and TNF-a act in concert to 
augment antiviral activity (Wong and Goeddel, 1986; Wong et al., 1988). 
Furthermore, IFN-y and TNF-a are involved in activation of 
macrophages to effector function (Stout, 1993). Concurrent 
administration of antibodies to neutralise TNF-a or IFN-y also failed to 
alter the resistance of C57BL/ 6 mice to R-MuLV induced disease. The 
data presented here suggest that the antiviral or immunoregulatory 
activities of these factors may not be essential for resistance to R-MuLV in 
C57BL/6 mice. 
Several factors should be considered in the interpretation of experiments 
described in which cytokine neutralising antibodies. Firstly, the question 
arises of the use of neutralising antibodies at sufficiently high 
concentrations at the sites of cytokine synthesis in order to inhibit 
cytokine activity. The antibodies and protocols used here have been 
extensively and successfully used elsewhere (Table 3.9) which strongly 
indicate that inhibitory concentrations of antibody were achieved in vivo. 
For instance, the IFN-y neutralising antibody, R4-6A2, has been used 
successfully to inhibit IFN-y dependent clearance of vaccinia (Karupiah et 
al., 1990; Ruby and Ramshaw, 1991) and NO induction during vaccinia 
infection (Rolph et al., 1996). In addition this antibody has been used to 
inhibit the ability of vaccinia-immune CTL to protect irradiated mice 
from vaccinia virus infection (Ruby and Ramshaw, 1991). As similar 
protocols were used in experiments described in this thesis it is difficult to 
believe that the regime of antibody administration did not achieve 
sufficient levels of antibody to inhibit cytokine activity during R-MuLV 
infection. The issue of effective cytokine neutralisation with antibodies 
may be circumvented by using mice lacking functional cytokines or 
cytokine receptors and was done here in the case of IFN-y R0 1° mice (see 
below). A second consideration is that the functions of cytokines often 
overlap, and therefore the neutralisation of a particular cytokine may not 
affect the overall response. Thirdly, only a single parameter of virus 
growth ie. spleen weight was determined. Although relatively simple 
and widely used (Chirigos, 1964; Ruprecht et al., 1986; Ruprecht et al., 
1990); also see Section 2.4), this method may not resolve small but 
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Table 3.9 Examples of model systems where cytokine activity has been neutralised by antibodies described in Section 3.3.3 
Cytokine 
IFN-y 
TNF-a 
IL-2 
IL-4 
IL-6 
IL-10 
Clone 
R4-6A2 
XT-22 
S4B6 
llBll 
20F3 
JES-2A5 
In vivo Model 
Vaccinia infection 
Ectromelia infection 
Schistosoma mansoni infestation 
Recombinant vaccinia expressing IL-2 
Leishmania major infestation, 
Respiratory syncytial virus vaccination 
E. coli infection 
Experimental endotoxemia 
Antibody production in vivo 
References 
Ruby and Ramshaw, (1991) 
Karupiah et al., (1993) 
Gazzinelli et al., (1993) 
Karupiah et al., (1990) 
Chatelain et al., (1992) 
Tang and Graham, (1994) 
Starnes et al., (1990) 
Marchant et al., (1994) 
Dabber et al., (1994) 
po ibl - ignificant differences in uus grow th. Determination of 
infectiou \-irus in pleen or plasma as "'ell as iral antigen in these sites 
ma pro\-ide a greater insight into the effect of cytokine neutralising 
antibodies and therefore the role of cytokines in the pathogenesis of 
R- uL infection. 
In mice lacking functional IF -y receptors, the disease caused by R-MuLV 
½ as clearl - \ er different from that observed in control mice. Wild type 
IF -y R+ I + mice exhibit little effects of the virus until 3 weeks p.i. where 
the characteristic splenomegaly in ol ing marked accumulation of 
progenitor haematopoietic cells in the spleen associated with R-MuLV 
infection occurred. In contrast, splenomegaly and elevated levels of 
progenitor haematopoietic cells in the spleen were found early in 
infection of IF -y R0 1° mice and were reduced with time p.i. In addition, 
impaired spleen 1 mphoc te proliferation associated with R-MuL V 
infection appeared to be dependent upon IF -y activity as the 
proliferation of cells from IF -y R +I + but not IF -y R0 1° mice was 
suppressed following R-MuL V infection. 
It is difficult to propose a model which might explain the differences in 
pathogenesis of R-MuLV infection in IFN-y R+I + and IFN-y R0 1° mice. 
Both mice exhibited features associated with infection of prototypic 
susceptible BALB I c mice ie. splenomegaly and accumulation of 
progenitor haematopoietic cells, however only mice lacking functional 
IF -y receptors seemed to control R-MuLV infection. It therefore 
appeared that IF -y may be required for the susceptibility of mice of the 
129 / S strain to R-MuL V infection. One hypothesis that may be 
proposed to explain the difference in the R-MuLV induced disease in 
IF -y R +I + and IF -y RO I O mice is that IF -y acts as a growth factor for 
major target cells of R-MuL V such as progenitor erythroid cells 
(Rauscher, 1962; Hanna et al., 1970a; de Both et al., 1978). Alternatively, 
IF -y may activate cells such as macrophages which support progenitor 
erythroid cell replication via production of the growth factor 
erythropoietin (Gallacchio and Murphy Jr, 1983; Vogt et al., 1989). 
However, these hypotheses seem unlikely as increased levels of 
progenitor haematopoietic cells are present in the spleen of IFN-y R 0 1 ° 
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mice. Furthermore, IFN-y has been shown to inhibit erythropoiesis in 
normal (Dybedal et al., 1995; Eng et al., 1995) and F-MuLV infected mice 
(Means Jr et al., 1994). 
It could be postulated that the lack of IFN-y activity in IFN-y R0 / 0 mice 
allows for an alternative and more effective immune response to 
develop which limits disease. As IFN-y has been shown to be involved 
in promoting a CMI response and inhibiting the generation of a humoral 
immune response (Belosevic et al., 1989; Scharton and Scott, 1993), the 
IF!'J-y R0 1° mice may be more resistant to R-MuLV by virtue of generating 
a humoral immune response. This hypothesis may be tested by 
determining if R-MuLV infected IFN-y R0 1 ° mice generate anti-R-MuLV 
immune responses with the characteristics of a humoral immune 
responses ie. the expression of high levels of type 2 cytokines and high 
plasma levels of IgGl and IgE (Mosmann et al., 1986a; Mosmann and 
Coffman, 1989). Further experiments may also examine R-MuLV 
induced disease at later time points to elucidate the outcome of R-MuLV 
infection in these mice. 
Interpretation of data obtained from IFN-y R0 1° mice is complicated by the 
fact that the mice used here were generated on a 129 /Sv background 
(Huang et al., 1993). These mice are genetically different to mice used 
elsewhere in this thesis and therefore the validity of comparisons 
between the data obtained from IFN-y R0 1° mice and the data presented in 
the rest of this thesis may be limited. Gene knock out mice generated on 
a BALB / c or C57BL/ 6 background may therefore be more suitable to 
answer questions relating to the role of cytokines in the pathogenesis of 
R-MuLV infection of these mice. Further work is required to resolve the 
apparent contrast between R-MuLV infection of IFN-y R 0 1 ° mice and 
BALB / c mice treated with IFN-y neutralising antibody. It would be 
interesting to compare the titres of virus and levels of viral antigen in the 
spleen and plasma in R-MuLV infected BALBI c mice treated with IFN-y 
neutralising antibody and IFN-y R0 1 ° mice. 
The data obtained from IFN-y R0 1° mice is also complicated by the fact 
that these mice have developed in the absence of IFN-y activity and 
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therefore may have generated functionally redundant pathways to 
compensate for this defect. This redundancy is illustrated in mice lacking 
the T cell growth factor, IL-2. In these mice, the lack of IL-2 is 
compensated for by other cytokines such as IL-4, IL-7 IL-9 and IL-13 (Di 
Santo et al., 1995). This possibility seems unlikely however, as to date no 
functional redundancy has been demonstrated for IFN-y. 
The role of IFN-y in resistance to R-MuLV may be clarified further by 
promoting expression of type 1 cytokines during infection of susceptible 
BALBI c mice. This may be achieved by administration of IL-12 which has 
been shown to promote IFN-y expression in other models of infectious 
disease (Gately et al., 1993; Gazzinelli et al., 1994a; Oswald et al., 1994a; 
Sieling et al., 1994). IFN-a also promotes the expression of 
predominantly type 1 cytokines (Finkelman et al., 1991) which raises the 
possibility that the limitation of R-MuLV infection of BALBI c mice by 
administration of IFN-a (Hekman and Trapman, 1985; Ruprecht et al., 
1990) may be due at least in part to elevated production of type 1 
cytokines. In this context it is also notable that Johnson et al., (1988) 
found that direct administration of IFN-y to susceptible Swiss mice with 
established F-MuLV infection led to permanent disease regression in a 
significant proportion of treated mice. It may be interesting, in this light, 
to examine the effects of IFN-y, IL-12 or IFN-a administration upon the 
course of R-MuL V infection. 
Hom et al., (1991) showed that both CD4+ and CDS+ T cells were required 
for optimal acquired resistance to secondary challenge with R-MuLV. In 
this chapter, the role of these T cell subsets in the pathogenesis of a 
primary R-MuLV infection was investigated. The depletion of BALBI c or 
C57BLl6 mice of CD4+ T cells was found to partially ameliorate the 
splenomegaly associated with R-MuL V infection. This finding was 
consistent in 2 experiments and suggests that CD4 + T cells may be 
required for optimal virus growth and disease pathology. This 
observation is similar to those made by Yetter et al., (1988) who showed 
that development of disease (MAIDS) during LP-BM5 MuLV infection of 
C57BLI 6 mice is dependent upon CD4 + T cells. 
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The role of CD4 + T cells in the pathogenesis of R-MuL V disease is 
unclear, however a number of possible functions can be postulated. 
Firstly, CD4+ T cells may be a major site of early virus replication and, 
without these cells, the progression of disease is partially inhibited. This 
hypothesis seems unlikely given the lack of F-MuL V replication in 
spleen T cells as reported by Isaak et al., (1979). This issue may be resolved 
by determining the level of R-MuL V infection of CD4 + cells. Secondly, 
CD4 + T cells may be required to allow the replication of R-MuL V within 
non-CD4+ target cells. CD4+ T cells influence the proliferation and state 
of activation of a number of cell types such as macrophages and B cells 
through cell surface interactions and the secretion of cytokines. CD4 + T 
cells have also been shown to produce cytokines involved in 
erythropoiesis ie. IL-3 and GM-CSP (Mosmann and Coffman, 1989; Kelso 
et al., 1991) which may facilitate the proliferation of R-MuLV infected 
progenitor erythroid cells. Thus, depletion of CD4 + T cells may inhibit 
the pathogenesis of R-MuLV by preventing the activation of target cells. 
In this context it interesting to note that the requirement for CD4+ T cells 
in the development of MAIDS is dependent upon their cell surface 
interaction with B cells which are the primary target of virus infection 
(Giese et al., 1994; Morse et al., 1995). 
A third possible role for CD4+ T cells in the pathogenesis of R-MuLV 
may be their mediation of inappropriate anti-viral immune responses at 
the cost of protective immune responses. Depletion of CD4 + T cells has 
been shown to modulate the type of immune response generated towards 
protein antigen (Field et al., 1992) or infectious agents (Sadick et al., 1987; 
Muller et al., 1993). In this context, the removal of CD4+ cells from 
R-MuLV infected mice may ablate the generation of an ineffective 
immune response and allow the expression of a protective immune 
response. It would therefore be of interest to compare levels of antiviral 
antibodies and CTL in intact and CD4+ T cell depleted mice. CD4+ T cells 
also mediate inflammation in a number of model systems. It may be that 
depletion of these cells reduces the influx of cells into the spleen thereby 
reducing the mass of the spleens in R-MuLV infected BALBI c and 
C57BL/ 6 mice. In light of this possibility, it would be important to 
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compare the structure and cellular composition of the spleen of intact or 
CD4+ T cell depleted mice infected with R-MuLV. Furthermore, 
alternative measures of virus growth such infectious virus in the spleen 
or in plasma as well as viral antigen in mice depleted of CD4 + T cells may 
provide a greater insight into the role of these cells in pathogenesis of 
R-MuLV infection. 
The depletion of CDS+ T cells from C57BL/ 6 mice enhanced the 
development of splenomegaly associated with R-MuLV infection. 
Resistance to a wide range of viral infections has been shown to be 
dependent upon CDS+ T cells. These include vaccinia (Ruby and 
Ramshaw, 1991), ectromelia (Buller et al., 1987a) and HSV (Nash et al., 
1987) infections. Furthermore, the high incidence of recovery from 
F-MuLV in Fv-2s!s, H-2b mice requires the generation of cytotoxic CD8+ T 
cells (Chesebro and Wehrly, 1978; Earl et al., 1986; Chesebro, 1990; 
Robertson et al., 1992). These observations raise the possibility that the 
increased splenomegaly following R-MuLV infection of C57BL/ 6 mice 
depleted of CDS+ cells may be due to the loss of antiviral CDS+ CTL. It 
would be interesting, therefore, to determine if antiviral CDS+ CTL are 
generated in resistant C57BL/ 6 and susceptible BALB / c mice. Depletion 
of CD8+ cells from BALB/c mice enhanced R-MuLV induced 
splenomegaly (experiment 1, Table 3.9). This observation suggests that 
these cells may, to some extent, limit R-MuLV disease progression in 
susceptible mice. However, a subsequent experiment suggested that CDS+ 
cells may play only a limited role in the control of R-MuL V infection 
(experiment 2, Table 3.9). The reason for these disparate observations are 
unclear however flow cytometry analysis demonstrated that the efficiency 
of depletion was approximately equal in both experiments. Furthermore, 
the effects of CDS depletion on R-MuL V induced splenomegaly in 
C57BL/ 6 mice were similar in both experiments. Clearly further 
experiments were required to resolve the role of CDS+ cells in R-MuLV 
infection of BALB / c mice. 
In summary, the data presented in this chapter indicate that both BALBI c 
and C57BL/ 6 mice predominantly produce type 1 cytokines following 
R-MuL V infection. Neutralisation of different cytokines with 
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monoclonal antibodies suggested that a number of these factors were not 
essential for resistance or susceptibility to R-MuLV. Depletion of T cell 
subsets suggested that CD4+ T cells may be required for optimal growth of 
R-MuLV in C57BL/6 and BALB/c mice. 
Chapter 4 
The role of nitric oxide in the pathogenesis 
of R-MuL V infection 
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4.1 INTRODUCTION 
The experiments described in this chapter examine the role of NO in 
R-MuLV infection of mice. NO has emerged as a major effector molecule 
in immunity to tumours (Drapier and Hibbs Jr, 1986; Stuehr and Nathan, 
1989; Kwon et al., 1991), bacteria (Stuehr and Marletta, 1987), parasites 
(Adams et al., 1990; Green et al., 1990; Wei et al., 1995) and helminths 
Games and J., 1989). Recently, it was shown that NO can also act as an 
antiviral effector molecule. Production of NO by IFN-y-activa ted 
macrophages was found to inhibit replication of HSV-1, ectromelia and 
vaccinia viruses in these cells (Croen, 1993; Karupiah et al., 1993b). The 
effect of NO on retrovirus replication is largely unexplored, however NO 
was recently found to inhibit replication of F-MuLV in vitro and in vivo 
(Akarid et al., 1995). Other reports indicate that peptides encoded by HIV 
induce macrophages to release NO (Mollace et al., 1993; Pietraforte et al., 
1994) which may have protective consequences or may contribute to 
neuropathology associated with HIV disease (Dawson et al., 1993; 
Hayman et al., 1993). 
NO has also been shown to mediate some of the pathology associated 
with infectious diseases. This includes the severe hypotension found in 
cases of septic shock and TNF-a therapy (Kilbourn et al., 1990a; Petros et 
al., 1991) and the profound immunosuppression observed during some 
parasitic infestations (Candolfi et al., 1994; Rockett et al., 1994a) and 
bacterial infections (Al-Ramadi et al., 1992; Gregory et al., 1993). In these 
cases, lymphocyte proliferation was found to be markedly suppressed, 
due, at least in part, to NO. Although the exact mechanism of NO-
mediated inhibition of lymphocyte proliferation is unclear, it has been 
postulated that the inhibition of key enzymes and other mechanisms (see 
Section 1.5.5) may suppress lymphocyte proliferation (Rockett et al., 
1994a). 
R-MuLV infection of susceptible mice is characterised by uncontrolled 
virus growth and erythroproliferation while in resistant mice, virus 
growth and proliferation of progenitor erythroid cells is limited. Given 
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the antiviral and antiproliferative properties of NO outlined above (see 
also Section 1.5.5), it is possible NO may inhibit virus replication and 
cellular proliferation in mice resistant to R-MuLV. In addition, NO 
production by infected mice may suppress potentially protective antiviral 
immune responses. The experiments described in this chapter were 
designed to address potential antiviral, antitumour and 
immunosuppressive properties of NO during R-MuLV infection. 
4.2 MATERIALS AND METHODS 
4.2.1 
Mice As described in Section 2.2.1 
Virus As described in Section 2.2.2 
Virus titration As described in Section 2.2.5 
R-MuL V ELISA As described in Section 2.2.7 
Statistics As described in Section 2.2.15 
4.2.2 RT-PCR detection of iNOS mRNA 
Messenger RNA was extracted from spleen cells of uninfected BALB / c or 
C57BL/ 6 mice or mice infected with R-MuL V as described in Section 3.2.8. 
cDNA was generated from 1 µg of total spleen cell RNA as described in 
Section 3.2.9. Inducible nitric oxide synthase cDNA was detected using 
PCR amplification with iNOS specific primers (Appendix 1; Oswald et al., 
1994b ). The primers were designed to span at least one intron to 
discriminate between amplification of cDNA and any contaminating 
genomic DNA. 
Amplification of iNOS cDNA was performed using reagents described in 
Section 3.2.10. After incubation of the reaction mixture for 3 min at 94°C, 
cDNA was amplified using the following conditions: denaturation at 
95°C for 5 sec, primer annealing at 60°C for 5 sec and primer extension at 
72°C for 1 min. The cDNA was amplified for between 25 and 35 cycles. 
Amplified cDNA products were analysed by electrophoresis through 1.5% 
agarose gels and visualised by ethidium bromide staining (Sambrook et 
al., 1989). 
To ensure that the iNOS RT-PCR procedure was specific, RNA was 
extracted from RAW 264.7 cells (American Type Culture Collection, MD, 
USA) which are known to transcribe iNOS mRNA following stimulation 
with LPS. Prior to RNA extraction, the cells were stimulated with 
1 µg / ml LPS (E. coli 0128:B12) for 6 h to induce iNOS mRNA expression. 
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RNA was isolated as described in Section 3.2.8. Total RNA from 
stimulated RAW 264.7 cells was reverse transcribed and amplified by PCR 
as described above. 
RAW 264.7 cells were maintained in RPMI supplemented with 10% FCS, 
10 mM HEPES, 2 mM L-glutamine and antibiotics. Cells were passaged 
every 2 days at a 1:10 dilution. 
4.2.3 Assay for Reactive Nitrogen Intermediates 
Reactive nitrogen intermediates (RNI) nitrate and nitrite are stable 
oxidation products of NO (Marletta et al., 1988). As an measure of NO 
production, RNI were measured using the Griess assay (Rockett et al., 
1994b ). The level of nitrite in 30 µl of culture supernatant or mouse 
plasma was determined. In each test, samples were diluted in 20 µl of 
water and reacted with 100 µl of Griess reagent (1 % sulphanilamide, 0.1 % 
naphthylethylenediamine dihydrochloride [Sigma] in 1 M H2SO4). 
Protein was precipitated by the addition of 100 µl of 10% trichloroacetic 
acid and removed by centrifugation at 12,000g for 5 min. The absorbance 
of each supernatant was measured at 540 nm, with a reference at 650 nm, 
using a microplate reader (Molecular Devices). To assay nitrate levels, 
nitrate was first reduced to nitrite. This was achieved by the addition of 5 
µl nitrate reductase (0.025 Units) and 15 µl reduced ~-nicotinamide 
adenine dinucleotide phosphate (NADPH, 20 µg; Boehringer Mannheim, 
Mannheim, Germany) to 30 µl of sample. The reaction was incubated at 
room temperature for 20 min. The amount of reduced nitrate was 
determined as for nitrite (described above) but without dilution of 
samples with water. Known amounts of sodium nitrate or sodium 
nitrite diluted in MLCM or normal mouse plasma were used as standards 
for the calculation of levels of nitrite or nitrate. 
4.2.4 Plasma RNI determination 
Blood was obtained from mice via cardiac puncture or from tail vein 
bleeding. Mice bled by cardiac puncture were first anaesthetised with 
500 µl of avertin (2% 2-methyl-2-butanol, 2% 2,2,2,-tribromoethanol; 
Fluka) given i.p. Blood from either source was collected, placed into a 
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microcentrifuge tube containing heparin sulphate (5 U in 10 µl per 500 µl 
blood) and stored on ice. Blood cells were collected by centrifugation at 
12,000g for 5 min at 4°C. The plasma was removed, aliquoted and stored 
at -70°C until assay for RNI. 
4.2.5 Spleen cell RNI production 
Single cell suspensions were prepared from pooled spleens of mice as 
described in Section 2.2.9. NO production by spleen cells was determined 
following stimulation with LPS in vitro. Cells were cultured at l.6xl06 
cells/well in flat bottomed 96 well plates (Nunc) in MLCM containing 
1 µg/ml LPS (E.coli strain 0128:Bl2, water phenol extracted; Sigma). After 
72 h, plates were centrifuged at 200g for 5 min and supernatants were 
removed and aliquoted. The samples were stored at -20°C until assayed 
for RNI concentration as described in Section 4.2.3. 
4.2.6 Production of RNI by T and B cell proliferation assays 
The production of NO by spleen cells under the conditions used 1n 
proliferation assays was determined. Spleen cells were prepared as 
described in Section 2.2.9. 2x105 spleen cells/well were cultured with 
immobilised anti-CD3 antibodies or LPS as described in Section 2.2.10. 
After 72 h, the plates were centrifuged at 200g for 2 min, supernatants 
were removed and stored at -20°C. RNI content was assayed as described 
in Section 4.2.3. 
L-N-methyl arginine (L-NMA) was added to T and B cell proliferation 
assays in order to block the production of NO. Spleen cells were cultured 
at 2x105 cells/well in MLCM containing various concentrations of L-
NMA (prepared and generously provided Mr M. Rolph, Division of Cell 
Biology, JCSMR) and stimulated with immobilised anti-CD3 antibodies or 
10 µg/ml LPS as described in Section 2.2.10. RNI accumulation was 
measured in supernatants taken after 72 h culture. Proliferation was 
determined by [3H]-TdR incorporation as described in Section 2.2.10. 
In order to inhibit the production of prostaglandins, indomethacin was 
added to LPS-stimulated, spleen B cell proliferation assays. Cells were 
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cultured using conditions described in Section 2.2.10 in the presence of 
various concentrations of indomethacin. Proliferation was measured by 
[3H]-TdR incorporation as described in Section 2.2.10. 
4.2.7 L-NMA therapy of R-MuL V infection 
BALB/c or C57BL/6 mice were used to examine the effects of L-NMA 
therapy on R-MuLV infection. Mice of each strain were infected with 
104 pfu R-MuL V i.p . in gelatin saline or were given gelatin saline only. 
Half of the infected and uninfected mice were injected twice daily with 
L-NMA (2 mg in 200 µl normal saline) i.p. and were given water 
containing 4 mg/ml L-NMA. The remaining mice were given water 
without additives and injected twice daily with normal saline. 
Treatment with L-NMA was started 8 h prior to infection with R-MuL V. 
After 14 days of therapy, plasma was taken from each mouse as described 
in Section 4.2.3 and stored at -70°C until assay for plasma RNI or 
R-MuLV. Spleens were also taken and weighed in tared sterile tubes 
containing 5 ml H16/5% FCS. Single cell suspensions were then prepared 
from each spleen and assayed for ecotropic virus expression using the XC 
infectious centre assay described in Section 2.2.6. 
4.2.8 TNF-a therapy of R-MuLV infection 
Recombinant murine TNF-a (rMu TNF-a) was generously provided by 
Genentech. The specific activity of rMu TNF-a was 107 U /mg. For 
injection into mice, stock rMu TNF-a was diluted in sterile PBS and 
administered in a volume of 200 µl i.v. Control mice were injected with 
PBS alone. In some experiments mice were bled 10 h later by tail vein. 
Plasma was isolated as described in Section 4.2.4. and subsequently 
assayed for RNI. The effect of TNF therapy on virus growth was 
measured by determining spleen weight 3 days after rMu-TNF-a 
injection and assaying viral antigen in plasma taken at the same time. 
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4.3 RESULTS 
4.3.1 Comparative analysis of inducible nitric oxide synthase (iNOS) 
mRNA expression by spleen cells 
RT-PCR amplification was used to determine the levels of mRNA 
encoding iNOS in the spleen after infection with R-MuLV (Figure 4.la). 
Equivalent levels of iNOS mRNA expression were found in spleen cells 
from uninfected BALB/c and C57BL/6 mice. R-MuLV infection of 
BALB/c mice induced iNOS mRNA expression at 1 week p.i. which 
increased with time to levels approximately 10 fold above normal levels 
by 3 weeks p.i. Expression of iNOS mRNA by spleen cells from R-MuL V 
infected C57BL/ 6 mice was elevated at 2 and 3 weeks p.i. and reached 
levels approximately 10 times those of cells from uninfected mice at 3 
weeks p.i. Amplification through 27 cycles of PCR yielded much less 
product DNA than after 30 cycles which indicates that PCR amplification 
of iNOS cDNA was logarithmic under the conditions used. 
To demonstrate that the amplification of iNOS cDNA was proportional 
to the amount of input cDNA and to the number of cycles of 
amplification, serial 10 fold dilutions of cDNA known to contain iNOS 
mRNA (equivalent to between 5000 and 5 pg total RNA) were amplified 
through 25, 30 or 35 cycles of PCR. Amplification of relatively high levels 
of input iNOS cDNA (5 ng total RNA) led rapidly to non-logarithmic 
amplification which yields only slight increases in product DNA with 
increasing numbers of cycles of amplification (Figure 4.lb ). Low levels of 
iNOS cDNA (5 pg total RNA) were readily detected after 35 cycles of 
amplification. 
4.3.2 Plasma RNI in R-MuLV infected mice 
In vivo, NO is readily oxidised to form the RNis, nitrate and nitrite 
(Marletta et al., 1988). The accumulation of RNI in the plasma of mice 
has been successfully used to measure NO production in number of 
model systems. The levels of RNI in the plasma of R-MuLV infected 
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Figure 4.1 RT-PCR analysis of iNOS mRNA expression during R-MuL V 
infection 
RNA was extracted from LPS stimulated RAW 267.4 cells and spleen cells 
of BALB / c and C57BL/ 6 mice which were uninfected or infected with 
R-MuLV 1, 2 or 3 weeks earlier. iNOS mRNA was detected by RT-PCR 
amplification. PCR products were electrophoresed through 1.5% agarose 
and stained with ethidium bromide. Data shown is representative of 2 
batches of RNA and at least 1 cDNA synthesis and PCR amplification of 
each batch of RNA. 
[A] RT-PCR of cDNA equivalent to 50 ng of total RNA amplified through 
27 or 30 cycles of PCR. 
[B] RT-PCR of LPS stimulated RAW 267.4 mRNA. cDNA equivalent to 
5000, 500, 50 or 5 pg total RNA was amplified through 25, 30 or 35 
cycles. 
[A] 
Cycles 
BALB/c 
27 
C57BL/6 
30 
BALB/c C57BL/6 
+ 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 -
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[B] 
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0 0 
0 0 
Lr) Lr) 
25 30 
0 
0 0 
0 0 0 0 
Lr) Lr) Lr) Lr) L.() 
0 
0 
0 
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35 
0 
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mice were determined, as it was important to confirm that elevated iNOS 
mRNA expression resulted in NO production. 
R-MuL V infection of BALB / c mice did not significantly alter plasma RNI 
levels during the first two weeks p.i. (Table 4.1). However, by 3 weeks p.i., 
plasma RNI was detected at significantly greater levels than those found 
in uninfected mice (Table 4.1; p=0.01). In contrast, plasma RNI levels in 
C57BL/ 6 mice did not differ significantly at each stage of infection 
(Table 4.1). The levels of plasma RNI found at 3 weeks p.i. were 
significantly greater than those found at 1 week (p=0.02) p.i ., however 
these differences may reflect the variability of low levels of plasma RNI 
and are therefore unlikely to be biologically important. Plasma RNI 
levels in BALB / c or C57BL/ 6 mice were not significantly different during 
the first 2 weeks of infection, however, at 3 weeks p.i. plasma RNI 
concentrations in BALBI c mice were significantly greater than those in 
C57BL/ 6 mice (p=0.03). 
4.3.3 Production of nitric oxide by splenocytes in vitro 
It was important to demonstrate that NO could be produced by 
splenocytes, given the expression of iNOS mRNA by spleen cells derived 
from infected mice. In vitro NO production by LPS-stimulated spleen 
cells was examined using cells taken from mice at various stages of 
infection. 
Significantly higher levels of RNI were produced by spleen cells from 
infected mice compared to control, uninfected animals (Table 4.2). 
Notably, peak production by BALB / c splenocytes occurred at 2 weeks p.i. 
and RNI levels were still elevated although at much lower levels at 3 
weeks p.i. RNI accumulation in supernatants from C57BL/ 6 cells reached 
high levels at 2 weeks p.i., however, these levels were significantly lower 
compared to those found in supernatants from BALB / c cells at the same 
time point (p=0.04). The RNI production by C57BL/ 6 splenocytes was 
sustained to 3 weeks p.i. Spleen cells from uninfected BALB / c and 
C57BL/ 6 mice produced background levels of RNI. 
Table 4.1 Plasma RNI following R-MuL V infection 
Strain 
BALB/c 
C57BL/6 
Weeks Post Infection 
Uninfected 
1 
2 
3 
Uninfected 
1 
2 
3 
Plasma RNI (µM)a 
20.6 + 3.7 
17.3 + 4.3 
18.6 + 2.7 
41.3 + 5.lbd 
17.4 + 3.3 
10.7 + 3.2 
13.4 + 4.3 
24.8 + 3.9C 
Blood was obtained from groups of 5 uninfected BALB / c or C57BL/ 6 mice or 
mice infected with 104 pfu R-MuLV i.p. 1, 2 or 3 weeks previously. Plasma 
was separated from blood cells and assayed for total RNI content. Data 
representative of 2 similar experiments. 
a) Mean plasma reactive nitrogen intermediates of 5 mice + SEM 
b) Significant, p=0.012, when compared with plasma RNI in uninfected 
BALB/c mice 
c) Significant, p=0.02, when compared with plasma RNI of 1 week infected 
C57BL/6 mice 
d) Significant, p=0.03, when compared with plasma RNI of 3 week infected 
C57BL / 6 mice 
Table 4.2 RNI production by LPS stimulated spleen cells from R-MuL V 
infected mice 
Mouse Strain Weeks Post Infection 
BALB / c Uninfected 
C57BL/6 
1 
2 
3 
Uninfected 
1 
2 
3 
Total RNI (µM) 
3.8 + 0.7 
14.6 + 3.8a 
80.9 + 8.8b 
25.2 + 7.la 
2.5 + 0.5 
23.0 + 6.4a 
38.6 + 13.1 
48.8 + 13.3a 
Spleen cells were isolated from mice at various times p.i. l.6x106 cells were 
stimulated with 1 µg/ml LPS for 72 h. Supernatants were assayed for nitrite 
and nitrate accumulation. Data shown represents mean total RNI in 4 wells 
at each time point + SEM. Data representative of 2 similar experiments. 
a) Mean total RNI significantly greater (p<0.05, Welch's t test) than mean 
total RNI produced by cells from uninfected mice 
b) Mean total RNI significantly greater (p<0.003, Welch's t test) than mean 
total RNI produced by cells from uninfected mice 
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4.3.4 Nitric oxide is not involved in suppressed T or B cell proliferation 
The expression of NO by spleen cells during R-MuLV infection raised the 
possibility that NO may be involved in the suppression of lymphocy te 
proliferation reported in Section 2.3.2. The production of NO using 
conditions under which lymphocyte proliferation was determined, was 
therefore examined. Spleen cells from uninfected or R-MuLV infected 
mice were stimulated with anti-CD3 or LPS as described for T and B cell 
proliferation assays (Section 2.2.9) and the accumulation of RNI in 
culture supernatants was measured. In addition, proliferation of spleen T 
and B cells was determined in the presence of L-NMA to inhibit NO 
synthesis. 
R-MuLV infection had a marked effect on RNI production by spleen cells 
derived from both BALB / c and C57BL/ 6 mice following anti-CD3 
stimulation of T cells (Table 4.3). At 2 weeks p.i. significant levels of RNI 
were found in culture supernatants while only low levels of RNI were 
found at 1 and 3 weeks p.i. Spleen cells from BALB / c mice produced RNI 
at levels similar to those of spleen cells from C57BL/ 6 mice at 2 weeks p.i. 
RNis were not detected in supernatants from anti-CD3 stimulated spleen 
cells from uninfected mice. 
Incorporation of L-NMA in culture media at 400 µM effectively inhibited 
production of NO by anti-CD3 stimulated cultures of spleen cells from 
infected BALB / c and C57BL/ 6 mice (Table 4.3). In contrast, the 
suppressed T cell proliferation was not ameliorated by the inclusion of 
L-NMA in culture media (Figure 4.2). At high concentrations, L-NMA 
has been shown to inhibit lymphocyte proliferation (Albina et al. , 1991; 
Schleifer and Mansfield, 1993; Gregory et al., 1994), however, T cell 
proliferation was unaltered in the present study when L-NMA was 
present at concentrations which effectively inhibited RNI accumulation 
( 400 µ M, Figure 4.2; 800 µ M L-NMA, data not shown). At high 
concentrations of L-NMA (2 mM) T cell proliferation was found to be 
inhibited by approximately 20 % (data not shown) . These observations 
suggest that NO does not play a role in suppression of in v itro T cell 
proliferation. 
Table 4.3 RNI production by anti-CD3 stimulated spleen cells from R-MuL V 
infected mice is inhibited by L-NMA 
Strain 
BALB/c 
C57BL/6 
Weeks Post 
Infection 
Uninfected 
1 
2 
3 
Uninfected 
1 
2 
3 
Total RNI (µM ) 
MLCM 
<2.5a 
<2.5 
16.1 + 0.6 
2.9 + 0.6 
<2.5 
2.6 + 0.4 
11.8 + 0.6 
4.3 + 0.2 
L-NMA 
<2.5 
<2.5 
4.5 + 0.1 
<2.5 
<2.5 
<2.5 
<2.5 
<2.5 
2xl05 spleen cells from R-MuL V infected or uninfected BALB / c or C57BL/ 6 
mice were stimulated with anti-CD3 antibody in vitro . Supernatants were 
taken after 72 hand assayed for RNI. Cells were cultured in MLCM or 
MLCM containing 400 µM L-NMA. Data points indicate mean RNI in 3 
replicate wells + SEM. Data representative of 2 similar experiments. 
a) Limit of detection was 2.5 µM RNI 
250] BALB/c + C57BL/6 
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Figure 4.2 Effect of L-NMA on anti-CD3 stimulated spleen cell proliferation 
2x105 spleen cells from uninfected and infected BALB / c and C57BL/ 6 mice were stimulated with anti-CD3 
antibody in MLCM (-a-) or MLCM containing 400 µM L-NMA ( • ). After 72 h, cultures were labelled with 
0.5 µCi [3H]-TdR for a further 16 h. Data points indicate mean proliferation of 4 replicate wells (+ SEM) as 
measured by [3H]-TdR incorporation. Data representative of 2 similar experiments. 
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Spleen cells cultured under the conditions used to assay B cell 
proliferation (10 µg/ml LPS, 2x105 cells cultured in round bottomed wells) 
did not produce significant amounts of NO (data not shown). 
Furthermore, culture of these cells in media containing L-NMA did not 
alter B cell proliferation at any time p.i. (Figure 4.3) except at high 
concentrations of L-NMA (2 mM) which slightly inhibited proliferation 
of cells from uninfected mice (data not shown). These findings suggest 
that suppression of B cell proliferation may be mediated by other 
mechanisms. 
4.3.5 Indomethacin does not alter splenic B cell proliferation 
Prostaglandins (PG) inhibit in vitro lymphocyte proliferation 1n a 
number of model systems. The addition of indomethacin, a potent PG 
synthesis inhibitor (Ferreira et al., 1971), to culture media in these systems 
was found to ameliorate suppressed lymphocyte proliferation (Albina et 
al., 1991; Gregory et al., 1994). In light of these observations, the role of 
prostaglandins in the suppressed proliferation of spleen B cells from 
R-MuL V infected mice was investigated. 
The suppressed proliferation of splenic B cells derived from R-MuL V 
infected mice was not ameliorated by the addition of indomethacin to 
culture media. Data in Figure 4.4 show B cell proliferation following 
addition of 5 µg/ml indomethacin to LPS stimulated cultures, however, 
similar results were found using 0.5, 1, 2 or 10 µg/ml indomethacin. 
Whilst PG synthesis was not measured, the concentrations of 
indomethacin described here have been shown to inhibit both the 
synthesis of PG and its suppressive properties in a number of 
experimental models (Albina et al., 1991; Schleifer and Mansfield, 1993) . 
These data suggest that PG are not involved in R-MuL V induced 
suppression of B cell proliferation. 
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Figure 4.3 Effect of L-NMA on LPS induced spleen cell proliferation 
2x105 spleen cells from uninfected or infected BALB / c or C57BL/ 6 mice were 
stimulated for 72 hours with 10 µg/ml LPS in the presence of 400 µMol L-
NMA (---- ) or MLC M only (--o- ). The cultures were labelled with 0.5 µCi 
[3H]-TdR for a further 16 h. Data points show mean proliferation of 4 
replicate cultures (+ SEM) as measured by [3H]-TdR incorporation. Data 
representative of 2 similar experiments. 
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Figure 4.4 Effect of indomethacin on LPS induced spleen cell 
pro Zif era ti on 
2x105 spleen cells from BALB / c or C57BL/ 6 mice, which were 
uninfected or infected with R-MuLV 1, 2 or 3 weeks earlier, were 
stimulated with 10 µg/ml LPS for 72 h in MLCM containing 5 µg/ml 
indomethacin (---) or MLCM alone (-er-). The cultures were labelled 
with 0.5 µCi [3H]-TdR for a further 16 h. Data points show mean 
proliferation of 4 replicate cultures (+ SEM) as measured by [3H]-TdR 
incorporation. Data representative of 2 similar experiments. 
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4.3.6 Effect of in vivo L-NMA treatment on R-MuL V growth. 
The data presented in Sections 4.3.2 and 4.3.3 demonstrate that NO 1s 
produced during R-MuLV infection. To explore the role of NO during 
R-MuLV infection in vivo, mice were given L-NMA in order to inhibit 
NO synthesis. 
Treatment with L-NMA had little effect on disease associated with 
R-MuLV infection. Spleen weights of L-NMA treated, R-MuLV infected 
BALB / c and C57BL / 6 mice were reduced compared to infected mice 
receiving saline injections and normal water, however given the range of 
the data, the effect was not statistically significant in either strain (p>0.05; 
Table 4.4). Virus expression by spleen cells from infected BALE/ c mice 
was largely unaltered following L-NMA therapy. In contrast, there was a 
slight increase in the number of virus producing cells in C57BL/ 6 mice 
treated with L-NMA (p=0.02). The amount of plasma viral antigen was 
similar in both L-NMA treated and control mice (Table 4.4). Plasma RNI 
levels in mice given L-NMA therapy were significantly lower than in 
mice which were not treated with L-NMA (Table 4.4). This effect was 
independent of R-MuLV infection and was observed in mice from either 
strain, which suggests that L-NMA therapy inhibited NO synthesis in 
vivo. Water consumption was approximately equal in all groups of mice 
and was independent of L-NMA treatment or infection with R-MuLV 
(data not shown). Average water consumption per mouse and therefore 
L-NMA dose per mouse was also equivalent, however the possibility that 
water consumption varied between each mouse within each group 
cannot be excluded. 
4.3.7 Effects of TNF-a on plasma RNI, splenomegaly and plasma viral 
antigen in R-MuLV infected mice 
Johnson et al., (1988) have reported that treatment with TNF-a limits 
F-MuLV induced disease. It was therefore of interest to determine if 
TNF-a also limited R-MuLV infection. As in vivo administration of 
TNF-a has been shown to induce production of NO in a number of 
models (Kilbourn et al., 1990a; Rockett et al., 1992), the observation made 
Table 4.4 Effect of L-NMA therapy on plasma RNI, development of splenomegaly and virus expression 
R-MuLV L-NMA Plasma RNI (µM)a Spleen weight Spleen infectious Plasma an ti gen 
(mg)b centres 
BALB/c 
22.1 + 1.0 112 + 5 - 40,40,40,40 
+ 3.8 + 0.5 146 + 3 - 40,40,40,40 
+ - 18.5 + 1.1 987 + 170 5.65 + 0.14 2560,2560, 1280, 1280 
+ + 5.0 + 0.7 678 + 36 5.46 + 0.07 2560,2560,2560, 1280 
C57BL/6 
7.1 + 0.8 97+ 11 - 40,40,40,40 
+ <2.5 72 +5 - 40,40,40,40 
+ - 12.3 + 0.9 246 + 37 1.07 + 0.11 160,80,80,80 
+ + <2.5 178 + 36 1.86 + 0.24 80,80,40,40 
Groups of 4 uninfected or R-MuL V infected BALB / c or C57BL/ 6 mice treated with either PBS or L-NMA for 2 weeks. Mice 
were then bled and plasma RNI and plasma viral antigen was determined. The spleen was taken from each mouse and 
weighed in tared, sterile tubes containing 4 ml of DMEM/ 5% FCS. Single cell suspensions were made from the spleen of each 
infected mouse and the number of infectious centres was assayed as described in the materials and methods. 
a) Plasma RNI was determined 18 h after cessation of L-NMA therapy. Data represents plasma RNI of 4 mice+ SEM. 
b) Mean spleen weight of 4 mice+ SEM 
Table 4.4 (cont) 
c) Log10 pfu of infectious centres producing ecotropic R-MuLV /107 nucleated spleen cells (mean+ SEM) 
d) Endpoint of R-MuL V specific ELISA. data shown represents endpoints of individual mice 
f) Similar spleen weight compared with infected mice not receiving L-NMA treatment, p>0.15 Welch's test 
g) Similar spleen weight compared with infected mice not receiving L-NMA treatment, p>0.15 
h) Significantly greater compared with untreated, infected mice, p=0.02 
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by Johnson et al., (1988) may be due to the antiviral (Croen, 1993; 
Karupiah et al., 1993b) or antiproliferative (Stuehr and Nathan, 1989) 
properties of NO. Therefore, the expression of NO following 
administration of TNF-a was also examined. 
Recombinant murine TNF-a induced significant dose-dependent release 
of RNI into plasma (Table 4.5). This effect was found in both uninfected 
and infected BALB / c and C57BL/ 6 mice. Infected BALB / c mice given 
500 ng of rMu TNF-a had higher plasma RNI levels than C57BL/ 6 mice 
given the same dose, the difference being significant at 7 (p=0.015, 
Welch's t test) and 21 days (p=0.001) p.i. Plasma RNI levels in C57BL/ 6 
mice infected for 7 or 14 days were higher in mice receiving 1000 ng of 
rMu TNF-a compared with levels in uninfected mice (p=0.015, Welch's t 
test). 
BALBI c mice infected with R-MuLV for 14 or 21 days exhibited classic 
symptoms of TNF toxicity, such as ruffled fur, lethargy and hypothermia 
of extremities, followed by death when high doses of rMu-TNF-a were 
given. BALB/c mice given 1000 ng or 800 ng of rMu-TNF-a at 14 days p.i. 
were all dead in less than 8h. In 1 of 2 experiments, 1000 ng of rMu TNF-
a was also lethal for BALB / c mice at 21 days p.i. (Table 4.5, Table 4.6). In 
contrast, BALB / c mice which were uninfected or at 7 days p.i did not 
exhibit symptoms of TNF toxicity and survived following treatment with 
high doses of rMu TNF-a. C57BL/ 6 mice survived treatment with all 
doses of rMu TNF-a and did not exhibit symptoms associated with TNF 
toxicity (Table 4.5, Table 4.6). Uninfected and infected mice were both 
unaffected by treatment with rMu TNF-a. 
Treatment of R-MuL V infected mice with rMu TNF-a had little effect on 
spleen weights of virus infected mice (Table 4.6). Similarly, plasma viral 
antigen was unaffected by rMu TNF-a therapy. Mice from both strains 
exhibited these phenomena. These observations suggest that treatment 
with rMu-TNF-a had little effect on R-MuL V replication. Furthermore, 
these data are consistent with NO playing a limited role in R-MuLV 
infection. 
Table 4.5 Plasma RNI in R-MuLV infected BALB/c and C57BL/6 mice 
following TNF-a therapy 
Days Post Infection TNF-aa (ng) 
Uninfected 
7 
14 
21 
PBS 
500 
1000 
PBS 
500 
1000 
PBS 
500 
800 
1000 
PBS 
500 
1000 
Mean Plasma RNI (µM) 
BALB/c 
10 + 1 
43 + 14 
62 + 7c 
13 + 1 
47 + 7ce 
86+ 17C 
8+1 
44+ 7c 
t 
t 
19 + 2 
63 + 6Ce 
t 
C57BL/6 
11 + 2 
56+3d 
15+ 2 
10+ 2 
101 + 17d 
16 + 1 
28+3d 
ND 
92 + 15d 
15 +5 
26+ 2 
81 +40 
Groups of 4 BALB/c and C57BL/6 mice which were infected with R-MuLV 
for 7, 14 or 21 days and then treated with a single dose of rMu TNF-a or PBS. 
Mice were bled 10 h later and plasma isolated. The concentration of RNI in 
plasma was assayed. Data shown is from a single experiment. 
a) rMu TNF-a was diluted in ice cold PBS to desired concentrations and 
given i.v. in volumes of 200 µl. 
b) Mean plasma RNI of 4 mice+ SEM 
c) Significantly greater plasma RNI compared with mice given PBS (p<0.05 
Welch's t test) 
d) Significantly greater plasma RNI compared with mice given PBS (p<0.02) 
Table 4.5 (cont) 
e) Significantly greater plasma RNI compared with C57BL/ 6 mice given 
500 ng rMu TNF-cx, day 7 p=0.015 Welch's t test, day 21 (p=0,001 Student's 
t test) 
f) Significantly greater plasma RNI compared with uninfected C57BL/ 6 mice 
given 1000 ng of rMu TNF-cx (p=0.015, Welch's t test) 
t All mice were dead in less than 10 h after injection of rMu-TNF-cx 
Table 4.6 Effect of TNF-a therapy on virus growth in R-MuL V infected mice 
Days Post Infection rMu TNF-a (ng) 
Uninfected PBS 
10 days 
17 days 
24 days 
500 
800 
1000 
PBS 
500 
800 
1000 
PBS 
500 
800 
1000 
PBS 
500 
800 
1000 
BALB/c 
Spleen Weighta 
151 + 5 
175 +6 
153 + 12 
200 + 12 
277 + 13 
367 + 33 
274 + 21 
263 + 21 
1141 + 173 
1032 + 43 
t 
t 
1784 + 133 
1527 + 46 
1508 + 116 
1557 + 134 
Plasma f\!1_tige~~ 
40 
53 + 13 
53 + 13 
53 + 13 
320 
480 + 160 
530 + 107 
320 
1280 
1707 + 430 
4267 + 850 
1280 
5120 
5120 
C57BL/6 
Spleen Weighta Plasma Antigenb 
104 + 5 
83 + 5 
85 + 21 
94 + 4 
144 + 10 
186 + 5 
184 + 8 
208 + 10 
212 + 53 
228 + 25 
243 + 40 
291 + 51 
276 + 36 
265 + 19 
245 + 24 
305 + 51 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
40 
80+ 30 
40 
Table 4.6 (cont) 
Groups of 3 BALB/c or C57BL/6 which were infected with 104 pfu R-MuLV for 7, 14 or 21 days were treated with various doses 
of rMu-TNF-a. rMu TNF-a was diluted in ice cold PBS to desired concentrations and given i.v. in volumes of 200 µl. Three 
days later virus growth was measured as a function of spleen weight and viral antigen in plasma. Data shown from a single 
experiment. 
a) Mean spleen weight of 3 mice(+ SEM) 
b) Endpoint titre of R-MuL V ELISA of viral antigen in plasma of 3 mice (mean + SEM) 
t All mice died less than 24 h after rMu TNF-a administration 
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4.4 DISCUSSION 
Experiments described 1n this chapter investigated the production of 
nitric oxide following R-MuL V infection of BALB / c and C57BL / 6 mice. 
Elevated levels of mRNA encoding the NO producing enzyme, iNOS, 
were found in the spleens of infected BALB / c and C57BL/ 6 mice. Splenic 
iNOS mRNA expression was elevated at 2 weeks p.i. in both strains and 
was expressed at levels at least 8 fold greater than in uninfected mice at 3 
weeks p.i. In contrast, experiments which examined the accumulation of 
RNI in the plasma of infected mice showed that RNI accumulation was 
not significantly elevated following infection of C57BL/ 6 mice and only 
significantly increased in BALB / c mice at 3 weeks p.i. 
There are a number of possible explanations for the apparent 
contradictory results described for iNOS mRNA expression and plasma 
RNI accumulation. Firstly, the difference between these two results may 
reflect differing sensitivities of each assay system. As plasma RNI 
estimation measures systemic production of NO, localised production of 
high levels of NO, such as in individual tissues, may not induce 
significant increases in plasma RNI. Alternatively, excretion of RNI in 
urine may contribute to removal of RNI from plasma (Green et al., 1981). 
Nevertheless, a wide range of studies have used plasma RNI levels to 
demonstrate NO production in vivo. 
Secondly, iNOS expression may be controlled at a post-transcriptional 
level. A number of studies have demonstrated that the expression and 
activity of iNOS is regulated by transcriptional and post-transcriptional 
mechanisms (reviewed in Xie and Nathan, 1994). Cytokines are 
important regulators of iNOS expression and activity. Factors such as 
IFN-y induce iNOS transcription (Xie et al., 1992) and enhance iNOS 
mRNA stability (Vodovotz et al., 1993). Results described in Section 3.2.2 
show that IFN-y mRNA expression by spleen cells was slightly induced 
during R-MuL V infection is coincident with the induction of iNOS 
mRNA expression in the spleen. The activity of IFN-y in induction of 
iNOS expression has been shown to be cross-regulated by TGF-~ which 
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inhibits the translation of iNOS mRNA and induces the degradation of 
both iNOS mRNA and protein (Vodovotz et al., 1993). Although the 
expression of TGF-~ in the spleens of R-MuLV infected mice was not 
investigated, it is interesting to note that infection of mice with the 
F-MuLV derived Fd-MIV retrovirus enhanced in vitro production of 
TGF-~ (Faxvaag et al., 1993). This observation raises the possibility that 
TGF-~ expression may be elevated during murine leukemia virus 
infections and, as a result, limit iNOS expression and activity. 
It is unclear whether the lack of increased plasma RNI is due to the 
inhibition of iNOS protein production or the regulation of iNOS activity. 
Analysis of iNOS protein expression or activity by western blot or 
enzymatic assay may be insufficient to resolve these questions. This is 
due to the regulation of iNOS activity by the availability of substrates 
such as L-arginine (Vodovotz et al., 1994) and co-factors such as 
tetrahydobiopterin (Kwon et al., 1989; Mellouk et al., 1994) and 
calmodulin (Cho et al., 1992). However, it remains to be shown if these 
potential regulatory mechanisms control NO production during R-MuLV 
infection. 
Splenocytes from R-MuLV infected mice expressed markedly elevated 
levels of NO following stimulation with LPS in vitro. Peak in vitro NO 
production was found using spleen cells from both BALB / c and C57BL/ 6 
mice infected 2 weeks previously. NO production by spleen cells from 
BALBI c mice was markedly reduced from these levels at 3 weeks p.i. 
while in C57BL/ 6 mice, levels produced at this time were similar to those 
found at 2 weeks p.i. These results demonstrate that during R-MuL V 
infection, spleen cells become activated and produce elevated levels of 
NO upon restimulation. This pattern of NO production by spleen cells 
from BALB/c mice was not in full agreement with splenic iNOS mRNA 
expression, as peak iNOS mRNA levels were found at 3 weeks p.i. while 
peak in vitro production occurred at 2 weeks p.i. The cause of these 
divergent findings is unclear, however they may reflect disparate NO 
inducing properties of different stimuli in each system. 
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The nature of the stimuli for NO production by spleen cells during 
R-MuLV infection is unclear. NO expression can be induced by cytokines 
such as IFN-y (Ding et al., 1988; Albina et al., 1991) and, as discussed 
earlier, the levels of expression of IFN-y mRNA by spleen cells is 
consistent with NO production in the spleen of infected BALB I c and 
C57BLl6 mice. Other cytokines, such as TNF-a, IFN-a or IFN-~ , 
synergise with IFN-y to augment NO production (Ding et al., 1988). 
Expression of TNF-a mRNA was found to be elevated in the spleens of 
infected BALBlc mice but reduced in C57BLl6 mice (Chapter 3). These 
observations are consistent with a role for TNF-a in NO production in 
BALBI c mice and suggest that other stimuli are required for NO synthesis 
in C57BLI 6 mice. IFN-a and IFN-~ were found to elevated in the sera of 
C57BLl10 mice which raises the possibility that these cytokines may play a 
role in the induction of NO production during R-MuLV infection of the 
closely related C57BLl6 mice (Toth et al., 1971c). On the other hand, 
R-MuL V infection of BALBI c mice does not induce expression of IFN-a 
or IFN-~ (Toth et al., 1971c). 
Activated T cells have been shown to induce IFN-y activated 
macrophages to produce NO via ligation of CD40 or LFA-1 molecules on 
the macrophage surface (Tao and Stout, 1993; Tian et al., 1995) . The 
generation of a strong anti-R-MuLV immune response in C57BLI 6 mice 
(McCoy et al., 1972) may thus induce NO production by macrophages. In 
contrast, BALBI c mice generate a weak anti-R-MuL V immune response 
(Fink and Rauscher, 1964; McCoy et al., 1967; McCoy et al., 1972) raising 
the possibility that T cell surface molecules are not major participants in 
NO expression by these mice. 
Retrovirus encoded peptides (Hayman et al., 1993; Mollace et al., 1993; 
Pietraforte et al., 1994) and tumour cells (Isobe and Nakashima, 1993; 
Zembala et al., 1994) can induce the production of NO by macrophages in 
the absence of IFN-y or LPS. As R-MuL V is expressed at high levels in the 
spleens of these mice (Rauscher, 1962; Boiron et al., 1965 and Section 
2.3.1), it is possible that the viral proteins may induce NO production by 
macrophages. Furthermore, R-MuLV induced tumour cells may induce 
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NO synthesis in BALB / c mice. As virus replication in C57BL/ 6 mice is 
somewhat limited (Rauscher, 1962; Boiron et al., 1965 and Section 2.3.1) 
and virus induced transformation is a rare event early in infection of 
these mice (McCoy et al., 1967), it seems likely that induction of NO 
production in these mice may be caused by other stimuli. 
The cellular source of NO produced by spleen cells from R-MuL V 
infected mice is unclear. Activated macrophages have been shown to 
produce NO in a wide range of infectious disease models such as viral 
(Croen, 1993; Karupiah et al., 1993b; Butz et al., 1994; Rowland et al., 1994) 
and bacterial (Al-Ramadi et al., 1992; Gregory et al., 1993) infections or 
parasitic infestations (Adams et al., 1990; Liew et al., 1990). Other cells 
such as T cells (Taylor-Robinson et al., 1994) and NK cells (Cifone et al., 
1994) have been shown to produce NO however these examples are 
relatively few in number compared with reports of NO production by 
activated macrophages. It therefore seems likely that activated 
macrophages are the source of NO produced by splenocytes from 
R-MuLV infected mice. Future experiments which assess NO production 
in cultures depleted of macrophages (by adherence to plastic for example) 
may resolve the role of activated macrophages in NO synthesis following 
R-MuL V infection. 
Activated macrophages have been shown to inhibit lymphocyte 
proliferation via the production of immunosuppressive molecules such 
as NO (Albina et al., 1991; Al-Ramadi et al., 1992). Examination of 
supernatants from splenic T and B cell proliferation assays showed that 
NO was produced by anti-CD3 but not LPS stimulated spleen cells from 
R-MuLV infected mice. Significant NO production by anti-CD3 
stimulated cultures was found only at 2 weeks p.i. As T and B cell 
proliferation was inhibited at all times examined, these results suggest 
that NO may not directly contribute to suppressed lymphocyte 
proliferation in R-MuL V infected mice. This conclusion was confirmed 
by the failure of L-NMA to reverse the suppression of T and B cell 
proliferation in vitro. Together, these results demonstrate that NO does 
not play a significant role in suppressed lymphocyte proliferation during 
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R-MuLV infection. Similar observations have been reported in nuce 
infected with LCMV (Butz et al., 1994) or LDV (Rowland et al., 1994). In 
these studies, spleen cells from infected mice produced high levels of NO, 
however NO was found to play only a minor role in the 
immunosuppression characteristic of LCMV or LDV infection. 
Activated macrophages may also inhibit lymphocyte proliferation by the 
production of PG. Albina et al., (1991) demonstrated that addition of 
thioglycolate elicited peritoneal macrophages to spleen cell cultures 
inhibited LPS stimulated B cell proliferation. This effect was reversible in 
part by the addition of the PG synthesis inhibitor, indomethacin. In the 
present study, addition of indomethacin to LPS stimulated spleen cell 
cultures failed to ameliorate suppressed B cell proliferation exhibited by 
spleen cells from R-MuLV mice. The expression of PG was not 
determined here, so it remains possible that PG production was not 
completely inhibited by indomethacin at the concentrations used. This 
seems unlikely, however, as a number of reports have shown that PG 
synthesis or the immunosuppressive effects of PG are reduced by 
indomethacin used at the range of concentrations employed here, ie. 0.5 
to 10 µg/ml (Albina et al., 1991; Schleifer and Mansfield, 1993). Since at 
these concentrations PG production should be efficiently inhibited, the 
suppression of B cell proliferation may be mediated by other 
mechanisms. Future experiments may examine the production of other 
inhibitory molecules such as hydrogen peroxide and TGF-P (Albina et al., 
1991) in suppressed lymphocyte proliferation during R-MuLV infection. 
Inhibition of NO production in vivo using the specific inhibitor of NOS, 
L-NMA, had little effect on levels of viral antigen in plasma or on 
R-MuLV induced splenomegaly at 2 weeks p.i. Virus expression by 
spleen cells was unaltered by L-NMA therapy of BALB / c mice but was 
moderately increased in C57BL/ 6 mice. These observations indicate that 
NO does not contribute to susceptibility of BALB / c mice to R-MuL V 
infection or play a major role in antiviral immunity in C57BL/ 6 mice. 
These results are in contrast with observations of Akarid et al., (1995) who 
showed that administration of L-NMA to F-MuLV-susceptible DBA/2 
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exacerbated F-MuLV infection. The reason for this difference is unclear, 
however it may reflect the much lower dose of F-MuLV given or 
different pathogenesis of F-MuLV in DBA/2 mice compared with 
R-MuLV infection of BALB/c or C57BL/6 mice. A possible explanation of 
the lack of effect of L-NMA upon R-MuLV infection in vivo may be that 
NO may not impair R-MuL V replication. This finding would be in 
marked contrast to other reports that NO limits virus replication and 
more recently limits F-MuLV replication (Croen, 1993; Karupiah et al., 
1993b; Akarid et al., 1995). It will therefore, be interesting to determine if 
NO limits replication of R-MuLV in vitro. 
The observation that plasma RNI was significantly suppressed in mice 
receiving L-NMA indicated that the protocol of L-NMA administration 
inhibited NO synthesis. Furthermore, Rockett et al., (1992) used an 
identical protocol to successfully inhibit the ability of high doses of 
recombinant human TNF-a to induce RNI accumulation in plasma of 
Plasmodium vinckei infected mice. However, it remains possible, albeit 
unlikely, that the regime of L-NMA administration used here did not 
achieve high enough concentrations of L-NMA to inhibit NO production 
at various sites of virus replication. Mice with the iNOS gene disrupted 
have recently become available (Wei et al., 1995) and may be useful in 
further examining the role of NO in R-MuLV infection. 
Treatment of R-MuLV infected and uninfected mice with rMu TNF-a 
induced a rapid dose-dependent release of RNI into the plasma. This 
phenomenon was observed in both BALB/c and C57BL/6 mice. The 
ability of rMu TNF-a to induce NO synthesis in vivo has been 
demonstrated in normal mice (Kilbourn et al., 1990a; Kilbourn et al., 
1990b) and is augmented by infection with organisms such as P. vinckei 
(Rockett et al., 1992; Rockett et al., 1994b) or L. major (Liew et al., 1990) . 
Interestingly, infection with R-MuLV also increased the release of plasma 
RNI following administration of rMu TNF-a compared with levels 
produced by uninfected mice. These observations suggest that R-MuL V 
infection primes or activates cells capable of producing NO in both strains 
of mice. This effect appears to be greater in BALB / c mice, as low doses of 
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rMu TNF-a (500 ng) induced higher plasma RNI release compared with 
similarly treated C57BL/ 6 mice, however this difference was only 
statistically significant at 1 and 3 weeks p.i . BALB / c mice which were 
infected for 2 or 3 weeks exhibited a marked sensitivity to the toxic effects 
of rMu TNF-a, with doses of 1 µg proving lethal. Uninfected BALB / c 
mice or those infected for 7 days survived treatment with 1 µg rMu TNF-
a. C57BL/6 mice survived a dose of 1 µg rMu TNF-a at any stage of 
infection. It is unclear whether the toxic effects of rMu TNF-a in infected 
BALBI c mice are mediated by NO. It is notable that mice infected with P. 
vinckei and treated with TNF-a, LT or IL-1 develop very high levels of 
NO which were 5-10 fold greater than those reported in Table 4.5 (500-
1000 µM plasma RNI) without significant mortality (Rockett et al., 1992). 
Mortality associated with the administration of TNF-a to rats has been 
shown to be due to profound hypoglycaemia and is preventable by 
infusion with glucose (Chajek-Shaul et al., 1990). Furthermore, 
P. vinckei infection of mice markedly enhances hypoglycaemia induced 
by TNF-a and IL-1 administration (Rockett et al., 1994b ). In light of these 
observations, it is likely that the lethal effects of rMu TNF-a 
administration to R-MuL V infected mice may not be due to NO synthesis 
but occurred rather as a result of impaired glucose homeostasis. The role 
of NO in toxicity associated with rMu TNF-a may be resolved by blocking 
NO synthesis with L-NMA following administration of TNF-a as 
described by (Rockett et al., 1992). 
The finding that treatment of R-MuLV infected mice with rMu TNF-a 
had little effect on virus growth suggests that R-MuLV may be not 
susceptible to the antiviral effects of TNF-a. In addition, these 
experiments provide further evidence that NO does not exert 
anti-R-MuLV effects. However, it may be that R-MuLV infection is only 
slightly affected by a single dose of rMu TNF-a and that multiple doses 
may be required for TNF-a to exert antiviral or antiproliferative effects. 
This contention is supported by the study of Johnson et al., (1988) which 
showed that single high dose treatment of F-MuL V infected inbred Swiss 
mice reduced virus induced splenomegaly in the short term, while 
multiple doses over 12 days of TNF-a alone, or in combination with 
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IFN-y, could induce significant long term regression in mice with 
established disease. In addition, the experiments reported in this chapter 
describe treatment of established disease with rMu TNF-a. Several 
studies have shown that treatment of mice with TNF-a prior to infection 
with HSV-1 lead to markedly prolonged survival of mice given a lethal 
dose of virus (Rossol-Voth et al., 1991). However, pretreatment of mice 
with TNF-a does not protect against all viruses, as the growth of LCMV 
(Klavinskis et al., 1989) or vaccinia virus (Lidbury et al., 1993) was not 
altered by prophylactic treatment with this factor. Clearly, further 
experiments are required before a definitive statement concerning the 
effects of rMu TNF-a on R-MuL V infection can be made. These may 
include examination of the ability of TNF-a to inhibit R-MuL V 
replication in vitro or by altering the regime of TNF-a administration in 
vivo as described above. 
In summary, the data presented in this chapter indicate that NO is 
expressed by BALB / c and C57BL/ 6 mice following R-MuL V infection 
however a role for NO in the pathogenesis of R-MuLV infection was not 
demonstrated. 
Chapter 5 
General Discussion and Concluding 
Remarks 
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5.1 GENERAL DISCUSSION 
Rauscher MuLV infection of BALB/c and C57BL/6 mice produces two 
different disease phenotypes. BALB / c mice are highly susceptible to 
disease and fail to control the virus while C57BL/ 6 mice are resistant to 
disease and rapidly limit virus growth upon infection (Rauscher, 1962; 
Pluznik and Sachs, 1964; Boiron et al., 1965 and Chapter 2). The growth of 
R-MuLV and the closely related F-MuLV is influenced by a number of 
heterologous genes (reviewed in Chesebro, 1990; Tsichilis and Lazo, 1991). 
Several of these genes confer resistance independently of antiviral 
immune responses (Mitchell and Risser, 1992). For example, Fv-4 
regulates virus entry into cells (Suzuki, 1975) while Fv-1 restricts the 
integration of the viral genome into host chromosomal DNA (Gautsch et 
al., 1978; DesGroseillers and Jolicoeur, 1983). In mice permissive to virus 
growth at these alleles (such as the C57BL/ 6 and BALB / c mice used in this 
study), functional T cell-dependent immune responses are required to 
mediate resistance to both R-MuLV (Ruprecht et al., 1990; Hom et al., 1991) 
and F-MuLV (Kitagawa et al., 1986; van der Gaag and Axelrad, 1990; 
Robertson et al., 1992) infection. 
The immune response to R-MuLV exhibited by C57BL/6 and BALB/c mice 
has been partially characterised. Several studies have indicated that 
BALBI c mice exhibit a poor anti-R-MuLV immune responses following 
R-MuLV infection. BALB/c mice challenged with R-MuLV generated a 
weak CMI response to R-MuLV (Mortensen et al., 1973; Peters et al., 1975) 
and only low levels of anti-R-MuLV antibody (Toth et al., 1971a; Toth et 
al., 1971c). In contrast, C57BL/6 mice produce strong CMI responses as 
measured by the macrophage migration inhibition test (Mortensen et al., 
1973) and high levels of anti-R-MuLV antibody (McCoy et al., 1972; 
Ishimoto and Ito, 1973). The aim of this thesis was to investigate the role 
of cytokines and CD4 + and CDS+ T cells in resistance or susceptibility to R-
MuL V and examine the role of the recently described antiviral molecule 
NO in the pathogenesis of R-MuL V infection. In addition, the 
mechanism(s) by which R-MuLV suppresses host immune responses was 
investigated. 
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The type of immune response generated toward an infectious agent often 
correlates with resistance or susceptibility. The inability to control a 
pathogen often results from the generation of an inappropriate immune 
response rather the failure to generate an immune response (Bretscher et 
al., 1992). Cytokines are integral to the generation and effector activities 
associated with an immune response. Moreover, the generation of certain 
immune responses has been associated with the production of certain 
patterns of cytokines (O'Garra and Murphy, 1994). Thus the production of 
certain patterns of cytokines may influence resistance or susceptibility to 
an infectious agent (Heinzel et al., 1989; Heinzel et al., 1991; Powrie and 
Coffman, 1993a). Examination of cytokine expression by spleen and lymph 
node cells demonstrated that predominantly type 1 cytokines were 
expressed following R-MuL V infection of both susceptible BALB / c and 
resistant C57BL/ 6 mice. This observation suggested that susceptibility of 
BALB/c mice to R-MuLV may not be due to production of an 
inappropriate pattern of cytokines and an ineffective immune response. 
Interestingly, in vitro restimulated spleen cells from R-MuL V infected 
C57BL/ 6 mice produced much higher levels of type 1 cytokines compared 
with spleen cells from infected BALB / c mice. These data raised the 
possibility that there may be quantitative differences in the antiviral 
immune response generated by these strains of mice and that insufficient 
IFN-y production may lead to an immune response that cannot clear R-
MuLV. Furthermore, this observation was consistent with the relatively 
strong anti-R-MuLV immune response generated by C57BL/ 6 mice 
compared with BALB/c mice. 
However, treatment of C57BL/ 6 or BALB / c mice with neutralising 
antibodies to a number of cytokines did not affect the disease associated 
with R-MuLV infection in these mice. This finding suggests that these 
factors were not required for resistance or susceptibility to R-MuLV 
infection. In particular, neutralisation of IFN-y had little effect upon 
R-MuLV induced splenomegaly which suggests that resistance to R-MuLV 
exhibited by C57BL/ 6 mice was not dependent upon expression of high 
levels of IFN-y. In contrast, 129 /Sv mice lacking functional IFN-y receptors 
appeared to be more resistant to R-MuLV infection than wild type 129 /Sv 
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mice. This finding suggested that IFN-y activity was an important factor in 
susceptibility to R-MuL V exhibited by 129 /Sv mice. It is unclear why IFN-y 
activity appears to affect R-MuLV induced disease in 129 /Sv and not in 
C57BL/ 6 or BALB / c mice. As discussed in Chapter 3, further studies are 
needed in IFN-y R0 1 ° mice to clarify the role of IFN-y and other cytokines 
in the pathogenesis of R-MuLV infection. 
The role of cytokines in the pathogenesis of another MuLV, LP-BM5, has 
been extensively investigated. Disease progression during LP-BM5 MuLV 
infection is associated with an increase in expression of type 2 cytokines 
and reduction in production of type 1 factors (Gazzinelli et al., 1992). It was 
therefore postulated that type 2 cytokines were involved in progression of 
disease. However, further studies using anti-cytokine neutralising mAb or 
mice lacking functional cytokines showed that the type 2 cytokines IL-4 
and IL-10 were not required for disease (Morawetz et al., 1994; Uehara et al., 
1994; Morse et al., 1995) but that IFN-y was integral to disease progression 
(Gazzinelli et al., 1994a; Uehara et al., 1994). These studies clearly 
demonstrate the complexity of cytokine interaction and the necessity for 
experiments that can clearly define the function of individual cytokines. 
A number of studies have also suggested that cytokine expression during 
HIV infection switches from predominantly type 1 to type 2 factors as 
asymptomatic infected individuals progress to AIDS (Clerici and Shearer, 
1993; Clerici and Shearer, 1994). However, this is not a universal finding 
(Emile et al., 1994; Maggi et al., 1994; Romagnani et al., 1994; Romagnani 
and Maggi, 1994). This issue may be clarified by treatment of infected 
individuals with recombinant cytokines and/ or antibodies to cytokines. 
Indeed, recent clinical trials have shown that treatment of HIV infected 
individuals with IL-2 (Kovacs et al., 1995) or antibodies to IL-6 (Emile et al. , 
1994) partially ameliorate disease. These reports also raise the possibility 
that HIV infection may be successfully managed with therapy that 
modulates cytokine activity. 
CD4+ T cells were found to be required for the full development of 
splenomegaly associated with R-MuL V infection of BALB / c and C57BL/ 6 
mice. The exact role of CD4+ T cells in the pathogenesis of R-MuLV 
,, 
I 
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infection is unclear. A number of possible functions for CD4 + T cells in 
R-MuL V infection may be proposed. For example, R-MuL V may replicate 
within CD4+ T cells and consequently, depletion of CD4+ T cells may 
impair virus growth. The level of infection of CD4 + T cells was not 
assessed, however the finding that replication of F-MuLV in T cells 1s 
limited (Isaak et al., 1979) suggests that this possibility may be unlikely. 
An alternative explanation may be that the depletion of CD4 + T cells may 
prevent the generation of an ineffective immune response. This 
hypothesis remains to be investigated, however it seems unlikely as 
depletion of CD4 + T cells limited R-MuLV induced splenomegaly in both 
resistant and susceptible mice. Furthermore, CD4 + T cells affect the 
generation and mediation of immune responses via the production of 
cytokines (Cher and Mosmann, 1987; Hodgkin et al., 1990; Powrie and 
Coffman, 1993a; O'Garra and Murphy, 1994) and neutralisation of a 
number of cytokines known to be produced by CD4 + T cells had little effect 
upon the development of disease associated with R-MuLV infection. 
Experiments which determine the effect of depletion of CD4+ T cells upon 
the generation of antiviral immune responses such as antiviral CTL and 
antibodies may resolve the role of CD4+ T cell-dependent immune 
responses in resistance or susceptibility to R-MuLV. 
CD4 + T cells are also required for the development of MAIDS associated 
with LP-BM5 infection of C57BL/6 mice (Mosier, 1984; Yetter et al., 1988). 
Chronic activation of CD4+ T cells and their interaction with B cells, and to 
a lesser extent macrophages, is thought to be integral in the development 
of MAIDS (Giese et al., 1994; Morse et al., 1995). It is not precisely known 
how CD4 + T cells facilitate the development of MAIDS, however Giese et 
al., (1994) recently reported that the presentation of antigen to CD4+ T cells 
by MHC II+ cells was required. These observations raise the possibility that 
CD4 + T cells may contribute to the pathogenesis of R-MuLV infection via 
activation of other cells. It may be speculated that CD4 + T cells may 
activate other cells via cytokines. Data presented in Chapter 3 did not 
support a role for a number of cytokines in the pathogenesis of R-MuLV. 
It remains possible however, that cytokines involved in haematopoiesis 
such as IL-3, GM-CSP and erythropoietin may promote the proliferation of 
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R-MuLV infected progenitor erythroid cells in the spleen of R-MuL V 
infected mice. It is therefore notable that activated CD4 + T cells have been 
shown to produce IL-3, GM-CSP (Mosmann et al., 1986b; Mosmann and 
Coffman, 1989) while activated macrophages may produce erythropoietin 
(Nathan, 1987; Vogt et al., 1989). 
The observation that CD4+ T cells were involved in splenomegaly 
associated with R-MuLV infection of resistant C57BL/ 6 mice is in contrast 
with the findings of Hom et al., (1991) who showed that CD4+ T cells from 
R-MuL V immune mice partially conferred resistance to naive BALB / c 
mice. The reason for these conflicting findings are unclear. It may be that 
the mechanism by which resistance is mediated in C57BL/ 6 mice may be 
different to that found in R-MuLV-immune BALBI c mice. Experiments 
which compare the anti-R-MuLV immune responses generated 1n 
C57BL/6 and R-MuLV immune BALB/c mice may resolve this issue. 
CDS+ T cells have been shown to be involved in the control of a range of 
virus infections such as vaccinia virus (Ruby and Ramshaw, 1991) and 
HSY (Nash et al., 1987). C57BL/6 mice depleted of CDS+ T cells were found 
to exhibit greater pathology during R-MuLV infection. This observation is 
consistent with the findings of Robertson et al., (1992) who showed that 
recovery from F-MuL V was dependent upon CDS+ T cells. In addition, the 
resistance to MAIDS exhibited by LP-BMS MuLV infected A/J mice is 
dependent upon CDS+ T cells (Makino et al., 1992). From the data 
presented in this thesis it is unclear how CDS+ T cells limit R-MuLV 
infection in C57BL/ 6 mice. CDS+ T cells limit replication of other viruses 
by the production of antiviral cytokines such as IFN-y (Ruby and 
Ramshaw, 1991) or antiviral chemokines (Cocchi et al., 1995) and/ or via 
lysis of virus infected cells (Zinkernagel and Althage, 1977). These reports 
,, raise the possibility that these mechanisms may be involved in the control 
! 
of R-MuL V infection exhibited by C57BL/ 6 mice. However, given that in 
vivo treatment with neutralising antibodies to antiviral factors such as 
IFN-y did not alter R-MuLV infection, it seems unlikely that CDS+ T cells 
limit virus infection by producing these cytokines. It will be therefore of 
interest to examine the production of chemokines and the generation of 
anti-R-MuLV CDS+ CTL in C57BL/6 mice. 
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Experiments in Chapter 4 have examined the role of NO in R-MuL V 
infection of BALB/c and C57BL/6 mice. iNOS mRNA was found to be 
expressed in the spleen of R-MuL V infected BALB / c and C57BL/ 6 mice. In 
addition, spleen cells from R-MuLV infected mice also exhibited a marked 
ability to synthesise NO. Given that NO has been shown to limit the 
replication of a number of viruses (Croen, 1993; Karupiah et al., 1993b; 
Harris et al., 1995; Karupiah and Harris, 1995) and impair proliferation of 
tumour cells (Drapier and Hibbs Jr, 1986; Kwon et al., 1991; Lepoivre et al., 
1991) and bone marrow cells (Punjabi et al., 1992), it seemed likely that NO 
would be involved in the control of R-MuLV. Furthermore, it was 
recently reported that NO produced by activated macrophages could 
impair F-MuLV infection in vitro and NO may limit F-MuLV replication 
in vivo (Akarid et al., 1995). However, similar levels of expression iNOS 
mRNA and NO by spleen cells from both susceptible and resistant mice 
following R-MuLV infection. Furthermore, inhibition of NO synthesis in 
vivo by treatment of infected BALB / c or C57BL/ 6 mice with the iNOS 
inhibitor L-NMA did not affect virus growth. Together, these 
observations suggest that NO may not play a role in resistance or 
susceptibility to R-MuLV. It remains possible that the use of competitive 
inhibitors of NOS did not completely prevent the production of significant 
levels of NO. Mice with the iNOS gene disrupted have recently become 
available (Wei et al., 1995) and may help to clarify further the role of NO in 
R-MuLV infection. 
The role of NO in other retroviral infections such as HIV is unclear. 
In vitro studies show that HIV proteins stimulate human macrophages to 
produce NO (Mollace et al., 1993; Pietraforte et al., 1994) . Cultures of 
human astrocytes or glial cells have been shown to produce NO following 
, exposure to HIV peptides. These findings raise the possibility that NO may 
I 
,, play a role in the neuropathology associated with HIV infection (Dawson 
et al., 1993; Mollace et al., 1993; Koka et al., 1995). However, examination of 
RNI levels in cerebrospinal fluid from people at various stages of HIV 
infection found no evidence for increased NO production by neural tissue 
(Milstein et al., 1994). The expression of NO in HIV infection is unclear as 
contradictory studies show that serum RNI levels are unchanged (Evans et 
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al., 1994) or elevated (Zangerle et al., 1995) in HIV infected people. It will 
be interesting to determine if HIV replication in vitro and in HIV infected 
individuals is inhibited by NO. 
A feature of R-MuLV infection of susceptible mice with R-MuLV is the 
marked suppression of both antibody production (Siegel and Morton, 1966; 
Ceglowski and Friedman, 1968; Millian and Schaeffer, 1968; Seidel and 
Lauenstein, 1969) and CMI responses (Gabrilovich et al., 1994). Resistant 
strains of mice such as C57BL/ 6 mice also exhibit suppressed antibody 
production following R-MuLV infection, however this effect is slight and 
transient (Seidel and Lauenstein, 1969) while the development of CMI is 
unaltered (Mortensen et al., 1973). The role of immunosuppression in the 
pathogenesis of viral infections is intriguing. While many retroviruses 
suppress immune responses toward retroviral and heterologous antigens 
(Bendinelli et al., 1985; Chesebro, 1990) and inhibit resistance to secondary 
infections (Buller et al., 1987b; Moors et al., 1990), the importance of 
immunosuppression to retrovirus persistence remains unclear. The 
correlation of the degree of R-MuLV-induced immunosuppression with 
the level of virus growth in C57BL/ 6 or BALB / c mice suggests that the 
suppression of potentially protective immune responses may facilitate 
viral persistence. Furthermore, Moloney MuL V infection is exacerbated in 
BALBI c mice co-infected with R-MuLV (Chirigos et al., 1968). However, 
(Morrison et al., 1986) found that F-MuLV infected A.BY mice (H-2blb, 
Rfv-3 5/s) had high titres of circulating virus without exhibiting the severe 
immunosuppression found in congenic A/WySn mice (H-2a!a, Rfv-3 515 ). 
Further studies indicate that F-MuLV induced immunosuppression is 
regulated by loci within the H-2D subregion while resistance to infection 
was associated with genes within the H-2K or I-A subregions (Morrison et 
al., 1987; Chesebro, 1990). These findings show that immunosuppression 
is not essential in the pathogenesis of F-MuLV and, by analogy, raises the 
possibility that the resistance or susceptibility to R-MuLV may be 
independent of R-MuLV-associated immunosuppression. 
Nevertheless, immunosuppression associated with retroviral infection is 
of increasing interest in light of the HIV pandemic. Experiments in this 
thesis were designed to explore the immunosuppression associated with 
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R-MuLV infection. A number of potential mechanisms by which 
R-MuLV induces immunosuppression may be proposed. R-MuLV 
infection of susceptible BALBI c mice leads to a marked accumulation of 
progenitor erythroid cells in the spleen. This observation raised the 
possibility that suppressed lymphocyte proliferation described in Chapter 2 
may be due to decreased proportions of lymphocytes in the spleen of 
infected mice. Examination of the proportion of T and B cells in the 
spleen of R-MuLV infected mice suggested that a reduction in the 
proportion of immunoreactive cells could not completely account for the 
immunosuppression associated with R-MuLV infection. 
Infection of immune cells such as T cells, B cells and macrophages is 
another possible cause of immunosuppression associated with retroviral 
infections (Bendinelli et al., 1985). The role of virus infection of immune 
cells in R-MuLV-associated immunosuppression was not investigated in 
this thesis. F-MuLV replicates in B cells and to a lesser extent in T cells of 
infected mice (Isaak et al., 1979). This observation raises the possibility that 
R-MuLV induced immunosuppression may be due at least in part to 
infection of lymphocytes. 
Further experiments described in this thesis also showed that spleen cells 
from R-MuLV infected BALB/c or C57BL/6 mice suppressed the 
proliferation of splenic T cells from uninfected mice. These data suggest 
that spleen cells from infected mice produce an immunosuppressive 
factor. The identity of this suppressive factor was not characterised, 
however similar co-culture experiments using spleen cells from F-MuLV 
indicate that F-MuLV is capable of suppressing immune cell function in 
vitro. This finding raises the possibility that R-MuLV itself is the 
suppressive factor described above. It would be interesting to determine if 
infection with R-MuL V is required for this effect. Alternatively, retroviral 
proteins may be responsible for the suppression described above as there 
are numerous reports that retrovirus encoded peptides can suppress 
immune responses (Fowler et al., 1977; Snyderman and Ciancolo, 1984; 
Orosz et al., 1985; Ruegg et al., 1989a). 
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Since IL-2 acts as an autocrine and paracrine T cell growth factor (Fraser et 
al., 1993; Seder et al., 1994), deficient IL-2 production is a potential 
mechanism of suppressed T cell proliferation. Indeed, suppressed IL-2 
production is associated with the impaired T cell proliferation which is a 
feature of infection with viruses such as LCMV (Saran et al., 1990) and 
MCMV (Blackett and Mims, 1988) and retroviruses including LP-BM5 
MuL V (Gazzinelli et al., 1992), F-MuL V (Lopez-Cepero et al., 1988) and HIV 
(Murray et al., 1984). However, in the examples cited above, T cell 
proliferation was not restored by the addition of exogenous IL-2 suggesting 
that the immunosuppression was not at the level of IL-2 production. In 
Chapter 3, in vitro IL-2 production by spleen cells from R-MuLV infected 
mice was unaltered except late in infection while proliferation splenic T 
cells from both BALB / c and C57BL/ 6 mice was impaired at all times p.i. 
examined. These observations are consistent with the hypothesis that 
suppressed T cell proliferation found in R-MuLV infected mice was 
independent of IL-2 production. The possibility that defective expression 
of IL-2 receptor or impaired signalling following IL-2 receptor ligation may 
account for suppressed T cell proliferation is not excluded by this data. 
These avenues of investigation may clarify the role of IL-2 in suppressed T 
cell proliferation associated with R-MuLV infection. 
Immunosuppression associated with infectious disease may also be due to 
suppressive effects of host derived molecules. Activated macrophages 
have been shown to produce immunosuppressive molecules such as NO 
and PG (Nathan, 1987; Albina et al., 1991). The immunosuppression 
induced by NO is due to a vigorous immune response involving the 
production of high levels of IFN-y (Al-Ramadi et al., 1992; Schleifer and 
Mansfield, 1993). Although IFN-y and NO were produced by spleen cells 
from R-MuLV infected mice, NO was not involved in suppressed T or B 
cell proliferation. These findings are similar to infection with LCMV 
(Butz et al., 1994) or LDV (Rowland et al., 1994), where NO is produced by 
activated macrophages but does not cause the immunosuppression 
associated with these infections. Prostaglandin production by 
macrophages has also been shown to impair B cell proliferation (Albina et 
al., 1991), PG were found to play little role in the suppressed B cell 
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APPENDIX 1 
Primer sequences used for PCR amplification of cDNA 
Cytokine Primer Primer Sequence Bases Reference 
S_eanneda 
IFN-y IFN y 5' 5'-TGA ACG CTA CAC ACT GCA TCT TGG-3' 71-94 Clonetech 
IFN y3' 5'-CGA CTC CTT TTC CGC TTC CTG AG-3' 508-530 II 
TNF-a TNFS 5'-GGC AGG TCT ACT TTG GAG TCA TTG C-3' 820-843 Murray et al., (1990) 
TNFAS 5'-ACA TTC GAG GCT CCA GTG AAT TCG G-3' 1102-1127 II 
IL-2 IL-2 S 5'-TTG ATG GAC CTA CAG GAG CTC CTG AGC-3' 201-227 Morris et al., (1995) 
IL-2 AS 5'-AGA GAG CCT TAT GTG TTG TAA GCA GGA GG-3' 565-592 II 
IL-4 IL-4 S 5'-GAA TGT ACC AGG AGC CAT ATC-3' 100-121 Svetic et al., (1991) 
IL-4 AS 5'-CTC ACT ACT ACG AGT AAT CCA-3' 463-485 II 
HPRT HPRTS 5'-GTT GGA TAC AGG CCA GAC TTT GTT G-3' 514-538 II 
HPRT AS 5'-GAT TCA ACT TGC GCT CAT CTT AGG C-3' 652-678 II 
iNOS iNOSS 5'-CCC TTC CGA AGT TTC TGG CAG CAG-3' 3199-3223 Oswald et al., (1994b) 
iNOSAS 5'-GGC TGT CAG AGC CTC GTG GCT TTG G-3' 3671-3695 II 
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Primer sequences were obtained from previously published or commercial sources. All primers were synthesised by the using 
standard phosphoramidite chemistry (Applied Biosystems, NJ, USA) at the Biomolecular Resources Facility of the JCSMR. 
Interferon-y primers were originally purchased from Clonetech Laboratories (Palo Alto, CA, USA) and subsequently synthesised by 
the JCSMR BRF. 
a) Numbering of sequences based on the following reports: IFN-y (Gray and Goeddel, 1983); TNF-a (Fransen et al., 1985); IL-2 
(Kashima et al., 1985); IL-4 (Lee et al., 1987); HPRT (Konecki et al., 1982), iNOS (Xie et al., 1992). 
